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Abstract  
 
Ocular mucous membrane pemphigoid (ocular MMP) is a visually devastating 
disease where up to 30% of patients become blind due to the consequences of 
conjunctival inflammation and aggressive fibrosis. Standard systemic 
immunosuppression controls inflammation, but is limited by toxicity. How well 
immunosuppressive therapy prevents fibrosis is unknown. The cellular and 
molecular mechanisms that lead to excessive conjunctival fibrosis in ocular MMP 
are incompletely understood.  Chronic inflammation and repair play an important 
role, but the conjunctival fibroblasts may also be autonomously activated.  
 
This thesis aimed to investigate potential mechanisms involved in conjunctival 
fibrosis in ocular MMP, for the purpose of proposing future anti-fibrotic therapies, to 
be used in conjunction with systemic immunosuppression.  
 
A retrospective review established that whilst conjunctival inflammation appeared 
to be controlled in 70% of patients, fibrosis progressed in 53%. A pilot randomised 
trial of adjunctive pulse intravenous methylprednisolone in patients with severe 
ocular MMP commencing both oral cyclophosphamide and oral corticosteroids did 
not reduce the time to control of inflammation, which had been hypothesised to 
prevent the progression of scarring.   
 
Both tumour necrosis factor-alpha (TNFα) and the T cell-derived fibrogenic 
cytokine interleukin-13 (IL-13) were expressed in active ocular MMP. Although this 
expression was reduced after treatment in clinically uninflamed ocular MMP, it was 
still significantly elevated compared to normal conjunctiva. Both TNFα and IL-13 
stimulated migration and altered matrix metalloproteinase expression by normal 
conjunctival fibroblasts. IL-13 also stimulated collagen contraction. Both TNFα and 
IL-13 upregulated surface expression of costimulatory molecules by conjunctival   4
fibroblasts, which suggests facilitation of a potential mechanism for fibroblast-T cell 
cross talk. 
 
Finally, pemphigoid conjunctival fibroblasts showed an altered phenotype 
compared to normal conjunctival fibroblasts, with increased cell division, migration, 
collagen contraction, type I collagen secretion, and secretion of eotaxin and matrix 
metalloproteinase-3.   
   
This thesis increases our understanding of the mechanisms involved in 
conjunctival fibrosis in ocular MMP, and provides new avenues for investigation of 
potential adjuvant therapies which could improve the prognosis in this poorly 
understood disease.  
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Introduction and overview 
Ocular mucous membrane pemphigoid (ocular MMP) is a visually devastating 
immunobullous disease characterized by conjunctival inflammation and 
progressive conjunctival fibrosis. It is one of the most difficult external eye diseases 
to manage and up to 30% of patients become blind. The conjunctival inflammation 
in ocular MMP causes discomfort, limbitis which leads to corneal stem cell failure, 
and conjunctival fibrosis. This resulting fibrosis causes additional damage to the 
external eye including dry eye secondary to lacrimal duct occlusion, conjunctival 
shortening and scarring, leading to both corneal exposure and inturned lashes. 
These anatomical changes increase the susceptibility to corneal infection and 
ulceration, with resultant corneal vascularisation, opacity, keratinisation and ocular 
surface failure.   
 
Standard treatment of ocular MMP with systemic immunosuppressive therapy 
controls inflammation, but the effectiveness of systemic immunosuppression in 
controlling inflammation is limited by its toxicity. There is no reliably effective 
therapy specific for fibrosis. Furthermore, it is not known how well 
immunosuppressive therapy prevents fibrosis.  The cellular and molecular 
mechanisms that lead to excessive conjunctival fibrosis in ocular MMP are 
incompletely understood.  In common with many fibrotic disorders, chronic 
inflammation and repair are believed to play an important role, but it has also been 
proposed that functional characteristics of the conjunctival fibroblasts may be 
altered in ocular MMP, similar to the findings in fibroblasts derived from patients 
with systemic sclerosis.  
 
The aims of this thesis were threefold: 
1. To assess how well current conventional immunosuppressive treatment 
controls inflammation and fibrosis in ocular MMP.   22
 
 2. To investigate the potential roles of two key inflammatory cytokines, 
tumour necrosis factor-alpha (TNFα) and interleukin-13 (IL-13), in 
conjunctival fibrosis due to ocular MMP.  These cytokines were chosen for 
study because they are important mediators of inflammation and scarring in 
diseases affecting other systems, and inhibitors are either available, or 
being developed, for therapeutic applications. 
 
3. To investigate whether the phenotype of conjunctival fibroblasts from 
ocular MMP patients differs from that of normal conjunctival fibroblasts, and 
how this contributes to conjunctival fibrosis in ocular MMP.  
 
Chapter 1 provides the background to the clinical problem and current 
understanding of the pathogenesis of conjunctival scarring in ocular MMP.   
 
The next two chapters investigate how well systemic immunosuppressive therapy 
prevents clinically relevant fibrosis. Chapter 2 is a retrospective review of the 
clinical outcomes of conventional immunosuppressive treatment, in a large cohort 
of patients, in terms of both control of inflammation and fibrosis. Chapter 3 
describes a prospective randomised controlled trial of adjuvant pulsed intravenous 
methylprednisolone in severely affected ocular MMP patients commencing 
maximal immunosuppressive treatment with oral cyclophosphamide and oral 
corticosteroids. The primary outcome measure of the trial was to evaluate whether 
the use of adjuvant pulsed intravenous methylprednisolone reduced the time to the 
control of inflammation, and the secondary outcome measure was to identify 
whether it reduced the progression of scarring. 
 
Chapters 4 to 6 describe laboratory studies investigating the effect of systemic 
immunosuppressive treatment on the conjunctiva in MMP at the cellular and 
molecular level, by comparing conjunctival biopsies taken from eyes with active   23
inflammation due to ocular MMP, with biopsies taken from clinically uninflamed 
white eyes where inflammation has been controlled by immunosuppressive 
treatment.  
 
Chapter 4 describes a study investigating the expression of tumour necrosis factor-
alpha (TNFα) in the conjunctiva in ocular MMP in both active disease and in 
clinically uninflamed eyes following immunosuppressive treatment, and evaluating 
the effects of TNFα on normal conjunctival fibroblasts in vitro. TNFα was selected 
as the candidate for study in Chapter 4 because, although there are readily 
available TNFα inhibitors used successfully in other autoimmune inflammatory 
conditions, the current scientific rationale for their use in ocular MMP, either 
systemically or as potential local adjuvant therapy, is lacking. There are limited 
studies investigating the expression of TNFα in MMP tissue. Furthermore, given 
that TNFα could have either pro-fibrotic or anti-fibrotic effects, inhibition of a 
molecule with potentially anti-fibrotic effects would be undesirable in the context of 
ocular MMP.   
 
Chapter 5 similarly investigates whether the key profibrotic mediator interleukin-13 
(IL-13) is expressed in the conjunctiva in ocular MMP before and after treatment, 
and the direct effects of IL-13 on normal conjunctival fibroblasts. Preliminary 
studies on T cells derived from ocular MMP were carried out, with the intention of 
investigating the contribution of T cell-fibroblast interactions in ocular MMP. 
Interleukin-13 was selected for this investigation because previous studies have 
shown that T cells predominate in the substantia propria during the subacute and 
chronic phases of ocular MMP. IL-13 is a cytokine secreted by type 2 helper T 
cells, that plays a key role in orchestrating fibrosis in other settings. It is expressed 
in mucosal sites during inflammation, and might play an important role in fibrosis in 
this disease, as it does in liver, lung and colonic fibrosis. IL- 13 inhibitors are also 
being developed for clinical use.   
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Chapter 6 investigates whether fibroblast phenotype-dependent mechanisms could 
be involved in fibrosis in ocular MMP, by evaluating whether conjunctival 
fibroblasts derived from ocular MMP patients behave autonomously in a profibrotic 
manner compared with normal conjunctival fibroblasts, as assessed by functional 
fibroblast assays. 
 
As each chapter deals with a particular aspect of the treatment and pathogenesis 
of ocular MMP, a review of the literature relevant to that chapter is provided at the 
beginning of the chapter. Specific methods that were used to obtain the results of 
each chapter are described within the relevant chapter. These results are then 
discussed within the context of prior literature. The findings described in the 
chapters and their significance are then synthesised in the final concluding chapter.   25
 
Chapter 1  
 
Background 
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1.1 Introduction 
Mucous membrane pemphigoid (MMP) is part of a spectrum of a systemic 
autoimmune subepithelial blistering disease, where inflammation and scarring are 
the distinguishing features. Scarring is responsible for the blinding complications of  
MMP when it affects the eyes (ocular MMP). Immunosuppressive therapy to 
control inflammation is the present standard treatment.  Current knowledge of the 
cellular and cytokine interactions that lead to fibrosis in ocular MMP are 
summarised here. The rationales for selecting TNFα and IL-13 for investigation in 
ocular MMP are also explained.  
1.2 Mucous membrane pemphigoid 
Mucous membrane pemphigoid (MMP), previously known as cicatricial pemphigoid 
(CP) describes a heterogeneous group of immunobullous diseases characterised 
by recurrent subepithelial blistering of mucous membranes and sometimes skin, 
where the clinical hallmark is healing of lesions with excessive scar tissue 
formation. Mucous membranes which can be affected in varying combinations 
include the mouth, conjunctiva, pharynx, larynx, oesophagus, nose, genitalia and 
rectum. In some patients, clinical disease is confined to the mouth (oral MMP) or 
the eye (ocular MMP). MMP blisters affecting the mouth and scalp are illustrated in 
Figure 1.1.  
 
MMP is an uncommon condition, with an incidence of 1.16 per million population 
per year (Bernard et al., 1995).  No racial or geographic predilection has been 
reported.  The female: male ratio is 2:1 (Foster, 1986).  Although the average age 
of onset is 65 years, it can occur in children and young adults (Cheng et al., 2001). 
 
Autoantibodies against epithelial basement membrane zone (BMZ) components 
are believed to play a role in the pathogenesis of this group of diseases (Oyama et 
al., 2006). Whilst circulating autoantibodies in a given patient tend to target a single   27
antigen, autoantibodies from MMP patients with similar clinical phenotypes may 
target different autoantigens, and the heterogeneity of clinical presentations and 
diversity of target autoantigens make it difficult to characterise this condition 
immunologically (Chan et al., 2002).  
 
The problem of heterogeneity of both clinical features and autoantigen targets is 
further complicated by the fact that in patients with pure ocular disease, the 
frequency of detection of autoantibodies binding to the BMZ of salt-split skin by 
indirect immunufluorescence microscopy (IIF) s often low (7%) (Chan et al., 1993) 
although others have reported weak low titre binding in up to 91% (Bhol et al., 
1996). In comparison, autoantibodies binding to salt-split skin can be detected in 
50-84% of patients with mouth and skin MMP (Schmidt et al., 2001; Setterfield et 
al., 1998), and additional immunoblotting techniques on sera from patients with a 
similar phenotype can increase the sensitivity to 100% (Schmidt et al., 2001).  
When conjunctiva is used as the substrate for detection of circulating antibodies, 
antibodies can be detected in up to 50% of patients with ocular involvement 
(Leonard et al., 1988), suggesting that conjunctival basement membrane contains 
antigens not present in the skin BMZ. Although some investigators have found a 
correlation between antibodies binding to β4 integrin in sera from MMP patients 
with ocular involvement, and α6 integrin in sera from patients with pure oral MMP 
(Rashid et al., 2006), these findings have not been easily replicated by other 
groups, possibly due to the method used to demonstrate the presence of binding 
antibodies. Another group have identified IgA antibodies reacting specifically with a 
45kD protein in patients with pure ocular MMP, but the nature of this protein has 
not been elucidated as yet (Smith et al., 1993). These findings suggest that pure 
ocular disease, and pure oral disease, may be distinct subsets of MMP. 
 
The severity of scarring and functional consequences of scarring in MMP vary 
depending on the anatomical location affected. Excessive scarring of the 
oesophagus and larynx can be fatal and requires surgical intervention. In contrast,   28
lesions of the mouth frequently do not cause scarring.  The reason for the widely 
differing amounts of scarring according to location is unclear, but could relate to 
differences in the inflammatory response of the tissues, and site-specific 
characteristics of the fibroblasts (Flavell et al., 2008). It has been noted that the 
mouth is much less prone to scar formation in response to injury, and that this 
correlates with its reduced inflammatory profile (Szpaderska et al., 2003). Specific 
localization of the target antigen in MMP in deeper layers of the BMZ (Lee et al., 
2003) has also been postulated as a reason for the tendency to heal with scarring. 
The focus of this thesis is MMP affecting the eye, where the scarring response can 
be severe and aggressive, and the functional consequences devastating, with 
permanent blindness resulting in 27% of those with ocular involvement (Hardy et 
al., 1971).  
 
 
Figure 1.1 Mucous membrane pemphigoid blisters affecting the mouth and 
scalp   29
1.3 Ocular mucous membrane pemphigoid (ocular MMP): clinical 
presentation 
As the focus of this thesis is MMP with ocular involvement, henceforward this 
review will be limited to discussion of current knowledge and understanding about 
patients with “ocular MMP”, which includes both patients with isolated pure ocular 
MMP, and MMP patients with ocular plus extraocular involvement.  Where 
evidence has been described as having been obtained from MMP patients without 
ocular involvement (“extraocular MMP”), or from patients with isolated pure ocular 
MMP, this is stated in the text.  Many studies on MMP with ocular involvement do 
not segregate results from patients with pure ocular disease, from those with ocular 
plus extraocular disease.  
1.3.1 Anatomy of the conjunctiva 
Ocular MMP affects the external eye, which consists of the cornea, conjunctiva, 
limbus, and eyelids. The cornea is the transparent, avascular dome-shaped 
window covering the front of the eye, that provides 2/3 of the eye’s focusing power. 
Vascularisation of the cornea leads to blindness due to permanent scarring and 
irregular astigmatism. The limbus is the transition zone between the cornea and 
sclera. It is the site where stem cells of the corneal epithelium reside. Damage to 
these cells leads to limbal stem cell failure, where healthy clear corneal epithelium 
is not able to regenerate, and instead the surface of the cornea is covered with 
opaque vascularised conjunctival epithelium.  The conjunctiva is a thin, 
translucent mucous membrane that derives its name from the fact that it attaches 
the eyeball to the eyelids. It consists of a superficial epithelium which varies in 
structure depending on location, from a stratified squamous non-keratinizing 
epithelium (close to the lid margin) to a stratified columnar epithelium (bulbar). The 
conjunctival epithelium consists of 2 to 7 layers of epithelial cells, and includes 
other cell types: goblet cells, melanocytes and Langerhans’ cells. The conjunctival 
epithelium is continuous with the corneal epithelium at the limbus, and with the skin 
at the lid margin. Underlying the conjunctival epithelium is a loose vascular   30
connective tissue stroma called the lamina propria. The lamina propria has a 
looser lymphoid layer above, and a deeper fibrous layer. In a healthy eye the 
lamina propria contains immunocompetent cells, including mast cells, eosinophils, 
plasma cells, and lymphocytes, forming diffuse or discrete subepithelial aggregates 
called conjunctiva-associated lymphoid tissue (CALT). Below the lamina propria 
lies the fascia bulbi (also known as Tenon’s capsule), under which lies the 
episclera and the scleral wall of the eye.  
 
The conjunctiva is reflected from the anterior portion of the sclera at the superior 
and inferior fornices, onto the tarsal surface of the eyelids, forming a potential sac, 
the conjunctival sac. The conjunctiva can be described as consisting of 3 main 
regions: (1) Tarsal (palpebral) conjunctiva lines the inner surface of the eyelids 
and is tightly bound to the tarsal plate; the subepithelial connective tissue stroma is 
thin in this region. (2) Forniceal conjunctiva lines the superior and inferior 
conjunctival fornices and are continuous at the medial and lateral canthi. The ducts 
of the lacrimal glands producing aqueous tears empty into the superolateral fornix. 
(3) Bulbar conjunctiva clothes the anterior part of the eyeball, including the 
extraocular muscle insertions and Tenon’s capsule. Figure 1.2 shows the 
macroscopic and microscopic anatomy of the conjunctiva.   31
 
 
Figure 1.2 Anatomy of the conjunctiva. A. Macroscopic: The conjunctiva 
connects the eyelid to the eyeball and is composed of tarsal, forniceal and bulbar 
conjunctiva. The conjunctiva is continuous with the cornea at the limbus. B. 
Microscopic: The conjunctiva is composed of stratified columnar epithelium, 2 to 7 
cells thick, overlying a loose vascular connective tissue (CT) layer called the 
lamina propria. 
 
1.3.2 Clinical presentation of ocular MMP 
Ocular involvement in MMP, also known as ocular cicatricial pemphigoid (OCP), 
occurs in 70% of MMP patients (Hardy et al., 1971). Extraocular manifestations of 
MMP are present in 50% of ocular MMP patients (Saw et al., 2008). Ocular MMP 
typically presents with a red eye and persistent conjunctivitis that has not 
responded to topical therapy, or with recurrent entropion (inturned eyelid) and 
trichiasis (eyelashes abrading the globe), sometimes following surgical repair. It 
can also present with ptosis (droopy upper eyelid). About 10% of patients present 
with acute disease, manifested by acute conjunctivitis and limbitis (inflammation 
and oedema along the corneoscleral limbus) (Figure 1.3 A,B) which leads to 
rapidly progressive scarring and ocular surface failure (Saw & Dart, 2008a) (Figure 
1.3 C,D). Unlike other sites of MMP involvement, conjunctival blisters or ulcers are 
infrequently observed; acute sectoral or diffuse conjunctivitis are more typical in   32
acute disease. Nevertheless, the majority of patients (90%) present with subacute 
or low-grade chronic inflammation and slowly progressive scarring. Because the 
diagnosis is often delayed, symblepharon (bands of conjunctival fibrosis extending 
across from the globe to the conjunctival fornix or lid margin) and shortened 
fornices are usually present when the disease is first recognized. 
 
In patients with subacute disease, the earliest clinical sign in patients is medial 
canthal scarring, with loss of the plica and caruncle. Linear scarring along the 
marginal sulcus in the upper tarsal plate is sometimes present early in the disease. 
Other signs, in order of progression, are subepithelial fibrosis (Figure 1.4 Stage I), 
shortening of the conjunctival fornices (Figure 1.4 Stage II), symblepharon  
(Figure 1.4 Stage III) and cicatricial entropion followed by ankyloblepharon 
(complete adhesion between globe and eyelid margin) (Figure 1.4 Stage IV).  End 
stage disease is characterised by advanced conjunctival scarring with 
ankyloblepharon, severe dry eye due to obliteration of the lacrimal ductules, ocular 
surface failure and blindness due to keratopathy (corneal damage). The modified 
Foster staging of ocular mucous membrane pemphigoid, as proposed by Tauber et 
al (Tauber et al., 1992), is shown in Figure 1.4.  
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Figure 1.3 Acute onset ocular MMP. A. Conjunctival ulcer demonstrated by  
yellow fluorescein dye staining in acute ulcerative conjunctivitis. Such ulcers 
are infrequently seen. B. Limbitis (inflammation and oedema of the  
corneoscleral limbus) from 3 to 4 o’clock indicating inflammatory insult to limbal 
stem cells which regenerate the cornea with healthy clear epithelium.  
C. Rapid progression of conjunctival scarring in an acutely inflamed eye.  
D. Ocular surface failure as a sequela of acute uncontrolled limbitis which  
has damaged limbal epithelial stem cells, resulting in limbal stem cell failure and an 
opaque, keratinized corneal epithelium with associated vascularisation.    34
 
Figure 1.4 Tauber (modified Foster) staging of ocular mucous membrane 
pemphigoid (Tauber et al., 1992). 
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1.4 Ocular mucous membrane pemphigoid: treatment 
1.4.1 Principles and goals of treatment of ocular disease 
The primary goals of treatment of ocular MMP are to control inflammation and 
arrest fibrosis, in order to prevent progression of disease to more advanced stages 
and blindness.  Optimal management of inflammation in ocular MMP targets the 
inflammation due to systemic immunodysregulation with immunosuppressive 
agents, after treating inflammation due to local surface disease (blepharitis, 
trichiasis, dry eye), infection and toxicity (Saw & Dart, 2008b).  Systemic 
immunosuppression is necessary to control inflammation, as there is no evidence 
that topical or subconjunctival corticosteroid therapy alters the natural history of the 
disease (Foster, 1986; Mondino et al., 1979).  Most cicatrisation is believed to 
occur during active inflammation (Mondino et al., 1979), but the efficacy of 
systemic immunosuppression in preventing fibrosis has not been established.  
Without treatment, conjunctival scarring in ocular MMP progresses in 64% of 
patients over 10 to 53 months (Mondino & Brown, 1981).  Progression is more 
frequent in the advanced stages of disease (Mondino & Brown, 1983).  No current 
therapy is able to reverse the cicatrisation or ocular surface problems once they 
have developed.   
1.4.2 Immunosuppressive therapy 
Evidence for the use of current immunosuppressive therapy in ocular MMP comes 
from cohort studies (Foster et al., 1982; Mondino, 1990), interventional and 
retrospective case series (Doan et al., 2001; Elder et al., 1995; Elder et al., 1996b; 
Foster et al., 1992; Letko et al., 2001; McCluskey et al., 2004; Mondino & Brown, 
1983; Neumann et al., 1991; Rogers, III et al., 1982; Tauber et al., 1991; Thorne et 
al., 2008) and two randomized trials (Foster, 1986).  These have indicated a role 
for dapsone, sulfasalazine or sulphapyridine for mild to moderate inflammation; 
azathioprine or methotrexate for moderate inflammation or disease not responding 
to sulpha therapy; and cyclophosphamide with a short course of prednisolone for   36
severely active inflammation.  The calcineurin inhibitors ciclosporin and tacrolimus 
have failed to control inflammation in several studies (Foster et al., 1992; Letko et 
al., 2001; Neumann et al., 1991), and their use in ocular MMP cannot be 
recommended on the basis of current evidence. Tetracyline and niacinamide have 
been reported as safer alternatives to immunosuppression in mild-moderate 
extraocular and ocular MMP (Dragan et al., 1999; Reiche et al., 1998), and 
mycophenolate mofetil has been described in small case series to be effective in 
extraocular MMP (Ingen-Housz-Oro et al., 2005; Megahed et al., 2001) and ocular 
MMP (Zurdel et al., 2001).  The efficacy of the most frequently used 
immunosuppressive agents in controlling inflammation in ocular and extraocular 
MMP is summarized in Table 1.1.   
 
With current immunosuppressive regimens, progression of cicatrisation has still 
been observed in 10 to 43% of ocular MMP patients (Elder et al., 1996a; 
Miserocchi et al., 2002; Mondino & Brown, 1983).  How well immunosuppressive 
therapy controls conjunctival fibrosis in ocular MMP is not clear.  Furthermore, 
there is small subgroup of  MMP patients with ocular involvement who appear to 
have ongoing conjunctival fibrosis without overt clinical signs of inflammation 
(Elder, 1997c).  Despite the absence of clinical signs of inflammation, there may 
still be significant cellular infiltrate on histological evaluation (“white inflammation”) 
(Bernauer et al., 1993b; Elder et al., 1997).  Further systemic immunosuppression 
with potential systemic toxicity may not necessarily be helpful in these cases, for 
whom more specific local therapy targeting the cellular infiltrate or fibrogenic 
process would be ideal. 
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Table 1.1 Results of studies reporting the efficacy of conventional immunosuppressive agents in controlling 
inflammation in MMP (mucous membrane pemphigoid) with and without ocular involvement 
Immunosuppressive agent  Study  Severity of inflammation  % of patients responding to treatment  
Nicotinamide and 
tetracycline 
Reiche et al, 1998   Mild-moderate  63% (n=8) extraocular and ocular MMP 
Dapsone  Rogers et al, 1982  Mild-moderate  83% (n=24) extraocular and ocular MMP 
  Tauber et al, 1991  Mild-moderate  45% (n=69) ocular MMP 
  Foster, 1986  Mild-severe  70% (n=20) ocular MMP 
Sulphapyridine  Elder et al, 1996  Mild-moderate  50% (n=20) ocular MMP 
Sulfasalazine  Doan et al, 2001  Mild-moderate  45% (n=9) ocular MMP 
Azathioprine  Tauber et al, 1991  Mild-moderate  33% (n=11) ocular MMP 
Methotrexate  McCluskey et al, 2004  Mild-moderate  83% (n=12) ocular MMP 
Cyclophosphamide and 
steroids 
Thorne et al, 2008  Mild, moderate and 
severe 
91% (n=44) ocular MMP 
  Elder et al, 1995  Severe  15/19 eyes (79%) ocular MMP 
  Foster, 1986  Severe  100% (n=12) ocular MMP 
Cyclophosphamide  Tauber et al, 1991  Severe  89% (n=9) ocular MMP 
Tacrolimus  Letko et al, 2001  Severe  33% (n= 6) ocular MMP 
Ciclosporin  Neumann et al 1991, Foster 
et al 1992* 
Mild-moderate  2/22 patients (9%) ocular MMP 
Mycophenolate  Zurdel et al, 2001  Severe  9/10 eyes (90%) ocular MMP 
*combined results of two case seriesManagement of patients with recalcitrant disease or intolerance to conventional 
immunosuppressive therapy   38
1.4.3  Management of patients with recalcitrant disease or intolerance to 
conventional immunosuppressive therapy 
Alternatives to conventional immunosuppressive therapy have been sought where 
ocular MMP is resistant to treatment, or in patients who have been unable to 
tolerate conventional immunosuppressants. 
Intravenous immunoglobulin 
Severely active ocular MMP resistant to conventional immunosuppressive therapy 
has been treated with intravenous immunoglobulin (IVIg) by Ahmed et al, who have 
reported good results in several case series (Foster & Ahmed, 1999; Letko et al., 
2004; Sami et al., 2004). A major disadvantage of intravenous immunoglobulin 
therapy is its dependence on donated blood, an increasingly scarce and expensive 
resource.  In one series, during a national blood shortage, patients received ¼ to 
1/3 of previous doses, and every one of the 10 patients relapsed with dose 
reduction, albeit recovering full control within 4 cycles of full dose IVIg (Foster & 
Ahmed, 1999). Sudden discontinuation of IVIg therapy in 2 patients resulted in 
severe recurrence and loss of vision (Sami et al., 2004). This is worrying because it 
is sometimes not possible for patients to present for therapy depending on 
emergencies and personal situations.  Another disadvantage is the inconvenient 
and costly treatment regime. An infusion cycle of 4h daily on 3 consecutive days is 
required every 2 weeks until clinical improvement, then every 3-4 weeks, 
increasing to 16 week intervals for a total of 25-43 months.  The main benefits of 
IVIg appear to be its minimal side effects and effectiveness in disease refractory to 
conventional immunosuppression, although the studies are small and not 
randomised. 
Tumour necrosis factor-α antagonists 
Case reports of seven patients with MMP resistant to conventional 
immunosuppressive therapy have been described as improving after receiving the 
TNFα antagonists etanercept (n=6) or infliximab (n=1): 5 patients had ocular   39
involvement, 2 patients had pure oral disease (Canizares et al., 2006; Heffernan & 
Bentley, 2006; John et al., 2007; Prey et al., 2007; Sacher et al., 2002). This 
treatment was given either alone, or in combination with dapsone or other 
immunosuppressive therapy. In some cases, continued TNFα antagonist treatment 
was not necessary after achieving initial disease control, but in many cases weekly 
etanercept treatment was ongoing at the time of reporting.  
However, the scientific rationale for the use of TNFα antagonists in MMP based on 
present evidence is weak.  Although it has been reported that serum levels of 
TNFα are elevated in MMP compared with normal controls (Lee et al., 1993), there 
are limited studies examining TNFα expression in MMP tissue.  Tissue expression 
appears to be important because in rheumatoid arthritis, whilst there is no evidence 
that plasma TNFα levels can predict the clinical response to TNFα antagonists, 
synovial expression of TNFα appears to be a significant predictor of response to 
TNFα antagonists (Wijbrandts et al., 2007).  
Other biological agents  
Successful use of rituximab, a monoclonal antibody directed against CD20-positive 
B cells, has been reported in one case of MMP with severe ocular and extraocular 
involvement not responding to conventional immunosuppression (Taverna et al., 
2007), and there are preliminary reports of its successful use in 6 other MMP 
patients (Ross et al., 2009) (n=1), (Schumann et al., 2009) (n=1), (Doan S, et al. 
IOVS 2006;47:ARVO Abstract 94; n=4). This therapy is likely to be useful in 
preventing pathogenic autoantibody production by B cells. Further investigation of 
the efficacy of this therapy in MMP in controlled studies is needed.  
 
Daclizumab, a monoclonal antibody which binds CD25 (Tac subunit) of the human 
IL-2 receptor which is expressed on activated T lymphocytes, has been used 
successfully in one patient with ocular MMP (Papaliodis et al., 2003). Its use in 
ocular MMP has not been investigated further. 
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Systemic administration of campath-1H (alemtuzumab) a monoclonal antibody 
against CD52, which is the most prevalent cell surface antigen on lymphocytes, 
particularly T cells, has been reported to induce long lasting remission in patients 
with severe refractory noninfectious ocular inflammatory disease (Dick et al., 
2000). It has been given systemically by us to one patient with ocular MMP 
(unpublished data), but was unfortunately unsuccessful in controlling inflammation, 
and the patient developed atrial fibrillation. 
1.4.4 Corticosteroids 
Topical steroid treatment is ineffective in controlling progressive ocular MMP, 
offering only variable symptomatic relief (Hardy et al., 1971; Mondino et al., 1979). 
Its adverse effects of cataract and glaucoma generally outweigh the benefits.  
Subconjunctival steroids may be temporarily effective, but relapses occur when the 
injections are stopped (Mondino et al., 1979), and prolonged use also leads to 
cataract and glaucoma.   
 
High-dose oral corticosteroids appear to be effective at controlling acute disease 
activity because of their rapid onset of action (Hardy et al., 1971; Mondino et al., 
1979), however the high doses required to sustain disease control (greater than 
40mg prednisolone equivalents daily) can lead to severe adverse effects including 
pneumonia, gastrointestinal haemorrhage and cerebrovascular accidents in this 
elderly patient population.  Disease activity recurs when corticosteroid doses are 
tapered, and the response can be incomplete in 58% of patients (Foster, 1986).  
For this reason, oral corticosteroids are useful in acutely inflamed eyes as a short 6 
to 12 week course in combination with, and whilst awaiting the onset of effect of, 
immunosuppressive medication (Chan et al., 2002; Foster et al., 1992).   
 
The use of pulse intravenous methylprednisolone (IVMP) or dexamethasone to 
control active inflammation is mentioned in the management of ocular and 
extraocular MMP (McCluskey et al., 2004; Sacher & Hunzelmann, 2005), however   41
there are no studies evaluating its efficacy specifically in ocular MMP. Equivalent 
doses of oral prednisolone have been shown to give similar clinical and 
immunological effects when compared with pulse IVMP in rheumatoid arthritis 
(Smith et al., 1988). 
1.4.5  Antifibrotic therapy 
Currently, the only demonstrated means of slowing the progression of scarring is 
good control of inflammation with systemic immunosuppression. Mondino et al 
have previously reported success with systemic corticosteroids in suppressing 
acute disease activity and preventing the rapid shrinkage that accompanies active 
ocular MMP (Mondino & Brown, 1981).  Therapy specifically targeted at fibrosis in 
MMP is limited. Local therapies for conjunctival scarring would be ideal.  Mitomycin 
C, an alkylating agent which inhibits DNA synthesis and prevents fibroblast 
proliferation, has been injected subconjunctivally (Donnenfeld et al., 1999) or 
applied intraoperatively following division of symblephara in patients with ocular 
MMP (Secchi & Tognon, 1996) but no controlled treatment trials have been carried 
out.  In the Donnenfeld study, absence of progression at a mean of 2 years was 
observed in 8/9 eyes receiving the subconjunctival mitomycin C injection, and there 
was no recurrence of symblephara at 19 months.  Subconjunctival mitomycin C is 
not widely used in clinical practice for ocular MMP for several reasons, including 
variable efficacy, the adverse effect of tissue ischaemia which may affect the 
success of mucous membrane graft reconstructive surgery, and the potential risk 
of damaging limbal stem cells.  In Donnenfeld’s series all eyes receiving 
subconjunctival mitomycin C were Foster stage 3 with minimal or no inflammation.  
It may be that giving the injection at an earlier stage, whilst the disease is active, 
could prevent cicatrisation more effectively.   
1.5 The immunopathogenesis of fibrosis in ocular MMP 
The immunopathogenesis of fibrosis due to MMP in the eye or in any other site is 
incompletely understood. Our present understanding of the mechanisms and   42
pathways involved in fibrosis in MMP is limited because of the lack of animal model 
studies. The majority of evidence is descriptive, with limited scope for mechanistic 
insight. A rabbit model of acute anti-basement membrane antibody-mediated 
conjunctivitis to study ocular MMP has been described (Roat et al., 1990), but has 
not been utilized in further studies. The review presented here and in the sections 
following, is focused on current understanding of the pathogenesis of fibrosis in 
MMP affecting the conjunctiva. Where findings have been obtained from MMP 
affecting other sites, this is stated in the text.  
 
On the basis of available evidence, the current hypothesis is that an as yet 
unknown trigger, often in a genetically susceptible individual (Setterfield et al., 
2001), provokes loss of tolerance to one or more components of the basement 
membrane zone (BMZ) (Razzaque et al., 2001).  This generates specific B cell 
clones in germinal centres, which produce circulating IgG and IgA autoantibodies 
to those basement membrane antigens.  
 
Although the presence of autoantibodies is well established in MMP, the exact 
mechanism by which the autoantibodies cause subepithelial blistering has not 
been conclusively demonstrated.  It has been proposed that they bind to their 
target antigens in the basement membrane zone and initiate a type II cytotoxic 
hypersensitivity reaction, activating the complement cascade to cause subepithelial 
bulla formation (Elder, 1997b).  Evidence for a pathogenic role of autoantibodies in 
MMP blister formation include the correlation between elevated autoantibody titres 
and MMP disease activity (Setterfield et al., 1999), and demonstration of in vitro 
conjunctival BMZ separation following incubation with autoantibodies derived from 
patients with ocular MMP (Chan et al., 1999). Linear C3 complement deposition 
along the BMZ is characteristic in MMP, indicating complement cascade activity 
(Chan et al., 2002).   
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Subepithelial bulla formation results in acute inflammatory infiltration of the 
substantia propria with neutrophils, macrophages, T lymphocytes and dendritic 
cells (Bernauer et al., 1993b).  Continued T lymphocyte and macrophage 
proliferation and infiltration results in ongoing subacute inflammation. In ocular 
MMP, this inflammation stimulates formation of new connective tissue by 
proliferating fibroblasts.  Ongoing fibrosis of the conjunctiva leads to a hostile dry 
ocular surface susceptible to infection, inturned lashes and eyelids, and damage to 
limbal stem cells by inflammation and fibrosis leads to ocular surface failure and 
blinding keratopathy (Elder, 1997a). Figure 1.5 shows a diagrammatic 
representation of the proposed immunopathogenesis of fibrosis in ocular MMP, 
which is described in further detail below.        44
 
Figure 1.5 Proposed immunopathogenesis of fibrosis in ocular MMP. See next page for detailed legend.The 
potential roles of TNFα (tumour necrosis factor-alpha), IL-13 (interleukin-13) and profibrotic activated fibroblasts have 
not been elucidated clearly so far.         
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Legend to Figure 1.5 Proposed immunopathogenesis of fibrosis in ocular MMP 
 
INJURY PHASE: Autoreactive T cells recognise BMZ (basement membrane zone) antigens (BP180 bullous 
pemphigoid180kDa antigen, laminin 5, collagen VII, α6β4 integrin) causing B cells in germinal centres to produce 
autoantibodies IgG (immunoglobulin G) and IgA. These bind to the BMZ and initiate a type II cytotoxic 
hypersensitivity reaction, activating the complement cascade to cause subepithelial bulla formation.  
 
INFLAMMATION AND PROLIFERATION PHASE: Complement-mediated BMZ, epithelial and connective tissue 
damage cause vasodilation, release of blood cells and plasma proteins into the damaged site and attracts an acute 
inflammatory cell infiltrate consisting of neutrophils, activated macrophages, mast cells, platelets, Langerhans cells, 
and lymphocytes, as well as acute inflammatory cytokine IL-1 (interleukin-1) production. T cell activation and 
proliferation characteristic of a Th1 (type 1 helper T cell) response occurs, with IFNγ (interferon-gamma) and IL-2 
(interleukin-2) production. Th2 (type 2 helper T cell) cytokines IL-4 and IL-5 are also synthesised. Macrophages 
proliferate and play an important role in scar tissue formation, and also contribute to production of the fibrogenic 
cytokines TGFβ (transforming growth factor-beta) and PDGF (platelet-derived growth factor).  
 
FIBROSIS PHASE: Fibroblasts become activated, proliferate and synthesise increased extracellular matrix, CTGF 
(connective tissue growth factor), TGFβ and other cytokines. Endothelial cells may proliferate, forming fibrovascular 
granulation tissue. The scar tissue is then remodelled, becoming less cellular, and the final result is subconjunctival 
scarring.      
 
Other abbreviations in Figure 1.5: APC antigen presenting cell, m-CSF macrophage-colony stimulating factor, MIF 
macrophage migration inhibitory factor, NFkB nuclear factor-kappa B, HSP47 heat shock protein 47, ECM 
extracellular matrix, mmps matrix metalloproteinases, timps tissue inhibitors of matrix metalloproteinases.  
 
Adapted from Elder (Elder, 1997c) and Razzaque (Razzaque et al., 2003a)   46
                                  
1.6 Current knowledge about the inflammatory and fibrotic 
response in ocular MMP 
Unlike tissue remodelling that occurs after an acute non-repetitive injury, for 
example fibrosis following a chemical or thermal burn, fibrosis associated with 
chronic repetitive injury, such as that observed in MMP following autoantibody 
binding to the BMZ, is unique in that the adaptive immune response plays an 
important role (Wynn, 2004).  The persistent inflammatory stimulus leads to 
lymphocyte-monocyte interactions that sustain the production of growth factors, 
proteolytic enzymes and fibrogenic cytokines, which together stimulate continued 
connective tissue deposition.   
1.7  The inflammatory cell response in ocular MMP 
Immunohistopathology and cellular phenotyping studies have described the 
inflammatory cellular response in human ocular MMP (Bernauer et al., 1993b; Rice 
& Foster, 1990; Sacks et al., 1989). Bernauer et al evaluated the histopathological 
findings according to disease activity, in acute, subacute and chronic disease. 
These studies provide detailed phenotypic information but limited functional 
information. 
 
In acute disease, subepithelial bulla formation is accompanied by inflammatory 
infiltration of the substantia propria by neutrophils, macrophages, dendritic antigen-
presenting cells, T lymphocytes and some plasma cells.  In acute disease, there is 
an abundance of neutrophils (42-fold increase) and macrophages (5-fold increase), 
and a 10-fold increase in T lymphocytes (Bernauer et al., 1993b) in the substantia 
propria.  A relatively high CD4/CD8 ratio (1.0) occurs in acute disease, probably 
reflecting the role of CD4+ T helper cells in recruiting other inflammatory cells.  
There is also markedly increased (6-fold) expression of major histocompatibility 
class (MHC) II molecules (HLA-DR) by fibroblasts, macrophages and lymphocytes,   47
which indicates the potential for local antigen presentation to T helper cells 
(Bernauer et al., 1993b).  The epithelium in acute disease shows marked infiltration 
by neutrophils and macrophages, as well as increased numbers of dendritic cells, 
CD4+ lymphocytes and diffuse HLA-DR expression in some cases (Bernauer et al., 
1993b; Rice & Foster, 1990).  Other inflammatory cells present at increased levels 
in the substantia propria include mast cells (Hoang-Xuan et al., 1989; Yao et al., 
2003) and a small number of eosinophils (Letko et al., 2002).   
 
During subacute disease in the stroma, the greatest number of T lymphocytes is 
observed (36-fold increase) and the CD4/CD8 ratio is 0.4 (Bernauer et al., 1993b; 
Letko et al., 2002).  Stromal MHC class II expression is dramatically elevated (10-
fold), and, although less elevated than in acute disease, numbers of both 
macrophages (3-fold) and neutrophils (8-fold) in the stroma are still increased.  The 
epithelium in subacute disease still shows elevated numbers of neutrophils 
(Bernauer et al., 1993b).   
 
Chronic disease is characterized by cell-mediated immune processes, as 
evidenced by persistent elevation of T lymphocytes four- (Bernauer et al., 1993b) 
to 20-fold (Sacks et al., 1989), HLA-DR expressing cells (4-fold), macrophages (3-
fold) and dendritic cells (Sacks et al., 1989).  The CD4+/CD8+ ratio is 0.5 
(Bernauer et al., 1993b).  Both Bernauer et al. and Rice et al found only low 
numbers of B lymphocytes and natural killer (NK) cells at any stage of disease, 
however Sacks et al found elevated B cell and plasma cell numbers in chronic 
disease.  The epithelium in chronic disease can be normal (Bernauer et al., 1993b) 
or show increased numbers of T cells and dendritic cells (Sacks et al., 1989).   
 
Clearly, local T lymphocyte proliferation plays a role in acute, subacute and chronic 
“white” inflammation in MMP.  5-10% of the T cells in all phases of disease express 
IL-2 receptor (CD25), which in this setting is probably a marker of activation.  CD25 
can also be a marker for a subset of regulatory T cells (CD25
+CD4
+Treg) (Andre et   48
al., 2009).  In active ocular MMP there appears to be a disproportionately 
increased number of T cells expressing the T cell receptor γ/δ heterodimer, unlike 
the majority of T cells in normal conjunctiva which express the α/β heterodimer 
(Soukiasian et al., 1992).  γ/δ T cells recognize specific antigens such as heat-
shock proteins (HSP), which are known to be elevated in the substantia propria in 
ocular MMP (Razzaque et al., 2003b).  This interaction may be significant in the 
ongoing autoimmune inflammation observed in ocular MMP.   
1.8 The inflammatory mediator and cytokine response in ocular 
MMP 
Inflammatory mediator and cytokine events occurring during the acute phase of 
ocular MMP are likely to be similar to those described during acute inflammation 
following complement activation in other clinical settings. Circumstantial evidence 
suggests a role for several inflammatory mediators and cytokines in acute MMP, 
based on results of immmunohistochemical staining for protein expression 
(Bernauer et al., 1993a), in situ hybridization studies of mRNA (messenger RNA) 
expression (Caproni et al., 2003), and serum cytokine levels (Kumari et al., 2001; 
Lee et al., 1993).  
 
Although the actual pathways described here have not yet been demonstrated in 
ocular MMP, they are provided to give an indication of the most likely sequence of 
events. Activation of the complement cascade results in production of the 
inflammatory mediators C3a, C5a and bradykinin, increased blood supply, 
increased vascular permeability, and neutrophil and monocyte chemotaxis (Male & 
Roitt, 1998).   Damaged epithelial and/ or endothelial cells release inflammatory 
mediators that initiate an antifibrinolytic coagulation cascade, which triggers 
formation of blood clot and a provisional ECM (Wynn, 2008).  Platelets become 
activated upon exposure to ECM components, and can also be activated by 
platelet-activating factor (PAF) from neutrophils and macrophages. Degranulation 
of mast cells and platelets is important in the initiation and development of acute   49
inflammation, as sources of histamine and 5-hydroxytryptamine which produce 
vasodilation and increased vascular permeability. Matrix metalloproteinases 
(mmps) produced by epithelial and /or endothelial cells and activated fibroblasts 
disrupt the basement membrane and allow recruitment of inflammatory cells like 
neutrophils and monocytes. Monocytes transform into activated macrophages and 
release inflammatory mediators including interleukin-1 (IL-1), a multifunctional 
cytokine playing a key role in inflammation.  It is likely that they also release tumour 
necrosis factor-α (TNFα), another multifunctional acute inflammatory cytokine (see 
below).   
 
Both IL-1 and TNFα induce activation of macrophages and lymphocytes, increase 
leukocyte endothelial adhesion and induce lymphocyte secretion of 
proinflammatory cytokines such as interferon-γ (IFNγ) and IL-2 (Male & Roitt, 
1998).  They have also been shown to induce the expression of growth factors 
such as m-CSF (macrophage-colony stimulating factor) and macrophage migration 
inhibitory factor (MIF) by human conjunctival fibroblasts (Razzaque et al., 2002; 
Razzaque et al., 2004).   
 
Cytokines and chemokines produced by neutrophils and macrophages are 
mitogenic and chemotactic for endothelial cells, which help form new blood vessels 
and granulation tissue. During this period, lymphocytes infiltrate and become 
activated, and secrete cytokines.  The cytokine profile observed in the acute phase 
of MMP indicates a mixed helper T cell type 1 (Th1) and type 2 (Th2) response.  
Although the helper T cell populations playing a role in the mucosal immune 
response in MMP may be more complex than simply Th1 and Th2 subsets, the 
Th1- Th2 paradigm is useful as an initial framework.  Whilst the cellular source of 
the cytokines has not been confirmed as T cells or other cells in these studies, both 
IL-2 and IFNγ have been detected in MMP tissues in acute disease suggesting a 
Th1 response, since T cells are the main source of these two cytokines (Bernauer 
et al., 1993a; Caproni et al., 2003). IL-4 and IL-5 (Caproni et al., 2003; Razzaque   50
et al., 2003a) have also been detected, suggesting a Th2 response, although mast 
cells and other non-T cells can also secrete these cytokines.  Elevated serum 
levels of IL-5 during active MMP have also been reported (Letko et al., 2002).  In 
subacute and chronic disease, IFNγ and IL-2 are less frequently detected 
(Bernauer et al., 1993a) whilst IL-5, and some IL-4 in the epithelium, is still present 
albeit at lower levels (Caproni et al., 2003), indicating that a Th2- type response is 
still present but at reduced levels.    
1.8.1  Current evidence for the role of TNFα in ocular MMP 
Elevated serum levels of both IL-1α and β (Kumari et al., 2001) and TNFα, but 
decreased levels of IL-6 (Lee et al., 1993) have been reported in patients with 
active ocular MMP.  There have been 3 small studies investigating the presence of 
TNFα in MMP tissues:  Bernauer et al found abundant TNFα levels in both normal 
and diseased conjunctiva (Bernauer et al., 1993a);  Caproni et al reported 
moderate focal TNFα expression on the capillary endothelium and on the 
perivascular infiltrate in submucosal/ dermal tissue in patients with genital (n=2), 
oral (n=1) and ocular MMP (n=1) (Caproni et al., 1997), and Cordero Coma et al 
have reported absence of TNFα in normal conjunctiva and prominent TNFα 
expression in the conjunctival stroma and epithelium of 8 ocular MMP patients 
(Cordero et al., 2007). None of these studies evaluated the effect of systemic 
immunosuppressive treatment on tissue expression of TNFα.  
1.9 The fibrogenic growth factor and cytokine response in ocular 
MMP 
Profibrotic cytokines and growth factors previously detected in MMP include TGFβ, 
CTGF, IL-4, IL-5, PDGF, and FGF. 
1.9.1  Transforming growth factor-β (TGFβ) 
In acute ocular MMP, Elder and Bernauer found increased stromal levels of 
transforming growth factor (TGF) β1 & β3, which appeared to localize to   51
macrophages, fibroblasts and plasma cells (Bernauer et al., 1993a; Elder et al., 
1997). Caproni et al found similar TGFβ mRNA expression in the lesions of both 
acute and chronic MMP irrespective of disease activity, and also in bullous 
pemphigoid, a non-scarring immunobullous disorder.  They concluded from this 
that TGFβ may not play a key role in fibrosis in MMP, but given that the regulation 
of TGFβ is largely post-transcriptional (Leask & Abraham, 2004), their findings do 
not exclude a role for TGFβ in fibrosis in MMP.  
 
In subacute ocular MMP, TGFβ, PDGF and FGF are elevated, but in chronic 
disease these cytokines are only present at low levels (Bernauer et al., 1993a; 
Elder et al., 1997). This may indicate that once macrophages and fibroblasts are 
present in large numbers and activated, they become self regulating and remain 
functionally abnormal after the withdrawal of cytokine influences.  On the other 
hand, it may also indicate that fibrosis occurs predominantly during the acute and 
subacute low grade inflammatory phases, rather than in chronic, burnt out or 
inactive disease.   
 
Transforming growth factor (TGF)-β acts on most cell types and stimulates wound 
healing, fibrosis and matrix production, blocks matrix degradation by proteases, 
and facilitates cell adhesion to matrix components (Leask & Abraham, 2004).  
TGFβ1 is also an important immunoregulatory cytokine that maintains self-
tolerance and T cell homeostasis, by inducing regulatory T cell differentiation and 
inhibiting T cell proliferation and differentiation (Bommireddy & Doetschman, 2007). 
TGFβ1 has a distinct biphasic nature, functioning as a potent chemoattractant for 
macrophages/ monocytes, neutrophils and lymphocytes during the early 
recruitment or activation phase of the immune response, then later suppressing 
these events during the resolution of an immune response (Prud'homme & 
Piccirillo, 2000). Recently it has been shown that TGFβ plays a dual role in 
autoimmune-mediated organ damage in a mouse model of lupus, where 
decreased TGFβ in immune cells predisposes to autoantibody production, which   52
then causes tissue inflammation that triggers production of anti-inflammatory 
cytokines such as TGFβ in target organs to counter inflammation, but the 
enhanced TGFβ in target organs then leads to dysregulated tissue repair and 
fibrogenesis (Saxena et al., 2008). 
 
Both TGFβ1 and β3 have been detected in ocular MMP (Elder et al., 1997). All 3 
isoforms of TGFβ have been shown in vitro to stimulate collagen contraction, 
proliferation and migration of human Tenon’s capsule fibroblasts, and to induce 
conjunctival scarring in mouse model (Cordeiro et al., 2000), however addition of 
the exogenous TGFβ3 isoform to cutaneous wounds reduces scar tissue 
formation, and TGFβ3 has been developed for human trials as an anti-scarring 
therapy (Occleston et al., 2008).  Studies investigating therapeutic anti-TGFβ 
antibodies have so far been disappointing. A recent clinical trial of anti-TGFβ1 in 
systemic sclerosis patients showed no improvement in the extent of skin 
involvement (Denton et al., 2007). Despite initial promising results, subconjunctival 
injection of anti-TGFβ2 has not been shown to be successful in preventing 
conjunctival scarring following glaucoma filtration surgery (Khaw et al., 2007); 
modification of the dosing regimen may have improved the outcomes. It is also 
possible that TGFβ1 plays a greater role in conjunctival scarring than TGFβ2.  
1.9.2  CTGF (connective tissue growth factor) 
Connective tissue growth factor (CTGF), an important downstream mediator of 
TGFβ-induced collagen synthesis, has been shown to be expressed at increased 
levels in the stroma and by conjunctival fibroblasts in ocular MMP (Razzaque et al., 
2003c). TGFβ blockade reduces the expression of CTGF and type I collagen by 
conjunctival fibroblasts (Razzaque et al., 2003c). CTGF is the key profibrotic 
mediator of TGFβ1-induced matrix synthesis, myofibroblast differentiation and 
matrix contraction that is involved specifically in the TGFβ-induced tissue response 
to injury and not the other TGFβ-induced immune suppressor functions. It may thus 
be a more attractive, selective target for inhibition than TGFβ (Garrett et al., 2004).     53
1.9.3  PDGF and FGF 
Platelet derived growth factor (PDGF) is produced by activated macrophages, 
fibroblasts, endothelial cells and smooth muscle cells and stimulates both fibroblast 
proliferation and connective tissue production. Fibroblast growth factor (FGF), also 
produced by activated macrophages, appears to be less fibrogenic than PDGF, 
given that it stimulates fibroblast proliferation but not connective tissue production 
(Elder, 1997c).   
1.9.4  Interleukin- 4 (IL-4)  
Although Bernauer did not detect expression of the Th2 cytokine IL-4 in MMP, 
others have subsequently detected both protein and mRNA expression of IL-4  and 
IL-5 in MMP (Caproni et al., 2003; Razzaque et al., 2003a) (see section 1.5.2 
above).   
 
Although the extent to which IL-4 participates in the progression of fibrosis can vary 
according to the disease, some studies indicate that IL-4 is nearly twice as efficient 
at mediating fibrosis as TGFβ (Wynn, 2004).  IL-4 is produced by Th2 lymphocytes, 
mast cells, fibroblasts and eosinophils.  It acts on T lymphocytes, fibroblasts and B 
cells.  Its actions on fibroblasts include stimulating chemotaxis (Postlethwaite & 
Seyer, 1990), proliferation and synthesis of extracellular matrix proteins 
(Postlethwaite et al., 1992), and prevention of apoptosis (Fujitsu et al., 2005).  It is 
a potent inducer of TGFβ and macrophage colony-stimulating factor (m-CSF) 
production by pulmonary fibroblasts (Jakubzick et al., 2004).  It also has several 
actions on fibroblasts in common with IL-13 (see section 1.11), in part because 
both cytokines use the same IL-4 receptor α-chain signaling pathway.  The other 
actions of IL-4 include inducing differentiation of CD4+ cells into Th2 cells, 
amplifying inflammatory responses, regulating differentiation of, and increasing IgE 
production.  Blocking the bioactivities of IL-4 results in significant inhibition of the 
healing process (Jakubzick et al., 2004; Ong et al., 1998). Recently it has been 
reported that IL-4 promotes tissue inflammation by suppressing generation of   54
Foxp3
+ regulatory T cells, and that furthermore the combination of TGFβ and IL-4 
(as found in ocular MMP) induces the generation of a distinct population of Foxp3
- 
IL-9
+ IL-10
+ T cells that also promote chronic inflammation (Dardalhon et al., 2008).  
 
IL-4 is produced at increased levels by ocular MMP fibroblasts compared to normal 
fibroblasts (Razzaque et al., 2003a).  IL-4 has also been detected in lymphocytes, 
plasma cells, mast cells and eosinophils in oral and ocular MMP (Caproni et al., 
1997; Caproni et al., 2003). Serum levels of IL-4 are not elevated, indicating that 
only local tissue production of IL-4 takes place (Razzaque et al., 2003a).  IL-4- 
stimulated conjunctival fibroblasts produce increased levels of heat shock protein 
47 (HSP47), type I collagen and m-CSF (Razzaque et al., 2003a).   
1.9.5 IL-5 
IL-5 is a Th2 type fibrogenic cytokine produced by Th2 lymphocytes, mast cells, 
eosinophils and monocytes.  It stimulates the proliferation and activation of 
eosinophils, which have been shown to be key cellular sources of profibrotic 
mediators in pulmonary fibrosis.  Elevated serum levels of IL-5, as well as elevated 
numbers of eosinophils in the peripheral blood and conjunctival stroma, have been 
reported in active ocular MMP (Letko et al., 2002), however the numbers of 
eosinophils present in comparison to other inflammatory cells is not high (6 
eosinophil cells/cm
2 compared to 114 neutrophils/mm
2 or 74 T lymphocytes /mm
2) 
(Bernauer et al., 1993b), so the role of IL-5 in fibrosis in ocular MMP is probably 
limited.   
1.10 Summary of the fibrogenic cellular response in ocular MMP 
The key cells involved in fibrosis in ocular MMP include macrophages, T cells and 
fibroblasts. It is possible that epithelial cells and epithelial-mesenchymal transition 
(EMT) also play a role in fibrotic remodeling in MMP, given that chronic mucosal 
injury is involved, but to the author’s knowledge this has not yet been investigated 
in MMP.    55
1.10.1  Macrophages 
Macrophages are essential in wound healing and promote the transition from 
inflammation to new tissue formation by secreting growth factors like TGFβ, IL-4 
and PDGF (Mosser & Edwards, 2008).  Razzaque et al have shown that local 
macrophage accumulation in ocular MMP is due to increased macrophage 
migration inhibitory factor (MIF) and macrophage- colony stimulating factor (m-
CSF) expression in the epithelium and stroma.  Both of these growth factors are 
produced by MMP conjunctival fibroblasts and their production is induced by IL-1 
and TNFα and by TGFβ (Razzaque et al., 2002; Razzaque et al., 2004). 
1.10.2 T cells 
Although macrophages and fibroblasts are the main effector cells of fibrosis, the 
dramatic local tissue infiltration of T cells in subacute, acute and chronic ocular 
MMP suggests that they are likely to play a role in fibrogenesis in this disease.  T 
cells can contribute to fibrosis both directly by elaborating cytokines which recruit 
and activate fibroblasts, and indirectly by activating macrophages which then 
release fibroblast growth factors.  
Functional T cell subsets 
Studies of cytokine-deficient mice have shows that fibrogenesis is strongly linked 
with the development of a T helper 2 (Th2) CD4+ T cell inflammatory response, 
involving IL-4, IL-5 and IL-13. Th2-polarized immune responses are primarily 
induced by disturbances at mucosal surfaces (Mosser & Edwards, 2008).  In 
contrast, when T helper 1 (Th1) inflammatory responses dominate, and produce 
IFNγ, tissue fibrosis is almost completely attenuated (Wynn, 2004).  The cytokine 
profile observed in the acute phase of MMP suggests a mixed helper T cell type 1 
(Th1) and type 2 (Th2) response (see previous section 1.7).   
T cell activation and costimulatory molecules 
The process of activating T cells and the adaptive immune response first involves 
non-specific, reversible binding between antigen presenting cells (APCs) and T   56
cells via adhesion molecules, such as ICAM (intercellular adhesion molecule) 
interacting with lymphocyte functional antigen-1 (LFA-1).  Optimal T cell activation 
subsequently requires two signals to produce maximal amounts of cytokines and to 
proliferate: T cell receptor occupancy by the antigenic peptide bound to class II 
major histocompatibility complex (MHC) such as HLA-DR, as well as a second 
nonantigen-specific “costimulatory” signal provided by T cell-APC contact.  
Engagement of the T cell receptor in the absence of a costimulatory signal can 
induce anergy (Corrigall et al., 2000). Ligand-receptor pairs which play a prominent 
role in costimulating T cell activities include B7/CD28 which mediates afferent 
signals to T cells, and CD40/CD40 ligand which mediates efferent signals to the 
targets of T cells (Crow, 2006).  
 
The B7/CD28 costimulatory pathway consists of two ligands on APCs, B7-1 
(CD80) and B7-2 (CD86), each of which can engage CD28, the costimulatory 
receptor on T cells.  There is also an inhibitory receptor for the B7 ligands, CTLA-4 
(cytotoxic T lymphocyte- associated antigen 4 / CD152), which is upregulated after 
T cell activation has peaked, and limits the degree of activation.  Both B7-1 (CD80) 
and B7-2 (CD86) are constitutively expressed on dendritic cells, and their 
expression on macrophages and B cells and other APCs can be upregulated by 
activation with IFNγ or lipopolysaccharide (Bhatia et al., 2006).  Whilst B7-1 (CD80) 
is expressed in a tightly regulated manner on activated but not resting B cells, B7-2 
(CD86) is constitutively expressed on the cell surface of APCs and rapidly 
upregulated upon interaction with CD28, with peak expression at 48 hours.  
Expression of B7-1 (CD80) is slowly induced and is stable for 4-5 days.  CD80 and 
CD86 have been shown to modulate Th1/Th2 T cell differentiation.  CD80 
preferentially favours Th1-type T cell differentiation, while CD86 augments IL-4 
production and Th2 type T cell responses (Kuchroo et al., 1995).   
 
The CD40/CD40 ligand pathway plays a key role in T cell effector functions that 
determine the overall activity of the immune response (Crow, 2006). CD40 is   57
expressed on all APCs, including B cells and endothelial cells.  CD40 ligand 
(CD40L or CD154) is expressed on activated CD4
+T cells and on a subset of 
CD8
+T cells and natural killer cells.  CD40 stimulation triggers important signals for 
antibody production by B cells, and strongly induces B7 and MHC expression on 
APCs, thus increasing antigen presentation by an important co-stimulatory 
pathway.  The role of CD40 signalling in regulation of inflammation and fibrosis has 
been demonstrated in the lung (Kaufman et al., 2001; Sempowski et al., 1997). 
During an inflammatory response, fibroblasts increase their expression of CD40, 
and interactions between tissue fibroblasts and infiltrating T lymphocytes via the 
CD40/CD40L pathway have been proposed to to powerfully costimulate T 
lymphocyte proliferation as well as induce fibroblasts to produce proinflammatory 
and chemoattractant cytokines. This in turn may lead to fibroblast proliferation and 
extracellular matrix synthesis. Chronic stimulation through CD40 may hence lead 
to fibrosis. Furthermore, it has been reported that primary human lung fibroblasts 
express CD40 ligand (CD154), which is usually not known to be expressed on non-
bone marrow-derived structural cells (Kaufman et al., 2004). This expression is 
increased in fibroblasts from scarred lungs, and may promote fibroblast activation 
and interaction with CD40-expressing cells. 
 
In ocular MMP, Tesavibul et al have found upregulated subepithelial stromal CD86  
but not CD80 expression in active disease, which is consistent with the 
development of a Th2 type fibrogenic response (Tesavibul et al., 1998).  There do 
not appear to be any studies investigating the role of CD40 in MMP. 
 
Cell surface expression of ICAM, HLA-DR, CD80, CD86 or CD40 by fibroblasts 
acting as APCs in ocular MMP could indicate a mechanism for cross-talk between 
fibroblasts and T cells, which thus promotes fibroblast and T cell activation, chronic 
inflammation and fibrosis.     58
Direct lymphocyte-fibroblast interactions in wound healing and fibrosis 
Apart from the indirect effect of the Th2 cell-secreted cytokines IL-13 and IL-4 
acting on fibroblasts to cause fibrosis, there is evidence to suggest that direct 
interactions between T lymphocytes and fibroblasts perpetuate chronic 
inflammation, and this may hence lead to further fibrosis and remodelling. In 
rheumatoid arthritis, fibroblast-like synoviocytes and T cells in co-cultures have 
been shown to interact in a similar manner to professional APC-T cell interactions, 
to induce a proliferative response and increased release of inflammatory mediators 
(Tran et al., 2008). Ligation of CD40-positive human intestinal fibroblasts by CD40 
ligand-positive T cells generates fibroblast-derived chemoattractants that induce T 
cell migration (Vogel et al., 2004).  T cell viability is significantly greater when T 
cells are co-cultured with human Tenon’s fibroblasts, and fibroblast production of 
IFNβ, which prevents T cell apoptosis, appears to be the mechanism by which this 
occurs (Chang et al., 2001).  
1.10.3 Fibroblasts 
Activation and proliferation of fibroblasts is primarily responsible for the scarring 
response, and this has been detected in MMP (Bernauer et al., 1993a; Caproni et 
al., 1997).  Significant staining for both ICAM-1 (intercellular adhesion molecule-1) 
and VCAM (vascular cell adhesion molecule) on perivascular fibroblasts, indicating 
fibroblast activation, has been detected in oral and cutaneous tissue affected by 
MMP (Giomi et al., 2005).  
 
The absence of detectable fibrogenic cytokines TGFβ, PDGF and FGF in chronic 
ocular MMP, has led to a hypothesis that in chronic disease the fibroblasts may be 
hyperactivated and behave independently from cytokine influences, to sustain their 
own growth and cause fibrosis. There have been limited studies investigating this 
hypothesis. Ocular MMP conjunctival fibroblasts are reported to be 
hyperproliferative in culture compared with normal conjunctival fibroblasts (Roat et 
al., 1989).  Preliminary studies have also described expression of the proto-  59
oncogene c-myc by ocular MMP fibroblasts (Hunt LE, et al. IOVS 1991;32:ARVO 
Abstract 938), and ultrastructural changes indicating increased protein synthesis 
which persist in culture (Biesman BS et al. IOVS 1994;Suppl 35(4):ARVO Abstract 
170). Increased expression of collagen type I, TGFβ1, macrophage migration 
inhibitory factor, macrophage-colony stimulating factor, connective tissue growth 
factor and heat shock protein 47 by ocular MMP conjunctival fibroblasts compared 
with normal conjunctival fibroblasts has also been reported (Razzaque et al., 
2003b; Razzaque et al., 2004).  
 
Fibroblast synthesis of ECM (extracellular matrix) leads to formation of new 
connective tissue in the substantia propria. The degree of scarring is dependent on 
the balance between collagen synthesis by fibroblasts and collagen degradation 
controlled by matrix metalloproteinases (mmps) and their inhibitors (tissue 
inhibitors of matrix metalloproteinases, TIMPs). Unpublished observations suggest 
that expression of mmp-1 and -14 and TIMP-1,-2, and -3 are increased in 
fibroblasts isolated from the conjunctiva of ocular MMP patients (Razzaque et al., 
2001). 
 
The substantia propria of ocular MMP conjunctiva shows increased type I and type 
III collagen staining (Dutt et al., 1996; Razzaque et al., 2003b).  These collagen 
fibrils are highly disorganized (Galbavy & Foster, 1985).  There is also aberrant 
type IV and type VII collagen production, which appears to be repair in response to 
the basement membrane zone damage.  Formation of collagen in ocular MMP 
appears to involve heat shock protein 47 (HSP47), a collagen-binding protein 
which plays an important role in the biosynthesis of procollagens.  Razzaque et al 
(Razzaque et al., 2003b) have shown that HSP47 is expressed at increased levels 
by stromal conjunctival fibroblasts in ocular MMP, and its production is increased 
by TGFβ1.    60
Fibroblast functions in wound healing and fibrosis 
The fibroblast is the central cell in wound healing and fibrosis.  The functions of 
fibroblasts have been arbitrarily subdivided into four aspects: proliferation, 
migration, matrix synthesis and remodelling. Myofibroblasts, which are specialized 
differentiated fibroblasts, are involved in the latter two aspects of extracellular 
matrix synthesis, and tissue contraction and remodelling (Tomasek et al., 2002). In 
addition, fibroblasts function as regulators of the inflammatory response, prevent T 
cell apoptosis and contribute to persistent inflammation (Flavell et al., 2008). 
Fibroblast-induced prevention of T cell apoptosis could be an explanation for the 
persistent T cell infiltrate which has been observed in chronic (“white 
inflammation”) ocular MMP (Bernauer et al., 1993b; Elder, 1997c; Sacks et al., 
1989).  
 
In addition to being derived from resident mesenchymal cells, fibroblasts and 
myofibroblasts can be derived from other sources, including epithelial cells via 
epithelial-mesenchymal transition (EMT), and from circulating bone marrow-
derived cells called fibrocytes (Wynn, 2008). This may in part account for fibroblast 
heterogeneity that exists both within and between tissues. Fibroblasts from distinct 
bodily sites exhibit differences in their proliferative and biosynthetic capacity 
(Flavell et al., 2008), and this finding has subsequently been found to be true of 
fibroblasts from the same connective tissue bed, which have been isolated from 
different morphological locations within that connective tissue bed (Abraham et al., 
2007). Thus, it is believed that fibroblasts exist in distinct subpopulations within 
connective tissues, that can be considered distinct differentiated cell types. 
Migration 
Fibroblast migration plays an important role in fibrosis.  This is controlled by 
specific polypeptides acting as chemoattractants.  Overproduction of chemotactic 
factors may result in excessive scarring.  Other factors influencing fibroblast 
motility include mechanisms to clear space within the extracellular matrix, which   61
enable fibroblasts to penetrate and move through the matrix.  Space-clearing can 
be achieved by phagocytosis, as well as by enzymes such as plasmin, 
plasminogen activator, and matrix metalloproteinases (mmps) which include 
collagenases (mmp-1, 8, 13), gelatinases (mmp-2, 9) and stromelysins (mmp-3, 10 
and 13).  The movement of the cells may, in itself, cause traction and wound 
contraction.   
Extracellular matrix synthesis, remodelling and matrix contraction 
Fibroblasts are the principle biosynthetic cells secreting the extracellular matrix 
(ECM) components fibronectin, glycosaminoglycans and tropocollagen, which then 
cross-link to form collagen. Type III collagen is the first type of collagen to fill a 
wound. Type III is replaced by type I collagen, the mature form, with time. Collagen 
and ECM production by fibroblasts is remodelled with continuous synthesis and 
breakdown of the matrix.  The amount of ECM turnover at the wound depends on 
the extent of matrix metalloproteinase activity (Wong et al., 2002).  Apart from the 
key role of myofibroblasts in matrix contraction (Tomasek et al., 2002), fibroblast-
mediated matrix contraction in vitro has also been shown to involve matrix 
metalloproteinase (mmp) production, and mmp inhibition reduces this matrix 
contraction, as well as reducing collagen synthesis (Daniels et al., 2003a).  Matrix 
metalloproteinase physiology is complex and incompletely understood, given that 
increased mmp production can either increase scar tissue formation by promoting 
fibroblast migration and wound contraction, or decrease scar tissue by favouring 
matrix breakdown and reducing the net level of collagen present.     
Fibroblast-mediated chronic inflammation 
Although fibroblasts were originally thought of as merely structural cells, it is now 
clear that they take a much more active role in defining a tissue’s 
microenvironment by synthesizing chemokines, cytokines and growth factors (Filer 
et al., 2006), and provide navigation cues for retention of leukocytes within tissues 
via a stromal address code created by the expression of crucial molecules   62
(Parsonage et al., 2005).  Fibroblasts can also participate in direct cross-talk with 
lymphocytes by expressing CD40 (Kaufman et al., 2001).  
 
It has been proposed that fibroblasts regulate the switch from acute resolving to 
chronic persistent inflammation (Buckley et al., 2001).  Failure to switch off the 
inflammatory stimulus from fibroblasts may lead to the inappropriate survival and 
retention of leukocytes within inflamed tissue. Production of interferon-β by human 
Tenon’s fibroblasts, as a mechanism by which fibroblasts prevent T cell apoptosis 
and perpetuate chronic conjunctival inflammation, has been reported (Chang et al., 
2002). Dysregulated expression of CD40 ligand (CD154), which is usually only 
expressed by bone marrow-derived non-structural cells, has been reported in 
fibrotic lung tissue fibroblasts. Selective expansion of fibroblasts expressing such 
CD40 ligand could result in chronic autocrine and paracrine activation of fibroblasts 
via this pathway (Kaufman et al., 2004). 
Fibroblasts derived from diseased fibrotic tissue display an autonomously activated 
phenotype 
Whilst inflammation typically precedes the development of fibrosis in most fibrotic 
disorders, some experimental models suggest that fibrosis is not always 
characterized by persistent inflammation, and that to a degree, the mechanisms 
regulating fibrosis are distinct from those controlling inflammation (Stramer et al., 
2007).  In line with this viewpoint, fibroblasts derived from patients with systemic 
sclerosis, pulmonary fibrosis, colonic fibrosis and renal fibrosis have been shown to 
display a constitutively activated phenotype in the absence of the fibrotic tissue 
milieu, with aberrations in processes that govern nearly every aspect of the 
fibroproliferative response (proliferation, resistance to apoptosis, motility, 
contractile function, matrix synthesis) (Ramos et al., 2001; Rieder et al., 2007; 
Schuttert et al., 2003; Varga & Abraham, 2007; Wallach-Dayan et al., 2007). Whilst 
the abnormal phenotype has initially emerged in the context of exogenous signals 
from matrix, cytokines, chemokines and growth factors, it is retained during many   63
passages in vitro, indicating fundamental changes in gene expression pathways 
(Larsson et al., 2008).   
 
Together, this data suggests that in order to inhibit fibrosis in ocular MMP, local 
therapy targeting abnormally activated fibroblasts, or preventing the mechanisms 
leading to the abnormally activated phenotype, may be necessary.  Furthermore, 
this may control any ongoing fibroblast-stimulated chronic inflammation.   
1.11 Rationale for selecting TNFα for investigation 
Tumour necrosis factor-alpha (TNFα) is an important proinflammatory cytokine 
produced by macrophages, T and B lymphocytes, natural killer cells, neutrophils, 
smooth muscle cells, endothelial cells, and fibroblasts. TNFα exists in 2 forms, a 
membrane-bound form and a soluble form, both of which are functional and 
contribute to the effects of TNFα. TNFα has multiple actions, including 1) activating 
macrophages, neutrophils and cytotoxic T cells, 2) upregulating endothelial cell 
adhesion molecules to enable leukocyte entry into tissues, 3) being a comitogen 
for T and B cells and 4) inducing IL-2 receptor on activated T cells, and 5) having 
effects on fibroblasts.  
 
The effects of TNFα on fibroblasts and fibrosis are controversial because whilst 
some studies show anti-fibrotic effects of TNFα in vitro on dermal fibroblasts 
(Chizzolini et al., 2003; Goldberg et al., 2007) and on corneal fibroblasts (Saika, 
2007), others show profibrotic effects on fibroblasts in vitro (Chou et al., 1996; 
Sullivan et al., 2005; Theiss et al., 2005). Moreover, in vivo animal studies of TNFα 
antagonists and mice deficient in TNF receptors indicate that inhibition of TNFα 
signaling can prevent fibrosis (Farivar et al., 2005; Guo et al., 2001; Liu et al., 
1998; Piguet & Vesin, 1994; Sudo et al., 2005).  It has been proposed that these 
differences in results might be explained by TNFα playing a major proinflammatory 
role in triggering fibrosis in animal models, and the direct in vitro anti-fibrotic effects 
of TNFα on fibroblasts might be outweighed in animal models of fibrosis by its   64
important role in driving inflammation (Distler et al., 2008). Furthermore, a recent 
report suggests that in clinical practice (rather than in experimental models), TNFα 
antagonists are beneficial in the treatment of fibrotic disorders such as systemic 
sclerosis (Lam et al., 2007). 
 
TNFα antagonist therapy has been shown to safely and successfully control 
inflammation in autoimmune diseases such as rheumatoid arthritis and uveitis 
(Furst et al., 2008; Hale & Lightman, 2006). Apart from TNFα inhibition, this 
therapy has also been shown to induce regulatory T cell activity in rheumatoid 
arthritis (Ehrenstein et al., 2004), and to induce T cell apoptosis in Crohn’s disease 
(van den Brande et al., 2003). It would be opportune to use this therapy to control 
inflammation in MMP, and case reports have described seven MMP patients who 
improved following TNFα antagonist therapy (see section 1.4.4), however there 
are limited studies investigating whether TNFα is expressed in MMP tissues (see 
section 1.7.1). Tissue expression appears to be important because synovial 
expression of TNFα appears to be a significant predictor of response to TNFα 
antagonists in rheumatoid arthritis (Wijbrandts et al., 2007).  
 
Furthermore, given that fibroblasts isolated from different anatomical sites exhibit 
different functional properties (Flavell et al., 2008), the effects of TNFα on 
fibroblasts derived from the conjunctiva needs to be established before conducting 
larger controlled studies of the efficacy of TNFα antagonists in MMP, given that the 
therapy could potentially be profibrotic and could therefore worsen scarring. 
Leonardi et al have reported that TNFα increased mmp-9 and also mmp-1 
production, and decreased timp-1 production in response to TNFα stimulation, by 
conjunctival fibroblasts derived from vernal keratoconjunctivitis (VKC) patients 
(Leonardi et al., 2003).  The phenotype of VKC fibroblasts may be different from 
that of normal conjunctival fibroblasts, so the findings reported by Leonardi cannot 
be extrapolated to normal conjunctival fibroblasts, nor to ocular MMP conjunctival 
fibroblasts. Leonardi has reported elsewhere that normal conjunctival fibroblasts   65
secrete increased amounts of chemokines (IL-6, IL-8, MCP-1, RANTES, IP-10) in 
response to TNFα stimulation, thus confirming that normal conjunctival fibroblasts 
have receptors for and respond to TNFα stimulation (Leonardi et al., 2006). 
 
Therefore, one of the hypotheses investigated in my study was that TNFα is 
involved in inflammation in ocular MMP, and may have a profibrotic effect on 
conjunctival fibroblasts. 
1.12 Rationale for selecting IL-13 for investigation 
IL-13 is a major pro-fibrotic mediator which is produced by Th2 helper T cells, mast 
cells and basophils.  It regulates inflammation, mucus production, tissue 
remodeling and fibrosis in the lung, as well as playing a critical role in the response 
to nematode and intracellular parasite infections (Wynn, 2003).  It has become an 
important therapeutic target for a number of chronic inflammatory-fibrotic diseases 
including idiopathic pulmonary fibrosis, liver fibrosis and asthma, because animal 
models where IL-13 has been inhibited independently of IL-4 have identified IL-13 
as the dominant effector cytokine of  fibrosis (Blease et al., 2001; Chiaramonte et 
al., 1999; Kumar et al., 2002). IL-13 appears to exert its profibrotic activities via 
inducing production of latent TGFβ in macrophages, and stimulating enzymes that 
cleave and activate latent TGFβ (Wynn, 2008). It also appears to trigger fibrosis via 
TGFβ-independent mechanisms (Kaviratne et al., 2004).  
 
T cells are prominent in the conjunctival substantia propria in ocular MMP 
(Bernauer et al., 1993b), and whilst expression of the Th2 cytokines IL-4 and IL-5 
has been detected (Caproni et al., 2003; Razzaque et al., 2003a), it is not known 
whether IL-13 is expressed in ocular MMP. Anti-TGFβ therapies have not been as 
successful at preventing conjunctival scarring as initially hoped (Khaw et al., 2007), 
and it is possible that, if IL-13 is detected to be present in the chronic inflammatory-
fibrotic setting of ocular MMP, inhibition of IL-13 could block both TGFβ-mediated 
and non-TGFβ-mediated mechanisms of fibrosis.    66
 
IL-13 shares many functional activities with IL-4 because both cytokines bind to the 
type 2 IL-4 receptor (also known as IL-13Rα1, composed of heterodimeric IL-4Rα 
and IL-13Rα1 subunits), which is expressed on B cells, NK cells, monocytes, mast 
cells, endothelial cells and fibroblasts. In addition, IL-13, but not IL-4, binds with 
100-fold higher affinity for another receptor chain, IL-13Rα2, than IL-13Rα1. The 
IL-13Rα2 chain was formerly considered to only function as a decoy receptor, but 
more recently it has been shown in macrophages that IL-13 signaling via induction 
of cell-surface expression of IL-13Rα2, activates the TGF-β1 promoter to 
synthesise TGF-β and cause fibrosis (Fichtner-Feigl et al., 2006).  Induction of cell-
surface IL-13 Rα2 requires the presence of both IL-13 (or IL-4) and TNFα. My 
studies of both TNFα and IL-13 in ocular MMP could therefore be relevant to 
investigating whether this pathway is involved in fibrosis in ocular MMP. 
 
IL-13 is unique in that it is not thought to exert any control over T cell function 
(Hershey, 2003), so unlike IL-4 it does not appear to be important in the initial 
differentiation of CD4+T cells into Th2-type cells, but rather appears to be 
important in the effector phase of inflammation and repair, via its effects on 
monocytes/ macrophages, dendritic cells, fibroblasts and other inflammatory and 
stromal cells. Somewhat paradoxically, IL-13 was originally described as a T cell 
derived cytokine that inhibits inflammatory cytokine production, but its other 
effector functions were discovered from several unique animal models which 
promoted or blocked IL-13 activity (Wynn, 2003).  It has been proposed that the 
greater fibrogenic activity of IL-13 over IL-4 may in part be related to the much 
higher concentrations of IL-13 present, which often exceeds those of IL-4 by a 
factor of 10-100, and partly also due to IL-13 using an additional fibrogenic 
signaling pathway, which is distinct from the IL-4Rα pathway which it has in 
common with IL-4 (Wynn, 2008).  
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IL-13 has been shown to exert direct pro-fibrotic effects on fibroblasts isolated from 
human lung and skin (Ingram et al., 2003; Kohyama et al., 2004; Liu et al., 2002; 
Saito et al., 2003) including stimulation of proliferation, chemotaxis and collagen 
gel contraction, but fibroblasts isolated from different bodily sites exhibit different 
functional properties and site-specific gene expression (Flavell et al., 2008), so 
these effects cannot be extrapolated to fibroblasts from other tissues such as the 
conjunctiva. The effects of IL-13 on stimulating normal human conjunctival 
fibroblast proliferation, preventing apoptosis and decreasing matrix 
metalloproteinase 3 synthesis have been reported (Fujitsu et al., 2005; Fukuda et 
al., 2006), but its effects on other functional activities carried out by normal 
conjunctival fibroblasts have not been fully investigated. Leonardi et al have 
reported that IL-13 increased collagen synthesis, decreased production of matrix 
metalloproteinase 1 and increased production of tissue inhibitor of matrix 
metalloproteinase-1 (TIMP-1) by conjunctival fibroblasts derived from vernal 
keratoconjunctivitis (VKC) patients (Leonardi et al., 2003), which may have a 
different phenotype to that of normal conjunctival fibroblasts, and ocular MMP 
conjunctival fibroblasts. Normal conjunctival fibroblasts do appear to have 
receptors for, and respond to IL-13, given that increased secretion of eotaxin-1 and 
MIG has been reported following IL-13 stimulation of normal conjunctival fibroblast 
cultures (Leonardi et al., 2006).  
 
To our knowledge there are no previous studies evaluating the role of IL-13 in 
ocular or extraocular MMP. Given the prominence of T cells in the substantia 
propria in ocular MMP, we were also interested in potential fibroblast-T cell 
interactions and their contribution to conjunctival fibrosis. We therefore chose to 
investigate the hypothesis that IL-13 and fibroblast-T cell interactions play an 
important role in fibrosis in ocular MMP.   68
1.13 Conclusion 
Immunosuppressive therapy is standard treatment for controlling inflammation in 
ocular MMP, but how well it controls fibrosis is unknown. It has been reported that 
systemic corticosteroids can prevent fibrosis associated with acutely inflamed 
disease. When inflammation has been resistant to conventional 
immunosuppressive therapy, a handful of reports have described improvement 
following systemic TNFα antagonist treatment in ocular MMP, but the scientific 
rationale for such treatment is weak as there are limited studies demonstrating 
tissue expression of TNFα in MMP. TNFα appears to have either antifibrotic or 
profibrotic effects depending on the fibroblast type and experimental setting, so 
investigating its effects on conjunctival fibroblasts is important when considering 
use of TNFα antagonist treatment in ocular MMP.  
 
T cells are prominent in the substantia propria during acute, subacute and chronic 
ocular MMP, and are likely to play a key role in fibrosis. The type 2 helper T cell-
derived cytokine IL-13 is a key profibrotic mediator acting upstream of TGFβ in 
other chronic inflammatory fibrotic diseases of the liver and lung, and whether IL-
13 is expressed in ocular MMP, and its effects on conjunctival fibroblasts, are 
unknown. Finally, there is some evidence that conjunctival fibroblasts derived from 
patients with ocular MMP maintain a hyperproliferative phenotype and show 
increased secretion of inflammatory cytokines, but these findings have not been 
investigated further.    69
1.14 Aim and Hypotheses 
The aim of this thesis was to investigate potential candidate molecules and 
mechanisms involved in conjunctival fibrosis in ocular MMP, for the purpose of 
proposing future adjuvant systemic and/or local anti-fibrotic therapies, to be used in 
conjunction with systemic immunosuppressive therapy.  
 
My overall hypothesis is that it is inflammation, rather than acquired characteristics 
of the fibroblasts, which drives fibrosis in ocular MMP. 
 
My studies were designed to investigate the following hypotheses: 
1.  That current immunosuppressive treatment in ocular MMP controls  
inflammation but not necessarily fibrosis 
2.  That more rapid control of inflammation in ocular MMP using pulse 
intravenous methylprednisolone may more effectively prevent fibrosis 
3.  That the acute inflammatory cytokine TNFα is involved in inflammation in 
ocular MMP, and may have a profibrotic effect on conjunctival fibroblasts 
4.  That the type 2 helper T cell cytokine IL-13, and fibroblast-T cell interactions 
play an important role in fibrosis in ocular MMP 
5.  That conjunctival fibroblasts derived from ocular MMP patients behave in a 
functionally similar manner to normal conjunctival fibroblasts, and are not 
autonomously profibrotic    70
 
Chapter 2 
 
Retrospective review of current 
immunosuppressive therapy in ocular 
mucous membrane pemphigoid 
   71
2.1 Introduction 
The goals of treatment of ocular mucous membrane pemphigoid (MMP) with 
immunosuppressive therapy are the suppression of inflammation and arrest of 
cicatrisation, whilst minimising drug toxicity and potential long term adverse effects 
including neoplasia.  
 
Although several studies have reported the response of ocular MMP to individual 
therapeutic agents such as, for example, cyclophosphamide and high dose 
prednisolone (Elder et al., 1995; Foster, 1986), dapsone (Foster, 1986), 
methotrexate (McCluskey et al., 2004) or sulfapyridine (Elder et al., 1996b), in 
practice such treatments may only be received for a certain time period before they 
need to be switched to alternative agents because of side effects or lack of control 
of inflammation. Combination therapy may also be necessary. Treatment 
guidelines based on using dapsone as initial therapy for mild to moderate 
inflammation and cyclophosphamide as initial therapy for severely active 
inflammation, azathioprine for patients intolerant of dapsone, and subsequent 
substitutions or additions of agents depending on disease activity and drug 
tolerance have previously been described (Foster, 1986; Tauber et al., 1991).  
 
Only a few studies have investigated the overall results of such sequential 
conventional immunosuppressive therapy regimens in terms of success in 
controlling inflammation, and success in arresting cicatrisation (Elder et al., 1996a; 
Miserocchi et al., 2002; Tauber et al., 1991).   
2.2. Aim 
The aim of the study in this chapter was to establish, in a large cohort of ocular 
MMP patients, how well a stepladder treatment strategy using conventional 
immunosuppressive therapy controls both inflammation and cicatrisation in ocular 
MMP.   72
2.3 Specific methods and research design 
Given the rare nature of the disease and the requirement for prolonged follow up, a 
retrospective case note review was the most suitable method for investigating 
treatment outcomes in a large number of patients. The clinical records of 115 
consecutive patients with ocular MMP attending Moorfields Eye Hospital (London, 
United Kingdom) from January 1994 to August 2005 were reviewed.  
2.3.1 Inclusion  criteria 
The inclusion criteria were patients with a clinical diagnosis of ocular MMP and at 
least 6 months follow-up at Moorfields, after commencing systemic 
immunosuppression. A clinical diagnosis of ocular MMP was made if there was 
progressive conjunctival cicatrisation, after excluding other causes of progressive 
scarring such as Sjögren’s syndrome, atopic keratoconjunctivitis and rosacea 
(Thorne et al., 2004) by history, examination and investigations.  Drug-induced 
ocular MMP was diagnosed in patients with clinical features of MMP who had a 
history of causative medication use and progression of clinical signs despite 
ceasing the causative therapy.   
 
All reasonable attempts were made to obtain a positive immunopathological tissue 
diagnosis by conjunctival and/or other mucosal or skin biopsies; however, a 
negative or inconclusive biopsy did not exclude the diagnosis of ocular MMP 
(Ahmed et al., 2004; Bernauer et al., 1994), in the presence of characteristic 
clinical features. 
2.3.2 Data collected 
I collected the following data from the clinical records: date of diagnosis, biopsy 
results, extraocular manifestations, details of therapies, treatment-related side 
effects, and reasons for changes in therapy.  The ocular findings analyzed included 
best-corrected visual acuity, conjunctival inflammation and the most advanced 
Mondino and Foster stage (Foster, 1986; Mondino & Brown, 1981), at the first visit   73
and at last follow-up. It was not possible to record the Tauber (modified Foster) 
stage because the number and percentage extent of symblephara had not been 
consistently recorded in the notes. Conjunctival inflammation was graded as 0 
(absent) to 4 (severe) (Elder et al., 1995; Foster, 1986). The worst eye of each 
patient was selected according to the following criteria: highest Mondino stage, 
worst inflammation, worst visual acuity, or the right eye if both eyes were equal.  
2.3.3 Immunosuppressive treatment regimen: stepladder algorithm 
Immunosuppressive regimens employed either ‘step-up’ or ‘step-down’ treatment 
depending on the activity of MMP, as previously described (Rauz et al., 2005) 
(Figure 2.1). Briefly, for ‘step-up’ therapy, dapsone (diaminodiphenylsulfone) (25-
50 mg bd) or sulphapyridine (500mg od to bd, or sulfasalazine 500-1000 mg bd 
when sulphapyridine was unavailable) was prescribed for mild or moderate 
inflammation.  For disease not responding after 2-3 months of first-line therapy, 
azathioprine (1-2.5mg/kg/day) was added (when there was some response) or 
substituted (if there was no response). For those intolerant of or not responding to 
azathioprine, mycophenolate mofetil (500mg-1g bd) was used.  Severe 
inflammatory disease was treated with cyclophosphamide (1-2mg/kg/day).  As 
optimal effects with cyclophosphamide are not achieved until 8 weeks following the 
initiation of therapy, an adjunctive reducing regimen of oral corticosteroids 
(prednisolone commencing at 1 mg/kg/day) was employed, sometimes with 
intravenous pulses of methylprednisolone (500mg-1g, up to three doses over three 
days).  Due to an increased risk of bladder carcinoma (Knight et al., 2004), the safe 
duration of treatment with cyclophosphamide is limited to 12 months, so 
immunosuppression was “stepped-down” to the less toxic medications 
azathioprine, mycophenolate mofetil, methotrexate or dapsone at the end of this 
period.  Combination therapy was used for resistant cases, and included the 
combination of a sulpha (dapsone, sulphapyridine) and myelosuppressive agent 
(azathioprine, mycophenolate, cyclophosphamide), and/or the addition of 
prednisolone (either as a maintenance dose of ≤7.5mg/day or as a brief tapering 6-  74
8 week course).  Blood pressure, weight, urinalysis, and blood tests were 
evaluated regularly to screen for drug-related side effects records.  
 
 
 
Figure 2.1 Algorithm showing stepladder immunosuppression strategy 
For severe disease, commence with cyclophosphamide and plan introduction of 
less toxic drugs, and withdrawal of cyclophosphamide once the disease is under 
control.  For mild disease use dapsone (or sulfapyridine if dapsone is not tolerated) 
and step-up to azathioprine or mycophenolate. For treatment failures with this 
regimen, progress to cyclophosphamide.  Oral prednisolone for 6 weeks is usually 
combined with cyclophosphamide, whilst awaiting the commencement of 
immunosuppressive effect.  Combinations of a sulpha-based agent (dapsone or 
sulphapyridine) with a myelosuppressive agent (cyclophosphamide, azathioprine, 
mycophenolate) and prednisolone are also effective. iv = intravenous.   75
2.3.4 Treatment episode and outcome definitions 
A treatment episode was defined by the use of a single immunosuppressive 
agent or therapeutic combination of agents.  For each treatment episode, the 
success of immunosuppressive therapy in controlling inflammation was classified 
as a success (S), qualified success (QS) or failure (F).  “Success” (S) was defined 
as where there was induction of quiescence with a quiet, white eye for at least 3 
months from the commencement of therapy.  If, following initial success, a change 
in therapy was necessary due to a reactivation of inflammation uncontrolled by the 
current regimen, this was defined as “success then inflammation” (Si); if a 
change in therapy, following initial success, was necessary due to adverse effects, 
this was defined as “success then adverse effects” (Sa).  “Qualified 
success”(QS) was defined as where inflammation was partially controlled, with 
some residual inflammation.  “Failure” (F) was defined as where there was either 
no response and persistent inflammation (Fi), or where therapy had to be 
withdrawn within 3 months, due to unacceptable side effects, before a response 
could be expected (Fa).   
Treatment episodes were defined according to the principal agent used 
(cyclophosphamide, azathioprine, mycophenolate, sulphapyridine or sulfasalazine, 
dapsone), either as monotherapy or in combination therapy.  When treatment was 
stopped after a period of quiescence, and if it was not necessary to reinstitute 
immunosuppression for at least 6 months, disease was described as being in 
remission.  The induction of quiescence was a criterion for success (S), rather than 
the permanence of quiescence.  
2.3.5 Ethics approval and statistical analysis 
The study was conducted after approval from the Moorfields Eye Hospital research 
governance and ethics committee.  Fisher’s exact test was used to assess for any 
association between outcome after the first treatment episode and treatment.  The   76
Wilcoxon rank sum test was used to assess for any evidence of association 
between progression of cicatrisation (defined by progression in Mondino stage) 
and each of maximum recorded level of inflammation and duration of disease.  All 
analyses were conducting using Intercooled Stata software version 9.0 for 
Windows (StataCorp LP, Texas LA).    77
2.4 Results 
115 patients (223 eyes with ocular MMP) received immunosuppression.  The 
female: male ratio was 1.25:1.  The mean age at diagnosis was 66.9 years 
(standard deviation 14.4 years, range 17-92 years).  Unilateral disease was 
present in 6% (7/115) of patients, of whom 1 had unilateral drug- induced 
pemphigoid.  There were 3 patients with drug-induced pemphigoid and 2 patients 
with ocular MMP developing as a sequela of Stevens-Johnson syndrome.  The 
median duration of disease was 4.25 years, with an inter-quartile range of 2.17-
8.67 years.  For 90% of patients the duration of disease was within 14 years, and 
the longest duration was 25 years (1 patient).  
2.4.1 Biopsy  results 
Of the 62 patients in whom biopsy results were available, 69% (43/62) were 
positive.  2 patients had positive histology.  Direct immunofluorescence (DIF) 
studies in the remaining 41 patients were positive.  Conjunctival biopsies had been 
performed in 79% (49/62) of these patients, of which 61% (30/49) showed a 
positive DIF result.  Of the 14 buccal biopsy results available, 78.6% (8/14) were 
positive on DIF microscopy, whilst 57.1% (4/7) of the skin biopsies were DIF 
positive.  
2.4.2 Extraocular disease 
Extraocular manifestations were present in 50% (58/115).  These included lesions 
of the mouth in 78%, pharynx 15%, oesophagus 14%, nose 33%, skin 22%, larynx 
14%, rectum 5% and genitals 9%.  Associated autoimmune disease was present in 
16% (18/115). 
2.4.3 Treatment   
Three hundred and eighty-eight treatment episodes occurred. Twelve individual 
agents were used in 45 different therapeutic permutations, dictated by both 
disease severity and medication toxicity.  A successful outcome occurred in 50%   78
(196/388) of treatment episodes, and 27% (104/388) were considered a QS.  
Inflammation thus responded to immunosuppression in 77% (300/388) of the 
treatment episodes.  Treatment failed in 23% (88/388) of episodes, of which 51% 
(45/88) failed due to adverse side effects (Fa), and 49% (43/87) failed due to 
inability to control inflammation (Fi). The predominant outcome of each patient’s 
treatment course, calculated by determining the outcome present for the greatest 
duration of the treatment course, was S in 75% (86/115), QS in 20% (23/115) and 
F in 5% (6/115).  
2.4.4 Stepladder  Therapy 
Of the 115 patients who received treatment, 26 patients (23%) underwent only one 
treatment episode, 30 patients underwent two treatment episodes (26%), and the 
number of treatment episodes increased to a maximum of ten episodes in three 
patients (3%). The reasons for further therapy are shown in Table 2.1.  
Immunosuppressive treatment was “stepped-up” in 52% (60/115) of patients, 
“stepped-down” in 10% (12/115) of patients, and remained at the same level on the 
therapeutic stepladder in 38% (43/115).  
 
Table 2.1 Reasons for further immunosuppressive therapy 
Reason for further therapy n (%)*
Failure due to poor inflammatory control (Fi) 40 (14.7%)
Failure due to adverse side effects (Fa) 42 (15.4%)
Incomplete response (QS) 90 (33.0%)
Reactivation following initial success (Si) 25 (9.2%)
Adverse side effects following initial success (Sa) 38 (13.9%)
Maximum duration cyclophosphamide therapy 21 (7.7%)
Remission then relapse 5 (1.8%)
Patient stopped therapy then required recommencement 3 (1.0%)
Physician choice or other reason 9 (3.3%)
*Number of treatment episodes (% of treatment episodes requiring further therapy).
Fi = failure due to poor inflammatory control; Fa = failure due to adverse side effects; QS 
= qualified success; Si = initial success followed by reactivation; Sa = success followed 
by adverse side effects     79
2.4.5 Final  Outcome 
The final outcome of treatment was a white quiet eye in 70% (81/115) of patients 
and 78.5% (175/223) of eyes.  There was residual minimal or mild inflammation in 
21.5% (48/223) of eyes and 30% (34/115) of patients.  Of the 48 eyes with residual 
inflammation, 26 (54%) continued to receive treatment, treatment had ceased in 16 
(33%) eyes, and 6 eyes (3 patients) were lost to follow-up.  In the 16 residually 
inflamed eyes where treatment had ceased, side effects prevented further 
treatment in 5 eyes (3 patients), other illness unrelated to therapy resulted in 
treatment cessation in 2 eyes (1 patient), the residual inflammation was minimal 
and fluctuating and the risks of treatment were felt to outweigh the benefits in 6 
eyes (4 patients), and the patient wished to stop treatment in 3 eyes (3 patients).  
By the end of the study, 43.5% (50/115) of patients had ceased treatment.  Of 
these 50 patients, both eyes were white in 70% (35/50) and one or both eyes were 
residually inflamed in 30% (15/50).  Of the 65 patients (56.5%) in whom treatment 
was continuing, both eyes were white in 71% (46/65) and one or both eyes were 
residually inflamed in 29% (19/65).  Remission off treatment for at least 6 months 
occurred in 16 patients (14%).  Four additional patients suffered relapses following 
periods of remission off treatment lasting 4 to 24 months.  Thus the proportion in 
remission was 17% [(16 + 4)/115] and relapse occurred in 20% (4/20). 
2.4.6 Side  effects 
The adverse effects of therapy are listed in Table 2.2.  Three patients suffered 
major adverse effects.  Two patients on cyclophosphamide developed 
pancytopenia requiring transfusion.  A further patient developed severe anaemia 
during sulphapyridine treatment; therapy was later changed to cyclophosphamide 
for pemphigoid-related airway obstruction, from which she died.  No patients 
developed secondary malignancies.  
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Table 2.2 Adverse side effects 
Drug Status n (%) Adverse effect
Discontinued 28 (31%) Anaemia (8), rash (9), malaise (6), headache (2), diarrhoea (2), elevated LFTs (2), thrombocytopenia (1), 
dysplastic blood film (1), paraesthesia (2), back pain (1), stomach cramps (1), worsening of tinnitus (1)
Continued 5 (5%) Anaemia (5)
Total 33 (37%)
Discontinued 12 (25%) Rash (5), nausea & vomiting (3), malaise (1), depression (1), elevated LFTs & indigestion (1), lymphopenia (1), 
worsening of tinnitus (1), dizziness (1) 
Continued 3 (6%) Nausea (2), anaemia (2)
Total 15 (31%)
Discontinued 2 (29%) Elevated creatinine (2), hypertension (1)
Continued 2 (29%) Elevated creatinine (2), hypertension (1)
Total 4 (57%)
Discontinued 1 (25%) Elevated LFTs (1)
Discontinued 4 (7%) Osteoporosis (2), hallucinations (1), malaise (1)
Continued 1 (1%) Peptic ulcer (1)
Total 5 (9%)
Discontinued 24 (40%) Nausea & vomiting (8), headaches (4),  elevated LFTs (3), malaise (3), dizziness (2), tinnitus (1), depression 
(1), diarrhoea (1), myelosuppression (1), itch (1), arthralgia (1), myalgia (1), chest & back pain (1), numbness 
(1), shivering spells (1)
Continued 2 (3%) Dizziness (1), abnormal blood results (1)
Total 26 (43%)
Discontinued 5 (15%) Malaise (2), diarrhoea (1), rash (1), headache (1), shortness of breath & tremor (1)
Continued 4 (12%) Elevated LFTs (1), anaemia (1), myelosuppression (1), muscle cramps & insomnia (1)
Total 9 (26%)
Discontinued 17 (31%) Lymphopenia (5), lethargy & malaise (3), nausea & vomiting (2), diarrhoea (1), abdominal discomfort (2), 
anorexia & weight loss (2), severe pancytopenia (2), anaemia (1), elevated LFTs (1), rash (2), headache (1), 
insomnia (1), myalgia (1), unsteady on feet (1), shortness of breath (1), dysuria (1)
Continued 10 (18%) Lymphopenia (5)
Total 27 (49%)
LFTs = liver function tests. Anaemia, haemoglobin <13.3 g/dl (males) and <12.0 g/dl (females). Lymphopenia, <0.5x10
9/l. 
Prednisolone (n=55; 143 patient 
months short tapering course, 988 
patient months <20mg/day low dose)
Mycophenolate (n=34; 506 patient 
months)
Azathioprine (n=60; 1230 patient 
months)
Cyclophosphamide (n= 55; 512 
patient months)
Methotrexate (n=4; 58 patient 
months)
Ciclosporin (n=7; 65 patient months)
Sulfapyridine or sulfasalazine (n=48; 
514 patient months)
Dapsone (n=90; 2852 patient 
months)    81
2.4.7 Cicatrisation 
Conjunctival cicatrisation at presentation was Mondino stage I in 13%, II in 43%, III 
in 28% and IV in 16% of eyes, and Foster stages I through IV in 2%, 15%, 81% 
and 2% of eyes, respectively.  Progression of Mondino stage occurred in 53% of 
patients (61/115) and 41% of eyes (92/223), whilst Foster stage progressed in 8% 
of patients (9/115) and 4% of eyes (9/223).  Using Mondino’s staging system, 
progression occurred in 63% (19/30) stage I eyes, 48% (45/93) stage II eyes, 43% 
(25/58) stage III eyes and none of the stage IV eyes.  Using Foster’s staging 
system, progression occurred in 20% (1/5) stage I eyes, 18% (6/33) stage II eyes, 
1% (2/180) stage III eyes and none of the stage IV eyes.  There was evidence that 
progression of cicatrisation in the worst eye was associated with less severe 
inflammation (P = 0.0007) and longer duration of disease (P = 0.0048) (Table 2.3).  
2.4.8 Visual  acuity 
The best corrected visual acuity at presentation was better than 6/18 in 67% of 
eyes, 6/18 to 6/60 in 16%, 3/60 to 6/60 in 5% and less than 3/60 in 11%.  The final 
best corrected visual acuity was better than 6/18 in 48%, 6/18 to 6/60 in 19%, 3/60 
to 6/60 in 7% and less than 3/60 in 26% of eyes.  Ocular MMP was the cause of 
blindness (acuity less than 3/60) in 8% of eyes at presentation, and in 21% of eyes 
at the final visit.  During the course of follow-up, the proportion of eyes with visual 
acuity 6/60 or less due to ocular MMP increased from 13% (29/223) to 26% 
(57/223); whilst the proportion of eyes with visual acuity 6/60 or less from other 
causes (retinal vascular event, glaucoma, macular degeneration) increased from 
4% (8/223) at presentation to 7% (16/223) at the final visit.  The best recorded 
acuity often required contact lens correction, but not all patients could tolerate 
contact lenses so a greater proportion of eyes had worse functional visual acuities.  
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Table 2.3 Progression of cicatrisation while receiving immunosuppressive therapy 
 
Total patients No progression Progression P
No. of patients 115 54 (47%) 61 (53%)
Duration of disease (mths) 51 (6-300)  43 (6-204) 68 (7-300)   0.0048*
Max inflammation grade 4 22 19 (86%) 3 (14%)
Max inflammation grade 3 63 31 (49%) 32 (51%)
Max inflammation grade 2 29 11 (38%) 18 (62%)
Max inflammation grade 0 or 1 1 0 1 (100%) 0.0007*
Final acuity b 36 21 (58%) 15 (42%)
Final acuity svi 8 4 (50%) 4 (50%)
Final acuity vi 18 10 (56%) 8 (44%)
Final acuity n 53 26 (49%) 27 (51%)
Predominant outcome S 86 43 (50%) 43 (50%)
Predominant outcome QS 23 15 (65%)  8 (35%)
Predominant outcome F 6 3 (50%) 3 (50%)
Final inflammation present 31 19 (61%) 12 (39%)
Continuing therapy at last visit 65 33 (51%) 32 (49%)
Biopsy positive 43
† 27 (63%) 16 (37%)
Extraocular disease present 58 35 (60%) 23 (40%)
success,  F= failure. †Percentage of patients with biopsy results available. 
Duration of disease, median (range). Max inflammation = maximum recorded level of inflammation. b = blind, svi = severe visual impairment, vi = visual 
Progression defined by an increase in Mondino stage in the worst eye between initial and final visit. *Significant at P<0.01. n(%).  Worst eye of each 
patient selected according to the following criteria: highest Mondino stage, worst inflammation, worst visual acuity, or OD eye if both eyes equal.  
impairment, n = normal. Predominant outcome = the outcome present for the greatest duration of the treatment course.  S = success,  QS = qualified 
 
   83
2.5 Discussion 
Although the final outcome was a quiet white eye in 78.5% (175/223) of eyes and 
in 70% (81/115) of patients, there was evidence of progressive cicatrisation in 41% 
(92/223) of eyes and 53% of patients (61/115).  In half of this group of 92 eyes 
(n=46), progressive cicatrisation was associated with ongoing minimal to mild 
inflammation which immunosuppressive therapy was unable to completely 
eliminate, or when treatment was discontinued for various reasons, including 
toxicity.  In contrast, the other 46 eyes with progression were reported as quiet and 
white.  Interestingly, the analysis in Table 2.3 also indicates that there seemed to 
be an association between less severe inflammation during the period of follow-up, 
and progression of cicatrisation.   
 
However, the maximum recorded level of inflammation, upon which this analysis is 
based, was dependent first on the level of inflammation being accurately recorded 
in the case notes, which may or may not have been accurate on every occasion, 
and second on the maximum level of inflammation being present when the patient 
attended for their visit. Furthermore, detection of progression depended on 
observing an increase in Mondino stage, and this was not recordable for those who 
started at Mondino stage 4; in contrast, progression was more likely to be detected 
in those commencing at a lower Mondino stage, and 73% (22/30) of the patients 
with less severe inflammation (up to grade 2) commenced at Mondino stage 1 or 2. 
For these reasons, one should be cautious about making conclusions from this 
analysis. However, it could suggest that more aggressive treatment given to 
patients with severe inflammation also more effectively prevented progression of 
cicatrisation, unlike less aggressive, less toxic treatment given for less severe 
inflammation.  Similar progression of cicatrisation despite reduction of inflammation 
has been reported previously (Elder et al., 1996a; Letko et al., 2004; Mondino & 
Brown, 1983). 
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Adverse side effects or the maximum safe duration of therapy to avoid adverse 
effects were the reason for changes in immunosuppressive therapy in 37% of 
treatment episodes (101/272) (Table 2.1). This indicates that the tolerability of 
immunosuppressive therapy in this elderly population of patients is limited, and the 
ability of physicians to use aggressive treatment doses and the most toxic agents 
to fully and completely suppress inflammation for prolonged durations is restricted. 
 
Tauber et al (Tauber et al., 1991) described results of a sequential regimen 
involving initial treatment of mild to moderate disease with dapsone, treatment of 
highly active disease with cyclophosphamide, and use of azathioprine for patients 
who did not respond to dapsone.  Disease was brought under control in 92% of 
patients after additions or substitutions in regimens, and progression of scarring 
using the Foster staging system was detected in 6% of eyes and 10% of patients. 
We found that only 8% of patients in our study progressed according to the Foster 
staging system, whereas progression was evident in 53% of patients using 
Mondino staging. Another retrospective review similarly reported 10% progression 
using Foster staging in a cohort of patients with 90% control of inflammation 
(Miserocchi et al., 2002); the results using the Mondino staging system reflect its 
increased sensitivity compared with the Foster system.   
 
The proportion of eyes with visual acuity of 6/60 or less because of MMP doubled 
from 13% (29/223) to 26% (57/223) by the end of the study. This indicates that 
although control of inflammation may delay or prevent the onset of surface failure, 
it is not adequate to eliminate loss of vision due to irreversible corneal 
vascularisation and scarring as a consequence of recurrent epithelial defects and 
microbial keratitis.  
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2.6 Conclusion 
Conventional immunosuppressive therapy using a stepladder regimen seems to be 
partially or completely successful in controlling inflammation to achieve a quiet 
white eye in three quarters of ocular MMP patients. However, there was evidence 
of progressive cicatrisation in half the patients. The extent to which maximum 
immunosuppressive therapy can be given is limited by its toxicity in this elderly 
patient group, and control of inflammation while limiting toxicity may not necessarily 
correlate with control of cicatrisation. More aggressive immunosuppressive 
treatment could more effectively prevent progression of cicatrisation, and more 
rapid control of inflammation could potentially be more effective at arresting 
cicatrisation.      86
 
 
Chapter 3 
 
A pilot randomised controlled trial of pulse 
intravenous methylprednisolone in severe 
ocular mucous membrane pemphigoid 
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3.1 Introduction 
The findings in chapter 2 indicate that our current conventional immunosuppressive 
therapy regimen does not arrest cicatrisation in just over half the patients. We 
hypothesise that more aggressive treatment and more rapid control of inflammation 
could more effectively prevent progression.  
 
It has been observed that systemic corticosteroids prevent conjunctival shrinkage 
and fibrosis in ocular MMP, when used in the setting of acute severe inflammation 
(Mondino & Brown, 1981). However, it is well recognised that systemic 
corticosteroid treatment alone is not appropriate treatment for ocular MMP, given 
that the high steroid doses required to sustain disease control are associated with 
significant morbidity and mortality in this elderly patient group, and because the 
inflammation recurs when the systemic corticosteroids are tapered (Hardy et al., 
1971).  
 
High dose intravenous methylprednisolone (IVMP) pulse therapy may be an 
effective additional measure to reduce the time to control of inflammation, in 
combination with cyclophosphamide and oral corticosteroids in ocular MMP. More 
rapid control of inflammation could more effectively suppress aggressive 
inflammation, and perhaps also delay cicatrisation.   Pulse IVMP is used 
anecdotally in clinical practice by physicians managing ocular MMP. It has been 
reported to be beneficial in an uncontrolled case series of severe inflammatory eye 
disease (Wakefield et al., 1986), and its use in ocular MMP has been mentioned 
(McCluskey et al., 2004; Sacher & Hunzelmann, 2005), but not formally 
investigated.  There is good evidence of the efficacy of pulse IVMP treatment in 
other inflammatory conditions such as optic neuritis, where pulse intravenous 
methylprednisolone (IVMP) followed by oral prednisone speeds the recovery of 
visual loss compared with oral prednisone alone (Beck et al., 1992). Pulse IVMP 
has also been shown in randomised controlled trials to give rapid temporary relief   88
of flares in rheumatoid arthritis, with clinical improvement lasting 6 weeks or longer 
(Liebling et al., 1981; Williams et al., 1982). 
 
In a study of severely inflamed ocular MMP patients by Elder et al (Elder et al., 
1995), using conventional treatment of oral cyclophosphamide and oral 
corticosteroids, ocular inflammation resolved in 26% (5/19 eyes) and 30% (3/10) 
patients by 6 weeks. In a study where the pre-treatment conjunctival inflammation 
may not have been as severe, Foster reported that inflammation had resolved and 
the eyes were white and quiet in 50% (6/12) of patients by 6 weeks (Foster, 1986).  
We therefore hypothesised that the proportion of patients with control of 
inflammation at 6 weeks could be significantly increased by pulse IVMP.  
3.2 Aim 
To date there have been only 2 prospective randomised trials evaluating treatment 
for mucous membrane pemphigoid (Foster, 1986); all other reports are 
interventional case series or cohort studies (Saw et al., 2008). The purpose of the 
study in this chapter was to establish the feasibility of conducting a randomised 
controlled clinical trial to evaluate whether there is any additive effect of pulse 
intravenous methylprednisolone, in reducing the time to control of inflammation in 
patients with severely active ocular MMP who are commencing oral corticosteroid 
and cyclophosphamide treatment, and to evaluate whether more rapid control of 
inflammation also more effectively arrests cicatrisation.  
3.3 Research design and specific methods 
I designed and coordinated a multi-centre pilot randomized controlled clinical trial 
which was conducted according to the guidelines of the Declaration of Helsinki. 
Patients were recruited from September 2005 through April 2008. The Moorfields 
Eye Hospital Research Governance Committee and the Oxfordshire Research 
Ethics Committee approved the study protocol, and informed consent was obtained   89
from all participants (see Appendix 3). The trial is registered on the International 
Standard Randomised Controlled Trial Number Register (ISRCTN51714283). 
3.3.1 Participants 
Inclusion criteria were as follows: patients with clinical features consistent with 
ocular MMP i.e. progressive conjunctival cicatrisation and inflammation where 
other causes of conjunctival scarring have been excluded, with or without a 
positive result on direct immunofluorescence (DIF) microscopy from any mucosa or 
skin biopsy showing linear basement membrane deposition of IgG, IgA, and/or C3, 
and/or a positive result on indirect immunofluorescence (IIF) testing for anti-
basement membrane zone antibodies. Presence of a clinical indication to 
commence cyclophosphamide therapy because of bilateral or unilateral ‘moderate’ 
(grade 3) or ‘severe’ (grade 4) ocular inflammation and/or active conjunctival 
inflammation uncontrolled by previous non-cyclophosphamide immunosuppression 
was a criterion for inclusion.  
 
Exclusion criteria included patients already receiving cyclophosphamide, patients 
with other causes of progressive conjunctival scarring (drug-induced pemphigoid 
with negative direct immunofluorescence biopsy, atopic keratoconjunctivitis, 
Sjogren’s syndrome, Stevens-Johnson syndrome, chemical injury), active 
secondary malignancy, HIV infection, pregnancy or breastfeeding.   
 
The study eye was chosen in each patient based on the eye with the greatest 
conjunctival inflammation at enrolment; where both eyes had similar inflammation, 
the right eye was chosen.   
3.3.2 Recruitment 
Patients were recruited as consecutive cases from the clinic population in 3 
centres: Moorfields Eye Hospital (n=16), Birmingham and Midlands Eye Centre   90
(n=3) and Bristol Eye Hospital (n=1). Study investigators and masked observers 
were chosen at each site.  
3.3.3 Intervention 
The intervention given to the treatment group was adjunctive intravenous 
methylprednisolone (IVMP) 1 gram daily for 3 consecutive days. Oral 
cyclophosphamide 1.5 mg/kg/day was commenced simultaneously, and a 12 week 
tapering course of oral prednisolone was commenced after the 3rd day of IVMP. 
The oral prednisolone dosage was 1mg/kg/day for 1 week, reducing by 10mg/ 
week until the dose was 60mg/day. Following this, the dose was reduced by 5mg 
each week and the treatment reduction was planned to result in a dose of 5 to 
7.5mg /day at week 12, then continued at 5 to 7.5mg/d for a further 3 months then 
ceased. At the week 4 visit, if the conjunctival inflammation was still grade 2 or 
above in each of the 4 quadrants (see Outcome Measures below), a second pulse 
of 3 grams IVMP was given.   
 
The control treatment was conventional therapy with oral cyclophosphamide 1.5 
mg/kg/day and a 12 week tapering course of oral prednisolone 1mg/kg/day. In all 
patients, cyclophosphamide was continued for up to 1 year providing no adverse 
events necessitated its discontinuation. At the end of 12 months cyclophosphamide 
was replaced with an alternative, less toxic immunosuppressant i.e. stepping down 
on the step-ladder algorithm of immunosuppressive therapy (see Chapter 1, 
Figure 1.1). All patients were commenced on alendronic acid 70mg weekly with 
oral calcium and vitamin D3, and omeprazole or a similar anti-dyspepsia agent until 
the oral corticosteroid doses had reduced to 7.5mg or less per day.   
3.3.4  Randomization and Masking 
A randomisation list was generated by the statisticians at the Clinical Trials Unit 
(CTU) at Moorfields, using random permuted blocks of varying sizes. This list was 
kept at the CTU and when a patient required allocation to treatment, the CTU were   91
contacted, the patient was registered with the CTU, and then assigned their 
treatment. Masked observers at each study site graded conjunctival inflammation 
at each visit and the cicatrising conjunctivitis severity score at enrolment and the 
final visit. Masked photographic grading of conjunctival inflammation at each visit 
was carried out in parallel at the Moorfields Eye Hospital Reading Centre. Study 
investigators and patients were not masked, and study investigators were informed 
of the treatment allocation by the biostatistician via a central telephone number at 
the time of randomization. The success of masking was maintained by ensuring 
that the masked observers were excluded at all times from access to the study 
folder which contained the treatment details, and they did not discuss treatment 
with the patient. The masked photographic grader did not have any access to 
information about the treatment allocation.   
3.3.5 Outcome  Measures 
Assessment tools for grading the outcome measures of conjunctival inflammation, 
fornix depth and severity of cicatrising conjunctivitis were created, based on 
modifications of previously described tools.  
 
The primary outcome measure was the proportion of patients achieving control of 
conjunctival inflammation in the most inflamed eye (the study eye) at 6 weeks. 
Control of conjunctival inflammation was defined as bulbar conjunctival 
inflammation grade 1.5 or less in all 4 quadrants (upper nasal, lower nasal, upper 
temporal, lower temporal), giving a total bulbar inflammation score of 6 or less, out 
of a potential total score of 16.  Grading of conjunctival inflammation in 4 quadrants 
was carried out because sectoral variation in conjunctival inflammation is often 
observed in ocular MMP, making it difficult to give an “overall” grade when the 
inflammation could be very severe in one quadrant, but minimal in another. 
Conjunctival inflammation was graded from grade 0 (nil), grade 1 (minimal), grade 
2 (moderate), grade 3 (marked), and grade 4 (severe), as described previously 
(Elder et al., 1995; Foster, 1986). For grading conjunctival inflammation, a grading   92
sheet showing representative photographs of each grade from 0 to 4 was created 
(see Figure 3.1).  
 
This grading sheet was used by the masked observers and the photographic 
grader.  Validation of this grading sheet for assessing conjunctival inflammation 
was carried out prior to commencing the study, using 3 observers in 10 sample 
patients with different grades of conjunctival inflammation, assessing inter-observer 
and test-retest reliability. Although other grading scales for conjunctival 
inflammation related to contact lens wear are in use e.g. the CCLRU grading scale 
(Efron et al., 2001), the severity of grade 4 conjunctival inflammation in ocular 
MMP is much more severe than in any of these grading scales, so an alternative 
disease-appropriate grading scale was devised by selecting suitable photographs 
of ocular MMP.  Conjunctival inflammation was graded at 2 weekly intervals for 3 
months, 4 weekly for 3 months, then 8 weekly for 6 months i.e. a total of 13 study 
visits over 12 months.   
 
Secondary outcome measures included time to control of inflammation in weeks, 
additional therapy required after week 12 for inflammatory control, progression of 
cicatrisation at 12 months or their final visit when this was earlier, change in 
cicatrising conjunctivitis severity score, visual acuity, and adverse side effects 
including change in bone densitometry.  
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Figure 3.1 Grading sheet for bulbar conjunctival inflammation and 
cicatrisation.   
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Evaluating progression of cicatrisation: developing a conjunctival fornix measuring 
instrument 
Progression of cicatrisation between the enrolment and 12 month visit was 
evaluated by Tauber staging of ocular cicatrisation (Tauber et al., 1992) by slit 
lamp exam and using a custom-made fornix measuring instrument (Figure 3.2). 
The design of the fornix measuring instrument was based on that of a previously 
published device (Schwab et al., 1992), and adapted by us (myself, Scott Hau: 
senior optometrist at Moorfields Eye Hospital and David Carpenter: ocular 
prosthetist at Moorfields Eye Hospital) to enable measurement of the upper 
conjunctival fornix. Schwab et al have demonstrated that this type of fornix 
measuring instrument has good inter-rater as well as test-retest reliability. The 
device, used with topical anaesthesia and disinfected with hypochlorite between 
patients, permits rapid measurement and does not cause any discomfort or pain.   
 
 
Fig 3.2 Fornix measuring instrument custom-designed to enable 
measurement of the upper and lower conjunctival fornices. The design of this 
device was an adaptation of a similar instrument described by Schwab et al 
(Schwab et al., 1992).  95
Evaluating progression of cicatrisation: investigating what is normal upper conjunctival 
fornix depth  
Tauber staging of fornix shortening is dependent on knowledge of the normal fornix 
depth (see Figure 3.1): Stage IIa is 0-25% loss of fornix depth, IIb is 25-50%, IIc is 
50-75%, IId is 75-100%. Whilst the normal lower conjunctival fornix depth has been 
evaluated and found to be 10-11mm for normal subjects aged 50 years or older 
(Schwab et al., 1992), with 10mm being the average fornix depth in subjects aged 
80 years or older, the normal upper conjunctival fornix depth is unknown. At the 
time of commencement of the trial in 2005, information about normal upper 
conjunctival fornix depth could not be found in any major ophthalmology reference 
books or by a literature search on Pubmed or google using the term “conjunctival 
fornix depth” or “conjunctival fornix measurement”.  
 
Almost all published studies in ocular MMP report only lower conjunctival fornix 
staging; the upper conjunctival fornix is often overlooked. McCluskey et al reported 
the upper conjunctival fornix cicatrisation staging in their patients, but it is unclear 
how they established, for example, that a patient had an upper fornix stage IIc 
(McCluskey et al., 2004). Asymmetrical severity of involvement between right and 
left eyes is a recognised feature of ocular MMP (Mondino & Brown, 1983), and it 
could be expected that similar asymmetry might occur between the upper and 
lower conjunctival fornices of each eye. For this reason, it was felt that evaluation 
of both lower and upper conjunctival fornices was the most accurate way to stage 
conjunctival cicatrisation, and that this was imperative in any prospective studies 
evaluating progression of conjunctival cicatrisation.   
 
Having designed an instrument that enabled us to measure upper conjunctival 
fornix depth, it was necessary to investigate and try to establish what range of 
measurements would be considered normal upper conjunctival fornix depth, in 
eyes with healthy conjunctiva. Approval from the Moorfields and Whittington Ethics 
committee was sought to commence a study where the aim was to establish what   96
range of measurements constitute normal upper conjunctival fornix depth (see 
Appendix 4). Based on preliminary results from 127 patients aged 50 years and 
older, the average upper conjunctival fornix depth was 15.2 ± 1.6mm, range 12 – 
20mm (see Appendix 4). These results were used to determine upper conjunctival 
Tauber staging (Tauber IIa 12-20mm, IIb 8- 11mm, IIc 4- 7mm, IId <4mm). 
     
A cicatrising conjunctivitis severity score was devised, based on previous 
grading schemes (Elder & Bernauer, 1997; Francis et al., 1990). This evaluated 
visual acuity, conjunctival inflammation, lid pathology and cicatrisation as well as 
keratopathy, to give an indication of the severity of disease affecting all aspects of 
the ocular surface (see Figure 3.3).  The cicatrising conjunctivitis severity score 
was assessed by the masked observers at enrolment and at the final visit, for each 
patient.   
 
Adverse side effects were recorded at each visit. To detect toxicity due to 
immunosuppressive therapy, the following parameters were monitored in all 
patients at commencement of therapy and at each study visit: blood pressure, 
pinprick blood sugar, dipstick urinalysis, full blood count, renal function and 
electrolytes, liver function tests. The cyclophosphamide dose was titrated to 
achieve a target lymphocyte count level is 0.5-1.0 x 10
9/L, aiming for lymphopenia 
without leukopenia (white cell count >3.0 x 10
9/L, neutrophils >2.0 x 10
9/L). 
Patients were admitted to hospital for the IVMP infusions, and their 
electrocardiograph, vital observations, blood sugar levels, full blood count, renal 
function and electrolytes, liver function tests were monitored. Bone densitometry 
was performed at enrolment and at the final visit.  Conjunctival biopsies and blood 
samples were also taken for concurrent laboratory studies.    97  98
 
Figure 3.3 Cicatrising Conjunctivitis Severity Score   99
3.3.6 Sample Size 
With conventional treatment of oral cyclophosphamide and oral corticosteroids 
there is a 26% (5/19 eyes) success rate at 6 weeks (Elder et al., 1995). On this 
basis, 9 eyes per treatment group would give 80% power to detect a treatment 
difference of 70%, at the 5% level (Fleiss, 1981). This does not include any 
adjustment for loss to follow−up because the study duration is short and the 
condition is severe.  
3.3.7 Statistical  Analysis 
Baseline characteristics of the treatment groups were compared to assess the 
adequacy of randomization.  Descriptive statistics were used because of the small 
patient numbers. The number of patients required for a definitive study was 
computed. Agreement between photographic and observer grading of bulbar 
inflammation was assessed using Bland Altman methods. Analysis was by 
intention to treat.     
3.4   Results   
3.4.1 Participants 
Of the 40 patients assessed for eligibility in the study, 18 declined to participate, 1 
did not meet the inclusion criteria as she had already been commenced on 
cyclophosphamide, and 1 was excluded because he had severe disease that the 
study investigator at that site wished to treat with IVMP and subsequently 
rituximab. The main reasons given by patients for declining to participate included 
the inconvenience, distance to travel, having domestic commitments to care for a 
disabled relative, and not wishing to be randomised to IVMP because of 
concomitant illnesses like diabetes. The remaining 20 patients were randomised to 
either IVMP or the control group. Figure 3.4 shows a flowchart of the progress of 
subjects through the phases of the trial.   100
 
Figure 3.4 Flowchart of the progress of subjects through the phases of the trial 
 
The primary outcome measure was analysed at 6 weeks for all 20 patients. Two 
patients in the IVMP group died: an 80 year old male who had received 3 grams of 
IVMP at enrolment died at week 16 of a pulmonary embolism which was thought to 
be unrelated to the study treatment; a 73 year old male died at week 10 of 
pneumonia and heart failure. The opinion of the physician managing the latter 
patient was that the IVMP was unlikely to have contributed to the development of 
heart failure.  Two patients in the control group died: an 83 year old male died at 
week 12 of community-acquired pneumonia and a 73 year old male died at week 
40 of metastatic lung carcinoma. The latter patient had previously been a heavy 
smoker and the carcinoma was diagnosed 5 months following enrolment in the 
study. It is likely that the systemic immunosuppression with both   101
cyclophosphamide and high dose corticosteroids was a predisposing factor for 
pneumonia in the 2 patients who developed this complication.  
3.4.2 Comparability  of  IVMP group and control group 
The 2 study groups were comparable in terms of disease duration, prior non-
cyclophosphamide immunosuppressive therapy, any lid surgery prior to enrolment 
or during the study follow-up period, and use of topical corticosteroids (Table 3.1). 
The median age in the control group was younger (58 years) than that in the IVMP 
group (76 years) but this difference was not significant with these numbers. 
Mucous membrane graft fornix reconstruction was carried out on the study eye in 2 
patients in the IVMP group (at weeks 24 and 39), and 1 patient in the control group 
(at week 26). Calculations of the bulbar inflammation scores following surgery in 
these patients excluded the quadrants involving the mucosal graft.  
 
Prognostic variables in the IVMP group appeared to be slightly worse than those in 
the control group, suggesting that any definitive trial would need to stratify for such 
factors in the randomisation. The study eye in the IVMP group had a higher initial 
bulbar inflammation score (median 12.5) compared with the control group (median 
11), more advanced cicatrisation (10/10 Tauber stage IIb or above and 10/10 
Tauber stage IIIa or above in the IVMP group versus 7/10 and 8/10 respectively in 
the control group) as well as shorter upper and lower fornix depths and a higher 
initial cicatrising conjunctivitis severity score (Table 3.2).  
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Table 3.1 Patient characteristics 
PATIENT CHARACTERISTICS All IVMP Control 
(n=20)  (n=10) (n=10)
Age (median, range) 61 (51 - 82) 76 (53 - 82) 58 (51 - 82)
Gender
Male 14 8 6
Female 6 2 4
Eye
Right 14 6 8
Left 6 4 2
IF positive 17 8 9
Extraocular Disease 10 4 6
Autoimmune Disease 220
Disease Duration in Years (median, range) 2 (0 - 18) 2 (0 - 10) 2 (3 - 18)
Any Lid surgery 633
Topical Steroids used during Trial 15 6 9
Prior non-cyclophosphamide immunosuppressive therapy 945
IVMP = intravenous methylprednisolone, IF = immunofluorescence  
Table 3.2 Clinical features of the study eye 
All IVMP Control 
(n=20)  (n=10) (n=10)
Initial Bulbar Inflammation Score ( / 16) 11 (8.5 - 16) 12.5 (10 - 16) 11 (8.5 - 12.5)
(median, range)
Initial Tauber Stage (lower lid)
II a 3 0 3
II b 4 4 0
II c 7 2 5
II d 6 4 2
Tauber stage IIb or greater 100% (10/10) 70% (7/10)
III a 5 1 2
III b 5 4 1
III c 3 0 3
III d 7 5 2
Tauber stage IIIa or greater 100% (10/10) 80% (8/10)
Fornix Depth (mm)
Upper (median, range) 11 (4 - 21) 10 (4 - 20) 12 ( 4 - 21)
Lower  (median, range) 4 (0 - 10) 3.5 (0 - 6) 4 (0 - 10)
Visual Acuity (LogMAR) 0.18 (0.00 - 1.00) 0.18 (0.00 - 1.00) 0.30 (0.00 - 1.00)
(median, range)
Initial MMP Severity Score ( / 63) 29 (15 - 43) 32.5 (19 - 43) 27 (15 - 39)
(median, range)
IVMP = intravenous methylprednisolone, MMP = mucous membrane pemphigoid    103
3.4.3 Primary  outcome 
The primary outcome measure, the proportion of patients with control of 
inflammation at 6 weeks, was 20% (2/10) in the IVMP group and 20% (2/10) in the 
control group (Table 3.3). A rapid response to IVMP was observed at 2 weeks, but 
the effect was short-lived and not maintained at 4 weeks. Additional therapy was 
required after week 12 due to poor inflammatory control in 33.3% (3/9 patients: 
rituximab in 2 patients, dapsone in 2 patients) and 30% (3/10: dapsone in all 3 
patients) of the patients in the IVMP and control groups respectively. A rebound of 
inflammation following initial control (which was persistent despite addressing 
potential ocular surface causes of a flare of inflammation including blepharitis, 
dessication, exposure, trichiasis, and was therefore likely to be due to the 
underlying immune disorder) was observed in 75% (6/8) and 40% (4/10) of the 
IVMP and control groups respectively. The median time to control was 8 weeks in 
the IVMP group and 14 weeks in the control group. Representative plots of the 
response of bulbar inflammation to treatment over the 12 month follow-up period 
are shown in Figure 3.5. 
 
The masked photographic grading scores of bulbar conjunctival inflammation 
tended to be higher than the masked observer scores, with larger differences 
observed where there was higher inflammation.  In no case was disagreement 
greater than 5 points. This is shown in Figure 3.6. 
 
An exploratory analysis suggested that factors associated with absence of control 
of inflammation at 6 months included a longer disease duration, a positive 
immunopathology result, any lid surgery, a higher initial cicatrising conjunctivitis 
severity score, and a longer duration to control of inflammation (Table 3.4). 
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Table 3.3 Control of inflammation at different time points 
All IVMP Control 
(n=20)  (n=10) (n=10)
% controlled at 6 weeks 20% (4/20) 20% (2/10) 20% (2/10)
% controlled at 16 weeks 40% (8/20) 37.5% (3/8) 55.6% (5/9)
% of these controlled at 6 mths 71% (5/7) 100% (3/3) 75% (3/4)
% of these controlled at 12 mths 71% (5/7) 66.7% (2/3) 75% (3/4)
% controlled at 6 months 43.8% (7/16) 50% (4/8) 37.5% (3/8)
% controlled at 12 months 66.7% (10/15) 62.5% (5/8) 71.4% (5/7)
Median time to control (weeks) 20 (2 - 52) 8 (6 - 52) 14 (2 - 48)
(range)
Additional therapy required after week 12 due to  31.5 (6/19) 33% (3/9) 30% (3/10)
poor inflammatory control
Inflammation rebound after initial control 55.6% (10/18) 75% (6/8) 40% (4/10)
 
Table 3.4 Factors associated with control of inflammation at 6 months 
Controlled at 6 months Not controlled at 6 months
 (n=7) (n=9)
Received IVMP 43% (3/7) 44% (4/9)
Age (median, range) 62 (51 - 82) 59 (53 - 76)
Immunopathology positive 71% (5/7) 89% (8/9)
Extraocular Disease 43% (3/7) 56% (5/9)
Autoimmune Disease 14% (1/7) 11% (1/9)
Disease Duration (years) (median, range) 0.25 (0.1 - 7) 2 (0 - 18)
Any Lid surgery 43% (3/7) 78% (7/9)
Topical Steroids used during Trial 71% (5/7) 89% (8/9)
Initial Bulbar Inflammation (median, range) 11 (8.5 - 14) 11 (8.5 - 16)
Initial Cic Conj Severity Score (median, range) 23.5 (15 - 27) 30.75 (17.5 - 43)
Fornix Depth- upper (mm) (median, range) 12 (10 - 16) 8.5 (3.5 - 21)
Fornix Depth- lower (mm) (median, range) 3 (1 - 10) 4 (0 - 10)
Median time to control (weeks) (range) 16 (6 - 24) 32 (2 - 52)
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Figure 3.5 Change in bulbar inflammation over 12 months 
Representative plots of the response of bulbar inflammation to treatment over the 
12 month follow-up period, for 5 patients in the IVMP intravenous 
methylprednisolone group, and 5 patients in the control group. 
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Figure 3.6 Bland Altman plot comparing the masked photographic score and 
masked observer score of bulbar inflammation. The Y axis shows the observer 
score minus the photographic score, the X axis shows the average of the 
photographic and observer scores. There are more points below the line than 
above, indicating a tendency for the photographic scores to be higher than the 
observer scores, with larger differences observed when there is greater 
inflammation. 
 
3.4.4  Progression of cicatrisation 
Of the 16 patients with 12 month follow-up data, there was a decrease in fornix 
depth of at least 2mm in 25% (2/8) of both the IVMP and control groups. An 
increase in the centripetal or circumferential extent of corneal pannus was detected 
in 75% (6/8) of the IVMP patients and 50% (4/8) of the control group patients 
(Table 3.5).  Although the small patient numbers limit  the ability to make 
conclusions from the data, there did not appear to be any correlation between time 
to control of inflammation and increase in fibrosis, but the median time to control of 
inflammation in patients without an increase in corneal pannus was shorter (week 
10) than in patients who did have an increase in corneal pannus (week 26), 
suggesting that more rapid control of inflammation is associated with a reduced 
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likelihood of progression in corneal pannus. The cicatrising conjunctivitis severity 
score at 12 months improved (a reduction in the score) in all 16 patients apart from 
one patient in the IVMP group where it worsened. Best corrected visual acuity 
worsened in 3 patients and improved in 1 patient in the IVMP group, and improved 
in 2 patients in the control group; there was no change in the remaining patients. 
Characteristics of the patients in whom progression of fibrosis at 12 months was 
detected are described in Table 3.6. 
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Table 3.5 Progression of cicatrisation 
All IVMP Control 
(n=16)  (n=8) (n=8)
Decrease in fornix depth 25% (4/16) 25% (2/8) 25% (2/8)
Time to control in patients with decrease in fornix depth Week 16 (week 8 to 52) Week 20, week 52 Week 12, week 8
Time to control in patients with no change in fornix depth (median, range) Week 20 (week 2 to week 48) Week 24 (week 6 to week 32) Week 18 (week 2 to week 48)
Increase in corneal pannus 62.5% (10/16) 75% (6/8) 50% (4/8)
Time to control in patients with increase in pannus (median, range) Week 26 (week 6 to week 52) Week 32 (week 6 to week 52) Week 20 (week 8 to week 48)
Time to control in patients with no change in pannus (median, range) Week 10 (week 2 to week 24) Week16 (week 8 to week 24) Week 10 (week 2 to week 20)
Reduction in Cicatrising Conjunctivitis Severity Score (median, range) 7.5 (increase 3.5 to reduction 12.5) 7 ( increase 3.5 to reduction 12.5) 8 (reduction 0.5 to reduction 12)
Change in visual acuity (median, range) Nil (loss 8 lines to gain 2 lines) Nil (loss 8 lines to gain 1 line) Nil (no change to gain 2 lines)
 
 
Table 3.6 Characteristics of patients who developed fibrosis 
Progression of fibrosis No progression
 (n=4) (n=15)
Received IVMP 50% (2/4) 47% (7/15)
Age (median, range) 69 (58 - 83) 60 (51 - 82)
Immunopathology positive 100% (4/4) 80% (12/15)
Extraocular Disease 50% (2/4) 47% (7/15)
Autoimmune Disease 0 13% (2/15)
Disease Duration (years) (median, range) 0.6 (0 - 5) 2 (0.1 - 18)
Any Lid surgery 50% (2/4) 67% (10/15)
Topical Steroids used during Trial 100% (4/4) 73% (11/15)
Initial Bulbar Inflammation (median, range) 12 (11 - 16) 11 (8.5 - 14)
Initial Cic Conj Severity Score (median, range) 35 (23.5 - 43) 28.5 (15 - 39)
Fornix Depth- upper (mm) (median, range) 9 (3.5 - 12) 12 (4 - 21)
Fornix Depth- lower (mm) (median, range) 3.5 (1 - 5) 4 (0 - 10)
Median time to control (weeks) and range 18 (8 - 52) 20 (2 - 48)
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3.4.5   Adverse effects 
With regard to adverse effects, IVMP was associated with transient increased 
blood sugar levels requiring adjustment of or additional hypoglycaemic medication 
in 40% (4/10), increased intraocular pressure and bone loss in one patient who had 
other osteoporosis risk factors including a slim build and lack of weight bearing 
exercise. No patients developed avascular hip necrosis. Weight gain was more 
frequent in the control group (50%, 5/10) than in the IVMP group (20%, 2/10) even 
though both groups of patients received similar 12 week courses of tapering oral 
corticosteroids (Table 3.7). 
   
Major adverse effects occurred in 2 patients in the IVMP group: 1 patient 
developed haemorrhagic cystitis when cyclophosphamide was withdrawn due to 
leukopenia and hepatotoxicity, another developed bacterial pneumonia and heart 
failure. Major adverse effects occurred in 2 patients in the control group: 1 patient 
developed pneumocystis pneumonia and disseminated cytomegalovirus infection, 
and another patient developed bacterial pneumonia. 
 
Cyclophosphamide was discontinued in 40% of patients (8/20) before the end of 
the preferred 12 months duration of therapy because of adverse effects, the most 
common reasons being lymphopenia/ leukopenia with or without associated 
secondary infection, hepatotoxicity, anorexia and lethargy.    
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Table 3.7 Adverse effects 
IVMP Control Total 
 (n=10) (n=10) (n=20)
Pneumocystis pneumonia and disseminated CMV 1 1
MAJOR ADVERSE EFFECTS Bacterial pneumonia 1 1 2
Haemorrhagic cystitis following  cessation of cyclophosphamide  1 1
Increased blood sugar levels 40% (4/10) 10% (1/10) 25% (5/20)
Weight gain 20% (2/10) 50% (5/10) 35% (7/20)
Sweating 10% (1/10) 10% (1/10) 10% (2/20)
STEROID Increased intraocular pressure 10% (1/10) 0 5% (1/20)
Increased systemic blood pressure 0 10% (1/10) 5% (1/20)
Hirstutism 0 10% (1/10) 5% (1/20)
Bone loss detected on bone scan 10% (1/10) 0 5% (1/20)
Lymphopenia 60% (6/10) 50% (5/10) 55% (11/20)
mild - requiring dose reduction 20% (2/10) 30% (3/10) 25% (5/20)
severe - requiring cessation 40% (4/10) 20% (2/10) 30% (6/20)
CYCLOPHOSPHAMIDE Lethargy 50% (5/10) 50% (5/10) 50% (10/20)
Diarrhoea 0 30% (3/10) 15% (3/20)
Anorexia 10% (1/10) 30% (3/10) 20% (4/20)
Insomnia 0 20% (2/10) 10% (2/20)
Increased micturition 10% (1/10) 10% (1/10) 10% (2/20)
Alopecia 20% (2/10) 10% (1/10) 15% (3/20)
Metallic taste in mouth 10% (1/10) 10% (1/10) 10% (2/20)
Liver function test abnormalities 10% (1/10) 0 5% (1/20)
Proportion of patients who stopped cyclophosphamide before 12 months because of adverse effects 40% (4/10) 40% (4/10) 40% (8/20)
No major adverse side effects with corticosteroid treatment 90% (9/10) 100% (10/10)95% (19/20)
No major adverse side effects with cyclophosphamide treatment 60% (6/10) 60% (6/10) 60% (12/20)  111
3.5 Discussion 
This pilot randomised controlled clinical trial did not detect any difference in the 
proportion of ocular MMP patients with control of inflammation at 6 weeks, between 
those that received adjunctive pulse intravenous methylprednisolone (IVMP) 
treatment, and the control group.  This study was powered to detect a very large 
treatment difference of 70%, that is, given the published success rate of 
conventional therapy being 20% at 6 weeks, a difference would have been 
detected if the efficacy of IVMP was 90% at 6 weeks.  
 
The number of patients recruited is small and the numbers who made it to one 
year’s follow-up are even smaller, so that there is considerable uncertainty 
regarding exact success rates.  It is not possible to rule out any treatment effect at 
this stage; it is also important to note that at baseline, the treatment group did 
appear worse with regards several prognostic factors. This study does suggest 
however that if a difference does exist, it is small and very large numbers of 
patients would be required for a definitive study.  For example, if we assume a 
success rate of 20 % at 6 weeks and believe that the smallest clinically relevant 
treatment difference to detect at the 5% level is 20%, in order to achieve a study 
with 85% power, 93 patients per treatment group would be needed. These figures 
would then need to be inflated to allow for loss to follow-up, which this pilot study 
suggests might be considerable.  In this study, randomisation was employed so the 
differences at baseline between the study groups are known to have occurred by 
chance, but this does emphasise the need to consider whether or not to stratify 
randomisation for a definitive trial.   
 
Whilst the majority of the side effects of IVMP in this study were minor, transient or 
manageable with additional medications, one patient did have detectable bone loss 
despite receiving bisphosphonate, calcium and vitamin D therapy. Bone loss in 
patients treated with IVMP but not receiving bisphosphonates or oestrogen has   112
previously been reported (Haugeberg et al., 2004).  Given these findings, the use 
of adjunctive pulse IVMP to control inflammation in severe ocular MMP cannot 
currently be recommended.  
 
The short-lived effects of pulse IVMP therapy have previously been observed in 
rheumatoid arthritis, where despite its effectiveness in achieving rapid, temporary 
relief of disease flares for up to 6 weeks (Williams et al., 1982), repeated monthly 
pulses over 12 months did not enhance or accelerate the effect of disease 
modifying drugs such as penicillamine and azathioprine (Hansen et al., 1990). 
Similarly in systemic lupus erythematosus, the additive effect of pulse IVMP on a 
background of conventional oral corticosteroid treatment showed an improvement 
in the first 2 weeks after IVMP administration, but this difference was not 
maintained at one month or subsequently (Mackworth-Young et al., 1988).  
Moreover, equivalent doses of oral prednisolone have similar clinical and 
immunological effects to IVMP in rheumatoid arthritis, indicating that pulse oral 
treatment can be administered without the inconvenience, cost and potential 
dangers of intravenous administration (Smith et al., 1988).      
 
Compared to previous studies, the study in this chapter found lower success rates 
of control of inflammation at 6 weeks, and at other time points during the 12 month 
follow-up period, with conventional oral corticosteroid and cyclophosphamide. 
Elder et al (Elder et al., 1995) evaluated 10 ocular MMP patients (19 eyes) in a 
retrospective study with similarly severe (grade 3 or 4) conjunctival inflammation, 
and found 5/19 eyes (26%) or 3/10 patients (30%) took 6 weeks or less for 
inflammation to resolve. It was not specified in Elder’s study whether the 
inflammation recurred, once it had apparently resolved in any eye, but if it is 
assumed that there was no recurrence of inflammation then by 6 months 15/19 
(79%) and 7/10 (70%) of patients had control of inflammation. In contrast, we found 
20% (2/10) of patients in the conventional treatment group had control of 
inflammation at the 6 week time-point, and only 3/8 (37.5%) at the 6 month time-  113
point. These differences may be partly due to our evaluations occurring at a 
specific time-point rather than describing the time taken for inflammation to resolve; 
with the former method, if inflammation has rebounded after initial control, then 
these patients would subsequently be considered to be uncontrolled at the later 
time-point of assessment. We found that inflammation rebounded after initial 
control, in approximately half the patients over the 12 month follow-up period (see 
Table 3.3 and Figure 3.5). The differences may also partly be due to our definition 
of control of inflammation being a total bulbar inflammation grade of 6 or less out of 
a potential maximum total of 16, as assessed by a masked observer. In the Elder 
study the observer was not masked, and the “grade 1” conjunctival inflammation 
which was accepted as a successful outcome was an overall grade, rather than 
specifying a grade for each quadrant of bulbar conjunctiva. Foster reported 
successful control of inflammation by week 6 in 6/12 (50%) of patients receiving 
oral prednisone and cyclophosphamide (Foster, 1986), but the pre-treatment 
conjunctival inflammation in these patients may not have been as severe as those 
in our study. These studies did not describe the need for additional therapy in 
combination with cyclophosphamide and oral corticosteroids. In our study, 
additional therapy (dapsone and /or rituximab) was required after week 12 due to 
poor inflammatory control in 33.3% (3/9) and 30% (3/10) of the patients in the 
IVMP and control groups respectively.  
 
We evaluated bulbar conjunctival inflammation by two methods: masked 
photographic grading and masked observer grading. The masked photographic 
scores tended to be higher than the masked observer scores, with larger 
differences observed where there was greater inflammation. This difference could 
have been due to inconstancies in exposure and lighting on the photographs 
influencing the photographic grading, as well as the quality of the photographs, 
given that it was sometimes difficult to clearly photograph all four bulbar 
conjunctiva quadrants due to the amount of conjunctival tethering and patient 
discomfort.    114
 
In this study, despite all patients receiving maximum tolerated levels of 
cyclophosphamide immunosuppression, and 40% needing to stop 
cyclophosphamide because of significant adverse effects associated with dose-
related toxicity, progression of conjunctival fibrosis (a decrease in fornix depth and/ 
or new symblephara) was detected in 4/16 (25%) of all patients reaching the 12 
months follow up. This suggests that systemic immunosuppressive therapy alone 
may not be sufficient to arrest cicatrisation, in part because the high doses required 
to sufficiently control the inflammation that is driving cicatrisation are not tolerated 
in this elderly patient population, and in part perhaps because systemic 
immunosuppression does not specifically control the matrix deposition and 
remodelling phases of fibrosis. 
 
To the best of the author’s knowledge, this is the first pilot clinical trial investigating 
the possible additive effect of IVMP on rapidity of control of inflammation in patients 
with severely active ocular MMP commencing conventional oral corticosteroid and 
cyclophosphamide treatment. However, interpretation of the results is limited by 
the low power of this pilot study to detect anything other than a very large 
difference in effect. It is possible that the IVMP group in this study had more severe 
disease that was difficult to control, indicating selection bias (Table 3.2). It would 
have been ideal to have minimised this selection bias in our randomisation method 
by stratifying according to severity of the inflammation as well as by study centre. 
However with such small patient numbers, multiple stratifications are not feasible; 
this may need to be considered in an appropriately powered trial of treatment for 
this condition. There was a high exclusion rate in our study, mainly due to the 
patients declining to participate (18/40 (45%) of eligible patients). This highlights 
the difficulty of carrying out prospective controlled treatment studies in ocular MMP, 
where the patients are elderly and reluctant to be involved in the inconvenience of 
a treatment trial, and the disease is uncommon so achieving the large numbers   115
necessary for sufficient statistical power to detect smaller treatment differences 
within a limited time period is difficult without multicentre international efforts.  
3.6 Conclusion   
Severely active ocular MMP responds slowly to conventional immunosuppressive 
therapy, and this pilot randomised trial has shown that adjunctive pulse IVMP is 
unlikely to provide any additional effect, although to make a definitive statement 
about this would require a trial that is too large (more than 90 patients per group) to 
be justified by these pilot data. Better treatments that act rapidly to extinguish the 
autoimmune inflammatory drive are needed, with the intention of suppressing the 
cicatrisation pathway that is initiated by acute inflammation. Biological treatments 
such as tumour necrosis factor-alpha antagonists or rituximab are attractive 
candidate therapies, and require further investigation. The results of this trial will be 
of substantial value in the design and planning of studies using these biological 
therapies.  
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Chapter 4 
 
Tumour necrosis factor-alpha (TNFα) 
expression in ocular mucous membrane 
pemphigoid and its effects on conjunctival 
fibroblasts   117
4.1 Introduction 
As shown in Chapter 3, severely active ocular MMP responds slowly to 
conventional immunosuppressive therapy, and progression of cicatrisation is 
observed despite giving maximally tolerated treatment. Alternative therapies that 
act more rapidly and maintain a sustained effect may more effectively arrest 
cicatrisation.   
 
Several case reports have described successful use of TNFα antagonists in MMP 
patients with recalcitrant disease (Canizares et al., 2006; Heffernan & Bentley, 
2006; John et al., 2007; Prey et al., 2007).  However, based on current evidence, 
the scientific rationale for the use of TNFα antagonists in MMP is weak.  Although it 
has been reported that serum levels of TNFα are elevated in MMP compared with 
normal controls (Lee et al., 1993), there are limited studies examining TNFα 
expression in MMP tissue.  Tissue expression may be important because in 
rheumatoid arthritis, whilst there is no evidence that plasma TNFα levels can 
predict the clinical response to TNFα antagonists, synovial expression of TNFα 
appears to be a significant predictor of response to TNFα antagonists (Wijbrandts 
et al., 2007).  
 
Given our findings in Chapter 2 of conjunctival fibrosis still progressing despite 
apparent clinical control of inflammation by conventional immunosuppressive 
therapy, better understanding of the immunological changes in treated tissue 
compared with actively inflamed tissue would assist and guide in developing 
adjunctive local therapies to target conjunctival fibrosis.   
 
There is controversy about whether TNFα is a pro-fibrotic or anti-fibrotic cytokine 
(Distler et al., 2008; Saika et al., 2006; Sullivan et al., 2005; Theiss et al., 2005); if 
it has anti-fibrotic effects on conjunctival fibroblasts, antagonist therapy could 
worsen conjunctival fibrosis.  Before large controlled studies of the use of TNFα   118
antagonists in ocular MMP can be recommended, further investigations are 
necessary, including confirming its tissue expression in ocular MMP, and 
establishing whether TNFα has pro-fibrotic or anti-fibrotic effects on human 
conjunctival fibroblasts.   
 
The pathophysiology of conjunctival fibrosis in ocular MMP is poorly understood.  
Observations from other chronic mucosal fibrotic disorders provide insights into 
what could be occurring in ocular MMP. The role of CD40 signalling in regulation of 
inflammation and fibrosis has been demonstrated in the lung (Kaufman et al., 
2001; Sempowski et al., 1997). Chronic stimulation through CD40 may hence lead 
to fibrosis. Rather than merely acting as structural cells, fibroblasts thus appear to 
participate actively in the immune response by producing cytokines and 
chemokines that initiate the recruitment and retention of bone marrow-derived 
immune effector cells (Flavell et al., 2008). Given that conjunctival fibrosis in ocular 
MMP can still progress despite apparent clinical control of inflammation by 
conventional immunosuppressive therapy, better understanding of the cellular and 
molecular changes in treated tissue compared with actively inflamed tissue would 
assist and guide in developing adjunctive local therapies to target conjunctival 
fibrosis.   
4.2 Aim 
The aim of the study in this chapter was to investigate whether TNFα is expressed 
in conjunctival MMP tissue, evaluate changes in TNFα expression after systemic 
immunosuppressive treatment, and to determine whether TNFα has pro-fibrotic or 
anti-fibrotic effects on normal human conjunctival fibroblasts.  
4.3 Research design and methods 
4.3.1   Conjunctival Biopsies 
Bulbar conjunctival biopsies between 3 x 3mm to 4 x 4mm were obtained from 
patients with ocular MMP. Topical anaesthesia with proxymetacaine 0.5% or   119
oxybuprocaine 0.4% was given and biopsies of superior bulbar conjunctiva distant 
from the fornix were obtained using spring scissors and blunt forceps, as shown in 
Figure 1. Superior bulbar conjunctiva was chosen because healing of the biopsy 
site would be facilitated by the upper lid providing protection from exposure; the 
fornix was avoided because biopsies of fornix have been reported to cause further 
scarring (Mondino et al., 1979). The biopsies were divided into 3 pieces: 1 piece for 
direct immmunofluorescence (DIF) microscopic diagnosis, 1 piece for 
immunohistochemistry, and 1 piece for conjunctival fibroblast explant culture. The 
piece of conjunctiva for DIF was placed directly into Michel’s medium, and the 
other 2 pieces were placed into Leibovitz L-15 medium containing 100IU/ml 
penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin B (all from Gibco 
Invitrogen Ltd, Paisley, Scotland UK ) to support cell growth in non-CO2-
equilibrated conditions during transportation to the laboratory.  
 
The patients were classified according to the grade of ocular inflammation present 
as having active disease with acute inflammation (Figure 4.2 A) (n=10), or chronic 
disease (n=10) without clinically apparent inflammation (Figure 4.2 B), after 
treatment with immunosuppressive therapy. The diagnosis of ocular MMP was 
based on clinical presentation and positive immunopathology. However, in the 
presence of characteristic clinical features, negative immunopathology did not 
exclude the diagnosis of ocular MMP. Conjunctivae from 10 individuals with normal 
conjunctiva undergoing routine cataract surgery were used as controls; these 
biopsies were harvested just before the surgical procedure began, after instillation 
of topical anaesthesia.  
 
Details of the patients from whom conjunctival biopsies were used for the TNFα 
experiments presented in this chapter are shown in Table 4.1.  A larger number of 
biopsies were taken but only approximately 50% of the biopsies harvested 
successfully grew conjunctival fibroblasts for culture. The tenets of the Declaration 
of Helsinki were followed, and approval from the Oxfordshire Research Ethics   120
Committee (for biopsies of normal conjunctiva and for conjunctival biopsies from 
ocular MMP patients participating in the clinical trial described in chapter 2; see 
Appendix 3) and from the Moorfields and Whittington Ethics Committee (for 
biopsies of active and uninflamed conjunctiva from clinic patients with ocular MMP; 
see Appendix 5) was granted. Informed consent was obtained from all patients 
and normal controls who provided conjunctival tissue for the study.   
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Figure 4.1 Biopsy of superior bulbar conjunctiva 
 
 
 
 
 
Figure 4.2 A. Patient with actively inflamed ocular mucous membrane 
pemphigoid (active case 1, L eye), B. Following immunosuppressive therapy, 
patient with clinically uninflamed treated ocular mucous membrane 
pemphigoid (uninflamed case 8, R eye)   122
Table 4.1 Details of patients and normal controls whose conjunctival biopsies were used in TNFα studies 
Disease Bulbar
Diagnosis Case  Age Gender duration inflammation Tauber stage Topical therapy Systemic therapy Other eye pathology
number (yrs)  grade (0 to 4) (Upper stage/ Lower stage)
1 54 F 0.5 3 IIcIIId/ IIcIIId hypromellose, acetylcycsteine, yellow soft paraffin nil
2 80 M 10 3 IIbIIIc(2)/ IIdIIId(2) carmellose mycophenolate + dapsone
3 60 F 2 3 I/ IIcIIIc(3) carmellose mycophenolate + dapsone
4 74 M 2 3.5 IIa/ IIcIIIc(2) dorzolamide, bimatoprost nil glaucoma
Active MMP 5 76 F 2 2.5 IIc/ IIbIIIa(2) prednisolone, hypromellose, carmellose mycophenolate + dapsone sicca, blepharitis
6 51 F 0.1 3 I/ IIIa(1) nil nil
7 57 M 0.5 3 IIb/ IIcIIIb(2) dexamethasone, lacrilube nil
8 64 F 1 2 IIa/ IIbIIIc(2) prednisolone nil
9 83 F 7 3 IIa/ IIbIIIb(2) brimonidine, latanoprost, timolol, dorzolamide, carmellose mycophenolate + doxycycline glaucoma
10 72 F 0.25 4 IIa/ IIcIIIc(2) ofloxacin, cyclopentolate, carmellose nil microbial keratitis
1 59 F 10 1 IIbIIIb(2)/ IIdIIId(2) carbomer 980 dapsone
2 86 F 15 1 IIb/ IIcIIIb(2) nil nil
3 78 F 10 1 IIbIIIb(2)/ IIdIIId(2) nil nil
4 84 F 2 0 IIb/ IIcIIIc(2) nil mycophenolate
Treated uninflamed MMP 5 66 F 2 0 IIb/ IIcIIIb(2) nil dapsone
6 76 F 4 1 IIc/ IIcIIIc(3) betaxolol dapsone glaucoma
7 59 M 4 1 I/ IIa hypromellose, carmellose, liquid paraffin, chloramphenicol cyclophosphamide
8 76 M 6 1.5 IIdIIId(2)/ IIbIIIb(2) chloramphenicol, hypromellose, retinoic acid, acetylcysteine cyclophosphamide blepharitis
9 60 F 3 1 I/IIaIIIa(1) carmellose cyclophosphamide + dapsone
10 62 F 0.75 0.5 IIa/ IIcIIIa(1) hyaluronate prednisolone
1 50 F - 0 - nil nil cataract
2 76 M - 0 - nil nil cataract
3 65 M - 0 - nil nil cataract
4 70 F - 0 - nil nil cataract
Normal control 5 65 M - 0 - nil nil cataract
6 73 M - 0 - nil nil cataract
7 84 F - 0 - nil nil cataract
8 57 M - 0 - nil nil cataract
9 84 F - 0 - nil nil cataract
10 62 M - 0 - nil nil cataract
MMP= mucous membrane pemphigoid    123
4.3.2 Immunohistochemistry  
Expression of TNFα protein was investigated by immunohistochemistry on glycol 
methacrylate (GMA) resin-embedded sections of conjunctiva, prepared as 
described previously (Bernauer et al., 1993b).  GMA-embedded sections generate 
an immunophenotypic profile similar to that obtained in frozen sections, while 
yielding far superior morphology and greater numbers of sections from small 
biopsies (Britten et al., 1993). Fresh biopsy tissue was immediately placed in ice-
cooled acetone containing protease inhibitors, stored overnight at -20
oC, then 
processed for, and embedded in, glycol methacrylate (GMA) resin using the JB4 kit 
(TAAB Laboratories, Aldermaston, UK). The blocks were stored at -70
oC. An 
ultramicrotome was used to cut 2µm sections, mounted on poly-L-lysine-coated 
slides and air dried.  
 
Endogenous peroxidase was inhibited using a solution of 0.3% hydrogen peroxide 
in 0.1% sodium azide for 10 minutes (Sigma-Aldrich, Dorset, UK), followed by 2 
five-minute PBS (phosphate-buffered saline) washes then incubation for 30 
minutes with 10% foetal calf serum to prevent non-specific binding of monoclonal 
antibody. The sections were incubated overnight at room temperature with a 
mouse antibody against human TNFα (Abcam Ltd, Cambridgeshire UK [ab9579]) 
at 1:50 dilution. After washing in PBS, biotinylated rabbit anti-mouse 
immunoglobulin 1:200 (Dako, Cambridgeshire UK) was applied to the sections for 
2 hours. Following a further wash in PBS, the slides were incubated with 
streptavidin-peroxidase 1:300 (Dako) for 2 hours, again washed in PBS and finally 
developed for 25 minutes with amino-ethyl carbazole (AEC, Dako), forming a red 
AEC reaction product.  For TNFα-CD3 double staining, the slides were washed 
with PBS and the immunohistochemistry process was repeated using a primary 
mouse antibody against human CD3 (Dako) at 1:10 dilution, biotinylated anti-
mouse antibody (Dako) as the secondary antibody, and  3,3’diaminobenzidine 
(DAB) instead of AEC as chromagen. This formed a brown DAB reaction product.    124
The specimens were counterstained with Meyer’s hematoxylin (Dako) and 
mounted with glycergel (Dako). Double staining was identified by a combined red-
black colour, due to the combination of a positive reaction to AEC and DAB.  
Human tonsil sections were used as positive controls, and the two negative 
controls used were substituting the primary antibody for foetal calf serum or an 
isotype matched, irrelevant monoclonal antibody (Dako).  The number of cells 
stained in the conjunctival stroma were counted in a masked fashion in at least 5 
representative high power fields per patient, using an Olympus BX51 microscope 
with image analysis software. The presence of positive stromal or epithelial 
staining was also graded on a scale of 0 to ++++, based on both the number of 
cells stained and staining intensity.  
 
The presence of protein expression by immunohistochemistry was considered to 
be sufficient evidence, given time constraints and limited amounts of tissue 
available, of TNFα being involved in the immunopathology of ocular MMP. 
Immunohistochemistry was favoured because double staining could give additional 
information about the cellular source of TNFα expression, whereas alternative 
methods such as Western blotting would involve utilizing the whole specimen to 
confirm protein expression, but could not give additional information regarding the 
cellular source. Once the staining method had been optimized including dilutions, 
all the immunohistochemical staining was carried out on the active (n=10), 
uninflamed (n=10) and control (n=10) sections at one sitting, to minimize variations 
in staining technique.  
4.3.3   Isolation of conjunctival fibroblasts 
Explant culture 
Fibroblasts were grown as explants from the conjunctival biopsies as previously 
described (Khaw et al., 1992). Using aseptic technique in a laminar flow hood, the 
piece of conjunctiva was placed in Dispase II (Roche Diagnostics, Basel, 
Switzerland) for 1 minute then scraped gently with a scalpel to remove the   125
epithelium. The tissue was placed in a collagen-coated well of a 24-well tissue 
culture plate (Fisher Scientific, Leicestershire UK), then a 10mm diameter glass 
cover slip (Raymond A Lamb, East Sussex UK) was placed on top, and the biopsy 
under the coverslip in the culture well was incubated at 37
oC for 30-45 minutes 
depending on the size and moistness of the biopsy (shorter duration for smaller, 
less moist biopsies, to avoid drying out and death of the cells), before gently 
adding 80µl of fibroblast culture medium (FCM, see below) to the well. The 
purpose of the coverslip and short period of initial incubation without cell culture 
medium were to promote tissue fixation and adhesion to the tissue culture surface, 
which is necessary to facilitate fibroblast outgrowth, prior to adding culture medium 
which would otherwise dislodge the tiny piece of tissue from the tissue culture 
surface. The coverslip also protected the small biopsy from potential displacement 
and loss when refeeding during early growth. After the first 24hours, when 
adhesion was evident, more culture medium was gently added so that there was at 
least 500µl medium in the well. The surrounding wells were filled with sterile PBS 
to ensure that the biopsy remained in a humid environment.  
 
The collagen-coated wells were prepared prior, using sterile 0.1mg/ml rat tail type I 
collagen mixture, prepared by diluting stock 5mg/ml collagen mixture (see section 
4.1.1 below for preparation of 5mg/ml collagen mixture) 1:50 using 1:1000 acetic 
acid solution, and incubating 500µl of this diluted collagen mixture per well of a 24-
well plate for 2 hours at 37
oC, then removing the collagen and washing the well 4 
times with sterile PBS to minimize cell toxicity due to the acetic acid contained in 
the collagen. These plates were then dried out under the flow hood, sealed with 
parafilm and stored at 4
oC.     
Feeding biopsies and harvesting passage 1 cells 
Fibroblast culture medium (FCM) was composed of Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% (v/v) heat inactivated foetal calf serum, 
100IU/ml penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin B (all from   126
Gibco) and the biopsies and cells were cultured at 37
oC with 5% (v/v) CO2 in air.  
The primary biopsies were fed once weekly, and fibroblasts were usually noted 
within 1-3 weeks of culture. Any residual epithelial cells appeared to die and were 
not evident beyond 4 weeks. Once the well was densely confluent at 4 to 8 weeks, 
the cells peripheral to the biopsy were displaced from the culture surface by 
aspirating the culture medium, washing twice with warm sterile PBS, followed by 
incubation with 400µl of prewarmed 1 x trypsin/ EDTA (Gibco) for 1-2 minutes, and 
then gentle pipetting and aspiration of the displaced cells peripheral to the biopsy, 
whilst avoiding dislodgement of the primary biopsy. The PBS washes were 
necessary to wash the serum off and allow the trypsin to work. The aspirated cell 
suspension was then placed into 6-well culture plates containing 2 ml FCM. It was 
necessary to subculture the passage 1 cells into 6 well plates as a first stage, 
because there were insufficient passage 1 cells to support growth in 25cm
2 flasks.  
Passaging cell cultures in plates and flasks 
Once the 6 well plates were confluent, cells were then passaged 1:3 with 
trypsin/EDTA, either in 6 well plates or in 25cm
2 to 175cm
2 cell culture flasks 
(Nunc, VWR International, Leicestershire, UK). Cells were assessed weekly by 
viewing with a phase contrast inverted microscope and passaged cells were fed 
once or twice weekly. Cells were passaged by aspirating the culture medium, 
washing twice with warm sterile PBS, incubating for 1-2 minutes with warm 
trypsin/ETDA then gently pipetting to mechanically dislodge the cells from the 
plates, or tapping the undersurface of the flasks. The plates or flasks were then 
viewed at x100 magnification with a phase contrast inverted microscope (Nikon). 
When most of the cells were seen to be rounded up, the action of trypsin was 
stopped by adding an equivalent volume of FCM containing 10% foetal calf serum. 
This cell suspension was then centrifuged for 5 minutes at 1000 rpm and the 
supernatant aspirated to obtain a cell pellet which was then resuspended in culture 
medium as necessary for passaging, or for experiments. Unless otherwise 
specified, cultures were used between passages 3 and 7 for experiments, and   127
cultures were assessed for typical fibroblast morphology by phase contrast 
microscopy before every experiment. By passage 3 onwards, contaminating 
epithelial cells had been eliminated in cultures that had been fed only FCM, due to 
the fastidious nutritional requirements of epithelial cells.  
Storage and recovery of cells in liquid nitrogen 
Additional cells were cryopreserved by resuspending the cell pellet in FCM which 
contained 20% foetal calf serum, then adding drop-wise an equivalent volume of 
20% dimethylsulfoxide (DMSO) solution (prepared by adding 2ml DMSO to 8ml 
20% serum-containing FCM).This cell suspension was then distributed into 1ml 
cryovials with approximately 1 x 10
6 cells/ml per vial, and the cryovials were placed 
into the inner chamber of a plastic container containing isopropanol in the outer 
chamber, which was designed to slowly reduce the temperature in the inner 
chamber by 1
oC increments to avoid cell toxicity. This container was placed in the -
70
oC freezer overnight, then the cryovials were transferred to liquid nitrogen 
storage (> -180
oC). Cryopreserved cells were recovered by gently defrosting the 
mixture in the cryovial using a 37
oC waterbath, then immediately adding the liquid 
mixture, drop-wise, to 10ml warmed FCM containing 20% foetal calf serum. This 
cell suspension was then centrifuged at 1000rpm for 5 minutes, and the cell pellet 
was resuspended in FCM for seeding into an appropriate sized flask or plates. The 
use of 20% serum-containing medium was found to protect the cells from DMSO 
toxicity.  
Serum-free medium (SFM) 
Serum-free medium (SFM), composed of Dulbecco’s modified Eagle’s medium 
(DMEM) and 0.1% bovine serum albumin (Sigma-Aldrich), supplemented with 
100IU/ml penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin B was 
used wherever possible in experiments where the effect of the addition of a 
cytokine was being evaluated. Testing under serum-free conditions eliminated the 
possibility that the observed response could be due to the activity of unspecified   128
cytokines and growth factors present in serum-containing medium, even with the 
use of heat-inactivated serum.   
 
The cultured conjunctival fibroblasts were used in experiments assessing several 
aspects of fibroblast activity, including migration, extracellular matrix contraction, 
matrix metalloproteinase production and surface expression of markers of 
activation and co-stimulatory molecules.   
 
The optimal concentration of cytokine (e.g. TNFα) used in experiments was initially 
determined from previous literature (Leonardi et al., 2003). If this level did not 
result in a significant response, a range of concentrations of TNFα [1, 10, 
100ng/ml] was then evaluated in a preliminary dose-response experiment. The 
concentration that showed the greatest response in this preliminary experiment 
was then selected as the optimal concentration for that assay. 3T3 cells (a mouse 
fibroblast cell line) were used for initial calibration experiments that compared a 
serum free negative control to a FCM positive control. 
4.3.4 Fibroblast  migration 
Cell culture inserts incorporating polyethylene terephthalate membranes with a 
pore size of 8µm (BD Falcon, VWR International, Leicestershire UK), which fit into 
wells in a tissue culture plate, were used to assess fibroblast migration in the 
presence of TNFα. Cells were seeded into the inserts at a density of 8000 per 
insert in 200µl SFM and allowed to attach to the upper surface of the membrane for 
4 hours. A volume of 700µl of the medium being tested for chemoattractant 
properties was added to the well in the tissue culture plate, so that the test medium 
was in contact with the undersurface of the membrane in the culture insert. To 
investigate the effect of TNFα on normal conjunctival fibroblast migration, 10ng/ml 
of recombinant human TNFα (R&D Systems Europe Ltd, Abingdon UK) in SFM 
was added to the culture well. SFM alone was used as a negative control, and 10% 
serum-containing FCM as a positive control. The cells were incubated for 16 hours   129
to permit migration through the pores, to the undersurface of the membrane.  The 
culture inserts were then washed with PBS to remove excess protein, fixed in 70% 
(v/v) methanol for 5 minutes, then stained with Mayer’s haematoxylin (Dako) for 30 
minutes and rinsed in tap water.  Settled cells on the upper surface of the 
membrane in the culture inserts were removed using cotton buds.  The number of 
migrated cells on the undersurface of the membrane was counted per 10x 
objective field (average of 5 fields) by taking photographs on an inverted phase 
contrast microscope and using cell counting software (Image J public domain Java 
image processing program http://rsb.info.nih.gov/ij/).   
4.3.5   Collagen contraction model 
To assess matrix contraction by conjunctival fibroblasts, fibroblast-populated 
collagen lattice models were used, similar to those described by Mazure and 
Grierson (Mazure & Grierson, 1992). The collagen gel contraction model was 
selected as an experimental method for these studies in part because it is more 
physiological, as the cells acquire tissue-like phenotypic characteristics not 
otherwise observed when growing cells in monolayers on plastic (Elsdale & Bard, 
1972), and in part because it maximized use of the limited numbers of primary 
conjunctival fibroblasts able to be obtained from the small conjunctival biopsies, in 
that it enabled use of one type of experiment to potentially assess 3 aspects of 
fibroblast function: (1) collagen matrix contraction, (2) secretion of matrix 
metalloproteinases, collagen and other molecules of interest in the conditioned 
medium, and (3) expression of surface or intracellular molecules on the fibroblasts 
in the collagen matrix by immunostaining and confocal microscopy.  
Preparation of fibroblast-populated collagen gels 
To prepare the collagen gels, a 5mg/ml collagen gel mixture was first made up by 
adding 1:1000 acetic acid solution (50µl glacial acetic acid in 50ml distilled water, 
filter sterilized) to 100mg of rat tail type I collagen (C-8897, Sigma-Aldrich) to give a 
total volume of 20ml. This mixture was incubated at 37
oC for 1-2 hours to dissolve,   130
then kept at 4
oC. The collagen gels were prepared by adding 0.6ml of the collagen 
gel mixture to 0.35ml concentrated medium stock solution (15ml of 10X DMEM 
(Gibco), 35ml sterile distilled water, 1.5ml of 10,000U/ml penicillin/10,000µg/ml 
streptomycin solution, 1.5ml of 2mM glutamine, and 4ml of 7.5% (w/v) sodium 
bicarbonate), which would provide enough mixture for 6 gels in a 48 well plate. The 
pH of this mixture was adjusted to 7.4 by adding 1M NaOH dropwise until the 
solution changed colour to pink. Then 0.15ml of the appropriate number of 
fibroblasts (see below) suspended in concentrated medium was added to the 
collagen mixture, and 150µl of this cellular gel mixture was quickly cast into each of 
6 wells of a 48 well plate. The plate was incubated at 37
oC for 2 hours to 
polymerise the collagen lattices.  
 
The gels were then fed with 0.5ml of the test culture medium (either SFM, SFM 
containing 10ng/ml TNFα, or 10% gelatinase-free serum-containing FCM) just prior 
to detaching the gels from the culture wells. This was done by using a micropipette 
to gently release the gel’s anchorage at 4 points around its circumference, whilst 
avoiding tearing the gels, then checking for free flotation of the gels using a gentle 
circular rotating motion. 
 
The gels were digitally photographed at days 1, 3 and 7, and the gel areas were 
calculated using image analysis software (Image J).  Conditioned media from the 
collagen lattice experiments was collected between days 0-3 and 3-7, or days 0-7, 
to assess matrix metalloproteinase secretion. At the end of the experiment, the 
collagen gels were washed with PBS and fixed with 4% paraformaldehyde (which 
was diluted to 0.4% paraformaldehyde after 24hrs) in order to preserve them for 
immunostaining and confocal microscopy at a later date.   
 
Gelatinase-free serum was produced by incubating foetal calf serum with gelatin 
sepharose beads (Gelatin Sepharose 4B, Amersham Biosciences, 
Buckinghamshire UK) at a concentration of 10% with gentle rocking for 2 hours.   131
This mixture was centrifuged at 4000rpm for 10 minutes to separate the beads 
from the gelatinase-free serum. 
Free-floating relaxed versus attached stressed collagen gel models 
In these free-floating relaxed collagen gels, contraction of collagen by the 
fibroblasts occurs in the absence of an external mechanical load. Alternative 
culture models also exist (Grinnell, 2000), where the gel matrix remains attached to 
the culture well (attached gel model), or where the collagen gel remains attached 
to the well for 48 hours before release (stress-relaxation gel model) (see Figure 
4.3). When the gel remains attached to the culture well, an external mechanical 
load develops during contraction of collagen by the fibroblasts, and assembly of 
actin stress fibres occurs within the cells, indicating differentiation into 
myofibroblasts (Garrett et al., 2004). This method was used in experiments which 
will be described in Chapter 6. 
Determining the optimum concentration of fibroblasts 
To determine the minimum number of human conjunctival fibroblasts required to 
give a measurable contraction of the collagen lattice over a period of 7 days, 
preliminary experiments were conducted, seeding lattices with fibroblasts at 5 x 
10
4, 1 x 10
5 and 2.5 x 10
5 cells per 0.15ml concentrated medium.  It was found that 
2.5 x 10
5 cells per 0.15ml concentrated medium yielded the required degree of 
contraction, when FCM was used as the test culture medium. This number of cells 
was therefore used for all subsequent experiments.     132
 
 
Figure 4.3 Models for the contraction of free-floating relaxed and stressed 
matrices. In the free-floating relaxed model, the cell-embedded matrix is released 
from the culture well immediately after matrix polymerisation. Polymerisation can 
be carried out for 1 or 2 hours. In the stress-relaxation model, the cell-embedded, 
polymerised matrix is cultured attached to the well, during which force exerted by 
the cells results in the development of isometric tension. Following this, the matrix 
is released (relaxed) to initiate contraction. Adapted from Grinnell F, 2000. 
 
 
4.3.6   Matrix metalloproteinase protein secretion 
Conditioned media collected from the collagen lattice experiments were analysed 
for protein expression levels of matrix metalloproteinase (mmp)-1, mmp-2, mmp-3, 
mmp-8, mmp-9, mmp-10, mmp-13 and tissue inhibitor of matrix metalloproteinase 
(timp)-1, timp-2 and timp-4 by using an antibody-coated membrane array kit 
(Raybiotech Inc, Norcross, GA, USA) in accordance with the manufacturer’s 
instructions. This antibody array uses a biotin-conjugated primary antibody to 
detect the mmp/ timp protein bound to arrayed anti-mmp/ anti-timp antibody on the 
membrane, horse radish peroxidase (HRP)-labelled streptavidin is then used to 
detect the biotin, the generation of light by chemiluminescent substrates of the   133
enzyme HRP is detected by exposure of the membrane array to X-ray film, and the 
signal intensities are quantified by densitometry. Mmp and timp levels in 10% 
gelatinase-free serum-containing FCM and SFM medium were subtracted from the 
appropriate conditioned medium results. The array detects both the pro- and active 
forms of mmps and timps.      
 
Reasons for selecting this antibody array method rather than gelatin zymography 
or ELISA (enzyme-linked immunosorbent assay) included: (1) it was more efficient 
in terms of both the time taken to acquire results, and the use of a limited volume 
of samples, given that it was able to detect 10 molecules simultaneously from 1ml 
of conditioned medium, (2) it is reported to have a greater sensitivity and greater 
detection range than ELISA, and (3) although it was only able to provide relative 
expression levels, rather than actual pg/ml concentrations as an ELISA would, this 
quantitation was more accurate than quantitation of zymography results, which 
relies on detecting differences in shades of light or dark from photographs. Before 
commencing the antibody array experiments, gelatin zymography was carried out 
on one occasion to confirm the presence of gelatinolytic activity in a selection of 
conditioned medium samples (data not shown).   
4.3.7   Fibroblast proliferation 
Fibroblast cell division was assessed by flow cytometric measurement of dilution of 
the fluorescent label CFSE (carboxyfluorescein diacetate, succinimidyl ester) 
(Vybrant® CFDA SE Cell Tracer Kit, Invitrogen, Paisley UK), bound to proteins in 
the cell. For each division, the amount of CFSE in each daughter cell is half that of 
the parent. This technique was selected after multiple unsuccessful experiments 
using alamar blue indicator dye to detect cell proliferation, where positive and 
negative control conditions did not give reproducible or logical results.  
 
Flow cytometric assessment of CFSE dye dilution offers advantages in terms of 
providing much more information about the kinetics of cell proliferation, given that it   134
permits visualization of eight to 10 discrete cycles of cell division, and can track 
proliferation in minor subsets of cells and follow the acquisition of differentiation 
markers or internal proteins linked to cell division (Lyons, 2000). A typical graph 
showing CFSE tracking of cell division is depicted in Figure 4.4. This technique 
also allows conjugated antibodies to be used to probe surface marker changes as 
cells divide, or changes in expression of internal molecules such as cytokines. An 
additional advantage of the technique is the ability to recover viable cells which 
have undergone defined numbers of cell divisions by flow cytometric sorting, 
allowing functional studies to be performed.  In comparison, other commonly used 
assays of cell proliferation give only limited information, as they usually measure 
division at a population level (Wallace et al., 2008). There were initial plans to 
simultaneously assess cell apoptosis during these cell division experiments, by 
labeling the cells with a marker such as Annexin V, but this work was not able to be 
carried out due to time constraints.    
 
Preliminary CFSE experiments were conducted using a fibroblast cell line (3T3) to 
determine the optimum cell density to be plated, the optimum incubation period for 
detection of maximal cell division, and the optimal CFSE concentration. Initially the 
effect of adding cytokine under serum-free conditions was attempted, but the cells 
did not survive these conditions so all further experiments were carried out using 
10% serum-containing FCM.  
CFSE cell division assay method 
Confluent fibroblasts were cultured in serum-free medium for 24 hours prior to 
commencing the experiment, in order to synergise their cell cycles.  The cells were 
detached from the flasks with trypsin/EDTA and the cell pellet was washed once 
with SFM. The volume of the cell pellet was assessed (eg 200µl). The CFSE stock 
was made up prior by adding 90µl DMSO (dimethylsulfoxide) to Component A, and 
aliquoted into 7µl units. This CFSE stock was then diluted 1:100 with SFM and 1µl 
of this solution was incubated per 200µl cell pellet at 37
oC in the waterbath for 10   135
minutes, then 1ml ice cold FCM was added to stop the reaction. This suspension 
was centrifuged and the cell pellet was resuspended in 1ml ice cold FCM for 30 
minutes at room temperature, to allow free CFSE to exit the cells. The final cell 
pellet was resuspended in FCM at 2 x 10
5 cells/ml. 1:4 of these CFSE-containing 
cells were immediately acquired for flow cytometry (time 0) (10,000 events; 
Facscalibur, BD Pharmigen). The remaining cells were seeded into 6-well culture 
plates at a density of 4 x 10
5 cells per well in FCM for 72 hours (time 72h). The 
effect of TNFα [10ng/ml] in FCM on cell division was compared to FCM alone. 
When there were sufficient cells, the wells were set up in duplicate or triplicate. 
After 72 hours, the cells were detached with trypsin/EDTA and at least 10,000 
events were acquired in the live region (Facscalibur, BD Pharmigen).  Winlist 
software (Verity Software House, Topsham, ME, USA) was used to assess the 
ratio of divided cells, which was calculated by measuring the number of cells with a 
diluted CFSE concentration per 5000 undivided cells.  
 
 
 
 
Figure 4.4 Representative plot showing CFSE tracking of cell division. B cells 
labelled with CFSE were harvested and analysed by flow cytometry after 3 days in 
culture. Cell division is characterised by sequential halving of CFSE fluorescence, 
generating equally spaced peaks on a logarithmic scale. Dashed lines indicate the 
division cycle number. Note the slow decay in intensity of peaks, independent of 
division. Adapted from Lyons AB, 2000.   136
 
4.3.8 Immunofluorescence  staining and flow cytometry  
Expression of markers of activation (HLA-DR, ICAM) and costimulatory molecules 
(CD80, CD86, CD40, CD40 ligand) on conjunctival fibroblasts in response to 
stimulation by TNFα was evaluated by flow cytometry. Confluent fibroblasts were 
cultured in 6 well plates in the presence of various concentrations of TNFα [1, 10, 
100ng/ml] or IFNγ [1ng/ml] (Peprotech, London UK) in SFM, for 72 hours. A range 
of TNFα concentrations was used for this assay because there was no previous 
data in the literature. If a response was observed, testing a range of concentrations 
could also indicate whether there was a dose-dependent effect. IFNγ was tested in 
parallel as a positive control, given that upregulated CD40 expression in response 
to IFNγ has previously been reported (Kaufman et al., 2001). For three-colour 
immunofluorescence staining, fibroblasts were washed with Ca
2+ and Mg
2+-free 
Hanks’ balanced salt solution (HBSS) (Gibco) and detached with collagenase 
[1mg/ml] (Sigma-Aldrich) in HBSS.  The cell suspension, containing at least 1 x 10
5 
cells, was centrifuged at 1000rpm for 5 minutes, the cell pellet was resuspended in 
10% mouse serum for 20 minutes to block non-specific binding, then the cells were 
stained with 5µl each of either anti-ICAM-1
PE, anti-CD80
FITCand anti-HLA-DR
PerCP, 
or anti-CD154
FITC, anti-CD86
PE, and anti-CD40
PECy5 for 30 minutes at 4
oC, before 
washing twice and acquiring 10,000 events for flow cytometry (Facscalibur, BD 
Pharmigen).  Isotype matched, irrelevant monoclonal antibodies were used as 
negative controls. Winlist software (Verity Software House, Topsham, ME, USA) 
was used for analysis.  Analyses were performed on a population of live cells gated 
by forward and side scatter to include the fibroblast population.  At least 10,000 
events were acquired in the live region, and the percentages of positive cells were 
calculated after subtracting background staining. Mean fluorescence intensity was 
used to measure of intensity of expression.      137
Excluding contamination by epithelial cells 
To be confident that the cells analysed in these flow cytometry experiments were 
fibroblasts alone, without any contaminating epithelial cells, cultures selected for 
these flow cytometry experiments were at least passage 4 or 5, had typical 
fibroblast morphology, and were unlikely to contain any epithelial cells by this time 
given that epithelial cells are more fastidious, requiring additional agents such as 
epidermal growth factor, cholera toxin and insulin in culture medium to ensure their 
survival.   
Investigating fibroblast and epithelial cell markers 
It was planned initially that flow cytometry experiments would be carried out on 
early passage (passage 0 or 1) cells to detect differences in activation marker 
expression between cells derived from ocular MMP tissue compared with normal 
conjunctiva. It was unknown whether the phenotype of the ocular MMP cells would 
be retained after passaging in tissue culture, and it was possible that the 
phenotype would revert to a “common” in vitro conjunctival fibroblast phenotype 
once the unique tissue environment had been removed, so evaluating the cellular 
phenotype of passage 0 or 1 cells was considered important. Given that 
contaminating epithelial cells were likely to be present in passage 0 or passage 1 
cell populations, and we wanted to be able to separately identify the fibroblasts 
from epithelial cells on flow cytometry, preliminary experiments were conducted to 
evaluate candidate fibroblast markers such as FSP1 (fibroblast surface protein-1), 
Thy-1 (CD90) and epithelial markers such as CD326, pan-cytokeratin, and CD44 
(see Appendix 6). Due to time constraints, these experiments were not repeated 
so the preliminary results could not be fully assessed, and no conclusions were 
able to be made.   
4.3.9   Statistical Analysis 
Differences between groups were examined for statistical significance using the 
Mann-Whitney U test, or one-way analysis of variance (ANOVA). Students’ t-test   138
was used when comparing means within each sample. Linear regression was used 
to analyse for a significantly non-zero slope relationship between TNFα 
concentration and intensity of ICAM expression. P < 0.05 was considered to be 
statistically significant.   139
4.4 Results  
4.4.1  Expression of TNFα in ocular MMP conjunctival tissue 
Expression of TNFα in the substantia propria of normal control conjunctival 
sections was confined to intravascular spaces, with very little expression in the 
stromal tissues, with sections from only 3 of the 10 normal patients (30%) showing 
occasional positive stromal cells (Figure 4.5 A). In contrast, in active ocular MMP 
there were many stromal cells expressing TNFα (234 ± 94cells/mm
2) (Figure 4.5 
B), 32% (76/234) of which were also positive for the T cell marker CD3 (Figure 4.6 
A). It is likely that the remaining TNFα+CD3- cells are monocytes/ macrophages, 
because they are, after lymphocytes, the second most abundant stromal 
inflammatory cells found in ocular MMP (Bernauer et al., 1993b; Rice & Foster, 
1990; Sacks et al., 1989).  
 
Following immunosuppressive therapy, in clinically uninflamed ocular MMP, the 
number of stromal TNFα-expressing cells was significantly reduced to 38% of the 
number of cells present in active disease (90 ± 46 cells/mm
2, P < 0.05), but this 
was still 9-fold greater than the number of stromal cells present in normal controls 
(10 ± 3 cells/mm
2, P < 0.05). The proportion of CD3-positive cells producing TNFα 
was similar across the 3 groups (32% (76/234), 33% (30/90), 35% (3.5/10)) 
(Figure 4.6 A).  There was no difference between the 3 groups with regard to the 
percentage area of the sections stained with intravascular TNFα (Figure 4.6 B). 
Stromal cell TNFα staining was present in 10/10 patients with active ocular MMP 
and 7/10 patients with treated ocular MMP (Table 4.2). Occasional stromal cells 
stained positive in 3/10 normal controls. Epithelial TNFα staining was present in 
4/10 patients with active ocular MMP, 4/10 patients with treated ocular MMP, and 
1/10 normal controls.   140
 
 
Figure 4.5 Human conjunctiva of mucous membrane pemphigoid patients 
shows tumour necrosis factor-alpha (TNFα) expression. 
Immunohistochemistry of bulbar conjunctival sections showing A. Intravascular 
TNFα+CD3- cells in a normal subject, B. Positive intravascular and stromal TNFα 
staining in a patient with actively inflamed ocular MMP. Small arrows indicate 
stromal TNFα+CD3- cells, arrowhead indicates stromal TNFα+CD3+ cell, large 
arrow indicates intravascular TNFα+CD3- cell. TNFα stained dark red (AEC), CD3 
stained brown (DAB). C. a negative isotype mAb control of a normal subject, D. a 
negative isotype mAb control of a patient with actively inflamed ocular MMP. Note 
the stromal inflammatory cell infiltrate. Bar = 100µm 
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Figure 4.6 Cell counts of positive stromal staining in human conjunctiva of  
ocular MMP patients and controls. A. Stromal TNFα/ CD3 double-staining cell 
counts.  Many stromal TNFα-expressing cells are present in patients with active 
ocular MMP (234 cells/mm
2), 32% (76/234) of which also express the T cell marker 
CD3. Following immunosuppressive therapy, in clinically uninflamed treated ocular 
MMP, the number of stromal TNFα-expressing cells is significantly reduced to 38% 
of the number of cells present in active disease (90 cells/mm
2, P <0.05), but this is 
still 9-fold greater than the number of stromal TNFα-expressing cells present in 
normal controls (10 cells/mm
2, P <0.05). B. Percentage area of the sections 
stained with intravascular TNFα.  There is no difference in intravascular TNFα 
staining between active, treated ocular MMP, or controls. Results are the mean 
and SE from 10 individuals per group, counting at least 9 fields per individual. * P 
<0.05.   142
 
Table 4.2 Stromal and epithelial TNFα staining results for each patient 
Diagnosis Case Stromal  TNFα Epithelial TNFα
number staining staining
(grade N to ++++) (grade N to ++++)
1 +++ N
2 + +++
3 +++ ++
4 +++ +++
Active MMP 5 ++ N
6+ + N
7 ++++ N
8 ++++ ++++
9+ + N
10 + N
1+ + +
2 + / N N
3 + / N N
4+ +
Treated uninflamed MMP 5 N N
6+ + + +
7N N
8+ N
9N N
10 ++ +
1N N
2N N
3N N
4 + / N N
Normal control 5 N N
6 + / N N
7N N
8 + / N +
9N N
10 N N
MMP= mucous membrane pemphigoid, N = nil staining    143
 
4.4.2  Normal conjunctival fibroblast migration, collagen contraction and 
proliferation in response to TNFα 
 
All the experiments described from this point onwards in this chapter were carried 
out on normal human conjunctival fibroblasts. 
 
The effect of TNFα on key fibroblast functions including cell migration, collagen 
contraction and proliferation was investigated.  Whilst TNFα stimulated conjunctival 
fibroblast migration under serum-free conditions (P < 0.0001, Figure 4.7), no 
significant contraction of fibroblast-collagen lattices was observed in response to a 
range of TNFα concentrations [1, 10, 100ng/ml] compared with the serum-free 
negative control (data not shown).  There was also no significant difference in 
fibroblast cell division after stimulation with 10ng/ml TNFα, compared with the FCM 
negative control (data not shown). 
 
Figure 4.7. Effect of TNFα on conjunctival fibroblast migration. Conjunctival 
fibroblasts were seeded into culture inserts incorporating porous membranes and 
allowed to migrate overnight towards the lower chamber containing the test 
substance. The negative control used was serum-free medium (SFM) containing 
0.1% bovine serum albumin (BSA), the positive control used was fibroblast culture 
medium (FCM) containing 10% foetal calf serum. TNFα stimulated fibroblast 
migration under serum-free conditions. * P <0.0001.   144
 
4.4.3  Matrix metalloproteinase protein production in response to TNFα 
Conditioned media from fibroblast-populated collagen lattices treated with TNFα 
were analysed using an antibody-coated membrane array testing a panel of 7 
mmps and 3 timps. Figure 4.8 shows that the level of mmp-9 increased (P =0.01) 
and the levels of timp-2 (P =0.01) and timp-4 decreased (P =0.04) in the presence 
of TNFα, compared with the serum-free negative control.   
 
 
Figure 4.8. Matrix metalloproteinase (mmp) and tissue inhibitor of matrix 
metalloproteinase (timp) levels in conditioned medium of conjunctival 
fibroblast-populated collagen gels incubated over 7 days in the presence of 
TNFα, as detected by antibody-coated membrane array. Data are relative 
values compared with the membrane array negative control. There was a 
significant increase in mmp-9 (P =0.01) and a decrease in timp-2 (P = 0.01) and 
timp-4 (P = 0.04) levels in the conditioned medium from TNFα-treated collagen 
gels, in comparison with the untreated control 0.1% bovine serum albumin (BSA) 
serum-free medium (SFM) collagen gels. Results are the mean and SE from 5 
individual donors. * P < 0.05 
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4.4.4  Immune Marker Expression by Conjunctival Fibroblasts in response to TNFα 
Interactions between tissue fibroblasts and infiltrating T lymphocytes via the 
CD40/CD40L pathway have been shown to powerfully costimulate T lymphocyte 
proliferation and to activate fibroblasts, thus potentially promoting fibrogenesis 
(Sempowski et al., 1997). Surface expression of HLA-DR, ICAM and T cell-
costimulatory molecules by conjunctival fibroblasts in response to 72hours’ 
stimulation with TNFα or IFNγ under serum-free conditions was investigated.  
 
ICAM was constitutively expressed by a high percentage of fibroblasts (84.3% ± 
13.5%) under basal conditions, and there was no significant change in the 
percentage level of expression after TNFα treatment (Figure 4.9 A).  However, the 
intensity of ICAM expression by the fibroblasts escalated in response to increasing 
concentrations of TNFα (mean fluorescence intensity in the negative control BSA 
(bovine serum albumin) 113 ± 29, 1ng/ml TNFα 1361 ± 402, 10ng/ml TNFα 2117 ± 
604, 100ng/ml TNFα 2133 ± 717, P = 0.03 linear regression, Figure 4.9 B).  
Fibroblast expression of the costimulatory molecule CD40 was significantly 
upregulated by TNFα, with the maximum percentage expression occurring in 
response to 10ng/ml TNFα (BSA 1.8% ± 1.3%, 1ng/ml TNFα 14.3% ± 8.3%, 
10ng/ml TNFα 27.7% ± 11.7%, P = 0.04, Fig. 6A).  No significant change in either 
the percentage or intensity of expression of HLA-DR, CD80, CD86 or CD40-ligand 
was detected. In comparison, IFNγ upregulated expression of HLA-DR, CD40 and 
CD154. 
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Figure 4.9 Fibroblast expression of surface markers of activation and 
costimulatory molecules in response to TNFα. Conjunctival fibroblasts were 
treated with various concentrations of TNFα [1, 10, 100 ng/ml] or IFNγ [1ng/ml] for 
72 hours under serum-free conditions, and the surface expression of HLA-DR, 
ICAM, CD80, CD86, CD40, and CD40-ligand was determined by flow cytometry. 
The negative control was serum-free medium (SFM) containing 0.1% bovine serum 
albumin (BSA). A. Percentage of conjunctival fibroblasts expressing surface 
markers and costimulatory molecules. All concentrations of TNFα significantly 
upregulated the percentage expression of CD40 (*P <0.05 in comparison to 
untreated control), with maximum expression occurring in response to 10ng/ml. 
Note the high percentage of fibroblasts expressing ICAM under basal conditions 
and in the presence of TNFα. B. Intensity of expression of ICAM (intercellular 
adhesion molecule) by conjunctival fibroblasts in response to TNFα stimulation. 
Whilst the percentage of cells expressing ICAM was high under basal conditions 
and in the presence of TNFα, the intensity of ICAM expression increased in 
response to TNFα stimulation (* P  =0.03). Results are the mean ± SE from 6 
individual donors.   
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4.5 Discussion 
The results in this chapter demonstrate increased tissue expression of TNFα in 
ocular MMP, thus systemic treatment with TNFα antagonists could be expected to 
ameliorate inflammatory activity in this disease.  Furthermore, it has been 
demonstrated that whilst systemic immunosuppressive treatment is associated with 
a significant decrease in tissue TNFα expression, there is residual persistent 
expression of TNFα even when inflammation clinically appears to be controlled.  A 
possible role for TNFα in the pathogenesis of conjunctival fibrosis in mucous 
membrane pemphigoid has also been demonstrated, in that TNFα is a 
chemoattractant for conjunctival fibroblasts. Migration of fibroblasts to the site of 
injury expressing TNFα could lead to a pathological accumulation of fibroblasts and 
excessive scarring at this site. TNFα increases mmp-9 production, and causes 
activation of conjunctival fibroblasts by upregulating the intensity of adhesion 
molecule expression and upregulating CD40 expression.   
 
No difference in cell division in response to 10ng/ml TNFα in FCM compared with 
FCM alone was detected in the experiments presented here, but proliferation of 
myofibroblasts in response to TNFα has previously been reported (Porter et al., 
2004; Theiss et al., 2005).  The normal conjunctival fibroblasts used in the 
experiments in this chapter had previously been assessed for myofibroblast 
characteristics using alpha-smooth muscle actin staining looking for assembled 
actin myofilaments, and these had been found to be absent (data not shown).  
Different TNFα concentrations may have stimulated proliferation in our assay, or it 
may be that TNFα- stimulated proliferation is a myofibroblast-specific response.     
 
TNFα has previously been reported to be present in 6/8 ocular MMP patients in a 
limited study by Coma et al; it is not clear whether these patients had active 
inflammation, or clinically uninflamed disease (Cordero et al., 2007). Bernauer et al 
previously found positive substantia propria expression of TNFα in all active MMP,   148
chronic MMP and normal conjunctival specimens (Bernauer et al., 1993a); this may 
have been due to intravascular staining which was similarly found, in the results 
reported in this chapter, to be present in all specimens.  In the results reported in 
this chapter, intravascular staining was evaluated separately from extravascular 
stromal TNFα staining, and the latter was found to be virtually absent in normal 
conjunctiva.  
 
The findings in this chapter of persistent residual TNFα expression, even when the 
conjunctiva is clinically ‘white’ and uninflamed after systemic immunosuppressive 
treatment, is in agreement with previous work proposing ongoing release of 
cytokines in the presence of a significant cellular infiltrate (‘white inflammation’) 
which cannot be seen on the slit-lamp (Elder, 1997c).  Progressive fibrosis despite 
immunosuppressive treatment may be driven by this underlying chronic 
inflammation. 
  
The results in this chapter support a profibrotic and proinflammatory effect of TNFα 
on conjunctival fibroblasts. The free-floating fibroblast-populated collagen lattice 
model is thought to represent contraction resulting from fibroblast migration 
through matrix (Grinnell, 2000). Although addition of TNFα did not stimulate matrix 
contraction, increased mmp-9 levels were detected in the conditioned medium of 
the fibroblast-populated collagen lattices. These findings are consistent with other 
studies reporting TNFα-induced mmp-9 expression by gingival fibroblasts and 
other cells (Kim et al., 2008; Porter et al., 2004). Leonardi et al have shown 
increased mmp-9 and also mmp-1 production, and decreased timp-1 production in 
response to TNFα stimulation, by conjunctival fibroblasts adherent to a tissue 
culture plate (Leonardi et al., 2003).  They did not examine timp-2 or -4 expression. 
The differences in mmp-1 and timp-1results between my study and theirs may 
reflect differences in the in vitro models used. The in vitro model of fibroblasts 
populating a 3-dimensional collagen gel matrix used could be seen as more 
physiological than fibroblasts cultured in a monolayer on plastic.     149
 
Matrix-metalloproteinase-9 (also known as gelatinase-B) degrades extracellular 
matrix collagens such as collagen type IV, the major component of basement 
membranes, and laminin, plays a role in regulating cell migration and cleaves 
latent TGFβ. The mmp-9 detected by the antibody array in this study could have 
been either the latent or active form.  Recently it has been shown that the 
proteolytic activities of mmps are not necessary for mmp-induced cell migration, 
and that the hemopexin domain of pro-mmp-9 plays an important role in cell 
migration (Dufour et al., 2008). The results of the migration assay experiments in 
this chapter, showing increased fibroblast migration in response to TNFα, may well 
be related to this increased mmp-9 production, noting that this would represent 
migration without concomitant matrix contraction, given that no contraction of the 
collagen lattices was observed in response to TNFα.  Decreased timp-2 and timp-4 
levels were also detected in the conditioned medium of the fibroblast-populated 
lattices. By virtue of their ability to inhibit mmp activity, all timps are believed to 
function as inhibitors of angiogenesis. Timp-2 has also been found to directly inhibit 
endothelial cell proliferation and angiogenesis by an mmp-independent effect 
(Stetler-Stevenson & Seo, 2005). Timp-4 has a growth promoting activity in vitro, 
prevents apoptosis, and inhibits TNFα converting enzyme (Wong et al., 2002). It is 
possible that the ability of TNFα to stimulate angiogenesis is related to this 
reduction in timp activity.  
 
T lymphocytes are significantly increased in the subepithelial cellular infiltrate 
across all phases of ocular MMP disease activity (Bernauer et al., 1993b), and T 
cell-fibroblast cross talk and feedback loops may be an important mechanism in 
fibrosis. IFNγ-stimulated lung fibroblasts have been shown to costimulate T 
lymphocyte proliferation utilizing CD40, but not via CD80 or CD86 costimulatory 
molecules (Sempowski et al., 1997). Interactions between tissue fibroblasts and 
infiltrating T lymphocytes, via the CD40/CD40 ligand pathway, augment 
inflammation and may promote fibrogenesis by activating both cell types.The   150
results in this chapter show that TNFα upregulates expression of CD40 on 
conjunctival fibroblasts, which may then interact with T cells via CD40 ligand, 
inducing the fibroblasts to proliferate, produce cytokines, and lay down extracellular 
matrix (Kaufman et al., 2001), as well as stimulating T cell proliferation and 
production of cytokines which could promote further fibroblast activation and matrix 
deposition. The effect of the addition of TNFα on functional fibroblast activity in the 
presence of T cell co-culture requires further investigation. The majority of the 
TNFα-expressing cells were not T cells, and are likely to be 
monocytes/macrophages. This should be confirmed by further experiments. 
4.6 Conclusion 
In summary, expression of TNFα is increased in the conjunctiva of patients with 
ocular mucous membrane pemphigoid, hence systemic TNFα antagonists could be 
expected to be useful in severe ocular mucous membrane pemphigoid not 
responding to conventional immunosuppressants.  TNFα appears to have a 
profibrotic effect on normal conjunctival fibroblasts. However, these profibrotic 
effects appear to have a limited scope, given that TNFα does not appear to cause 
collagen matrix contraction, which is a key aspect of wound contraction and 
remodelling. Furthermore, TNFα is likely to be mostly produced by macrophages 
and neutrophils, while most of the subacute and chronic inflammatory cell infiltrate 
in ocular MMP is composed of T cells. Th2- polarized responses are recognized as 
playing an important role in fibrogenesis. In searching for key molecules or 
mechanisms involved in fibrosis in ocular MMP, assessing the role of T cells and 
potentially important T cell-derived cytokines is thus pertinent.    151
 
Chapter 5 
 
Interleukin-13 (IL-13) expression in ocular 
mucous membrane pemphigoid, its effects on 
conjunctival fibroblasts and T cell studies in 
ocular mucous membrane pemphigoid   152
5.1 Introduction 
The findings in Chapter 4 indicate that TNFα plays a role in tissue inflammation in 
ocular MMP, and has some profibrotic effects on conjunctival fibroblasts, but these 
effects are modest. The aim of this thesis was to investigate potential key 
molecules and mechanisms involved in conjunctival fibrosis in ocular MMP, so 
given its prominent role in driving fibrosis in chronic inflammatory liver and lung 
disease, the Th2-type cytokine IL-13 was a prime candidate for investigation.    
 
Fibrosis associated with chronic inflammation is unique in that the adaptive 
immune response, and in particular a type 2 helper T cell (Th2)-polarized 
response, is thought to play an important role (Wynn, 2008). As in most 
fibroproliferative disorders (Azouz et al., 2004), both type 1 (Th1) (transforming 
growth factor-β, IFNγ) and type 2 (Th2) cytokines (IL-4, IL-5) are present in 
mucous membrane pemphigoid lesions (Bernauer et al., 1993a; Caproni et al., 
2003; Elder et al., 1997; Razzaque et al., 2003a), but it is not known whether the 
Th2 cytokine IL-13 is present. Given the predominance of T cells in the substantia 
propria infiltrate in ocular MMP, investigating their potential role in ocular MMP 
fibrosis by characterising their cytokine secretion profile including IL-13 secretion, 
and evaluating the effect of ocular MMP T cell-fibroblast co-culture on conjunctival 
fibroblast and T cell activity was of interest. T cell-fibroblast interactions may 
promote a chronic inflammation-fibrosis cycle in ocular MMP.  
 
Inhibition of the effects of IL-13 using a recombinant soluble form of IL-13Rα2 has 
been reported (Andrews et al., 2006). This soluble receptor, which lacks 
transmembrane and cytoplasmic domains, has inhibited IL-13-mediated responses 
in a dose-dependent manner. The mechanism by which this occurs is believed to 
be by binding IL-13 with high affinity and acting as a non-signalling decoy receptor.  
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Preliminary steps in assessing the potential importance of IL-13 and T cells in 
fibrosis in ocular MMP therefore include establishing whether IL-13 is expressed in 
ocular MMP, investigating the direct effects of IL-13 on conjunctival fibroblasts 
(given the potentially different functional characteristics of fibroblasts derived from 
different anatomical sites (Flavell et al., 2008), attempting to inhibit the effects of IL-
13 using an IL-13 inhibitor, and characterising the T cells in ocular MMP.  
5.2 Aim 
The aim of the study in this chapter was to investigate whether IL-13 is expressed 
in conjunctival MMP tissue including after systemic immunosuppressive treatment, 
to assess the effects of IL-13 on normal human conjunctival fibroblasts, and to 
characterise the T cells in ocular MMP conjunctiva and evaluate potential T cell-
fibroblast interactions. 
5.3 Research design and methods 
5.3.1 Conjunctival biopsies 
Bulbar conjunctival biopsies were obtained from ocular MMP patients and patients 
with normal conjunctiva as described in Chapter 4, section 4.3.1. Details of the 
patients (11 active ocular MMP, 10 treated uninflamed ocular MMP) and 9 normal 
controls whose conjunctival biopsies were used in the IL-13 experiments in this 
chapter are shown in Table 5.1. 
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Table 5.1 Details of patients and normal controls whose conjunctival biopsies were used in IL-13 studies 
Disease Bulbar
Diagnosis Case  Age Gender duration Eye inflammation Tauber stage Topical therapy Systemic therapy Other eye pathology
number (yrs) biopsied  grade (0 to 4) (Upper stage/ Lower stage)
1 54 F 0.5 L 3 IIcIIId/ IIcIIId hypromellose, acetylcysteine, yellow soft paraffin nil
2 59 M 3 L 2.5 I/ IIa hypromellose, lacrilube nil
3 76 M 5 L 3 IIaIIIa(1)/IIbIIIb(2) hypromellose, chloramphenicol mycophenolate amblyopia
4 80 M 10 R 3 IIbIIIc(2)/ IIdIIId(2) carmellose mycophenolate + dapsone
5 55 M 13 3 IIcIIIc(2)/ IIdIIId(1) dexamethasone, carmellose mycophenolate + dapsone + deflazocort
Active MMP 6 60 F 2 R 3 I/ IIcIIIc(3) carmellose mycophenolate + dapsone
7 76 F 2 R 2.5 IIc/ IIbIIIa(2) prednisolone, hypromellose, carmellose mycophenolate + dapsone sicca, blepharitis
8 51 F 0.1 L 3 I/ IIIa(1) nil nil
9 57 M 0.5 L 3 IIb/ IIcIIIb(2) dexamethasone, lacrilube nil
10 64 F 1 R 2 IIa/ IIbIIIc(2) prednisolone nil
11 83 F 7 L 3 IIa/ IIbIIIb(2) brimonidine, latanoprost, timolol, dorzolamide, carmellose mycophenolate + doxycycline glaucoma
1 59 F 10 R 1 IIbIIIb(2)/ IIdIIId(2) carbomer 980 dapsone
2 86 F 15 R 1 IIb/ IIcIIIb(2) nil nil
3 78 F 10 R 1 IIbIIIb(2)/ IIdIIId(2) nil nil
4 84 F 2 L 0 IIb/ IIcIIIc(2) nil mycophenolate
Treated uninflamed MMP 5 66 F 2 R 0 IIb/ IIcIIIb(2) nil dapsone
6 59 M 4 L 1 I/ IIa hypromellose, carmellose, liquid paraffin, chloramphenicol cyclophosphamide
7 76 M 6 L 1.5 IIdIIId(2)/ IIbIIIb(2) chloramphenicol, hypromellose, retinoic acid, acetylcysteine cyclophosphamide blepharitis
8 60 F 3 L 1 I/IIaIIIa(1) carmellose cyclophosphamide + dapsone
9 62 F 0.75 R 0.5 IIa/ IIcIIIa(1) hyaluronate prednisolone
10 51 F 1 L 1  I/ IIIa(1) nil cyclophosphamide + prednisolone
1 50 F - L 0 - nil nil cataract
2 76 M - L 0 - nil nil cataract
3 65 M - R 0 - nil nil cataract
4 70 F - R 0 - nil nil cataract
Normal control 5 82 F - L 0 - nil nil cataract
6 65 M - R 0 - nil nil cataract
7 75 F - 0 - nil nil cataract
8 73 F - 0 - nil nil cataract
9 62 M - R 0 - nil nil cataract  155
5.3.2 Immunohistochemistry  
Immunohistochemistry was carried out on GMA-embedded sections in an identical 
manner to that described in Chapter 4, section 4.3.2, apart from substituting IL-13 
for TNFα and using different primary and secondary antibodies. The primary IL-13 
antibody was a rabbit antibody against human IL-13 (Biogenesis Ltd, Poole UK 
[5378-8530]), diluted 1:100. The secondary antibody used for this was a 
biotinylated goat anti-rabbit immunoglobulin (Dako, Cambridgeshire UK), diluted 
1:200.  For IL13-CD3 double staining, IL-13 was stained red (AEC) and CD3 
stained brown (DAB), Human tonsil sections were used as positive controls, and 
the two negative controls used were absence of the primary antibody and an 
isotype matched, irrelevant monoclonal antibody (Dako).  The number of cells 
stained in the stroma were counted in a masked fashion in 5 or more high power 
fields per patient using a Leica DM RBE microscope at  x400 magnification with a 
10mm
2 eyepiece graticule (Leica, Milton Keynes UK). Counts were expressed as 
mean counts per mm
2. The presence of positive stromal or epithelial staining was 
also graded on a scale of 0 to ++++, based on both the number of cells stained and 
staining intensity. 
5.3.3  Isolation of Normal Conjunctival Fibroblasts 
Normal conjunctival fibroblasts were grown from the conjunctival biopsies and 
passaged as described in Chapter 4, section 4.3.3. 
 
To investigate the effect of IL-13 on direct profibrotic activity by normal human 
conjunctival fibroblasts, the effect of IL-13 on collagen contraction, matrix 
metalloproteinase and type I collagen secretion, fibroblast proliferation and 
migration was assessed. A concentration of 10ng/ml IL-13 was used initially for all 
assays, based on previously published data (Fujitsu et al., 2005; Leonardi et al., 
2003) showing a response at this concentration. If no response was observed, a   156
dose-titration experiment was set up to determine the optimum IL-13 concentration 
for that particular assay. 
5.3.4  Collagen contraction model 
Free-floating relaxed fibroblast-populated collagen gels were prepared as 
described in Chapter 4, section 4.3.5. The lattices were detached immediately 
after feeding with 10ng/ml IL-13 (recombinant human IL-13, R&D systems, 
Abingdon, UK) in SFM. SFM alone was used as the negative control, and 10% 
gelatinase-free serum-containing FCM was used as the positive control. The gels 
were digitally photographed at days 1, 3 and 7, and the gel areas were calculated 
using image analysis software (Image J).  
IL-13 Inhibition 
Blockade of the effects of IL-13 on collagen contraction was attempted, using a 
recombinant soluble form of IL-13Rα2 acting as a decoy receptor (monoclonal anti-
IL-13Rα2 from Diaclone, IDS, Boldon, Tyne and Wear, UK), as described by 
Andrews et al (Andrews et al., 2006). These authors had also shown that 24 hours 
of pre-treatment with IL-13 induced high surface expression of IL-13Rα2 on 
fibroblasts, and this then attenuated the cell responses to IL-13. For this reason, 
soluble IL-13Rα2 [1µg/ml] was added 24 hours after commencement of the 
collagen contraction assays, which had been fed with IL-13 [10ng/ml] at 
commencement. The combined addition of IL-13 [10ng/ml] with IL-13Rα2 [1µg/ml 
or 10µg/ml] at commencement of the collagen contraction assays was also tested. 
The assays of IL-13 inhibition were conducted over 3 days rather than 7 days, 
because it was believed unlikely that the inhibitor would be continuing to have an 
effect beyond 3 days.  
5.3.5  Matrix metalloproteinase protein levels 
Conditioned medium collected from the collagen lattice experiments between days 
0-3 and 3-7, or days 0-7, was analysed for matrix metalloproteinase-1 (mmp-1), 
mmp-2, mmp-3, mmp-8, mmp-10, mmp-13, tissue inhibitor of matrix   157
metalloproteinase-1 (timp-1), timp-2 and timp-4 protein levels as described in 
Chapter 4, section 4.3.6. 
5.3.6  Type I collagen secretion 
Conditioned medium collected from contracting lattices under both serum-free and 
serum-containing conditions, in the presence and absence of IL-13 [10ng/ml], was 
analysed for secretion of the C-terminal propeptide of type I collagen (CICP) using 
an ELISA (Quidel Corp, San Diego CA) carried out according to the manufacturer’s 
instructions.    
5.3.7 Proliferation 
Fibroblast cell division in the presence or absence of IL-13 was analysed by flow 
cytometry using the fluorescent probe CFSE (carboxyfluorescein diacetate, 
succinimidyl ester) as described in Chapter 4, section 4.3.7. The CFSE-containing 
cells were seeded into 6-well tissue culture plates at a density of 4 x 10
5 cells per 
well and stimulated with IL-13 10ng/ml in FCM.     
5.3.8 Migration 
Fibroblast migration experiments were conducted as described in Chapter 4, 
section 4.3.4, in the presence and absence of IL-13 [10ng/ml], with or without the 
addition of T cell culture supernatant (see below). SFM was used as a negative 
control, and 10% bovine serum FCM as a positive control.  
T cell culture supernatant 
Supernatant from a T cell line culture, derived from a conjunctival biopsy from an 
atopic keratoconjunctivitis patient, and stimulated with phytohaemagglutinin, was 
were obtained from previous experiments. Previous ELISA testing had indicated 
that this supernatant contained IL-5 and IFNγ. This supernatant was tested as a 
chemoattractant in the lower chamber of the tissue culture plate at a concentration 
of 1:10 in SFM, either alone or in combination with IL-13 [10ng/ml].    158
5.3.9      Immunofluorescence staining and flow cytometry 
Fibroblasts may actively engage in perpetuating chronic inflammation via direct 
fibroblast-T cell cross talk, and IL-13 may play a role in stimulating this activity. 
Surface expression of markers of activation (HLA-DR, ICAM-1) and costimulatory 
molecules (CD80, CD86, CD40, CD40 ligand) by normal conjunctival fibroblasts in 
response to stimulation by a range of concentrations of IL-13 [1, 10, 100ng/ml] and 
IFNγ [1ng/ml] (recombinant human IFNγ, Peprotech, London UK) for 72 hours was 
evaluated by flow cytometry in an identical manner to that described in Chapter 4, 
section 4.3.8.   
5.3.10  T cell studies 
Experiments to grow T cells from conjunctival biopsies and peripheral blood, based 
on a previously described method (Calder et al., 1999) were attempted.  
T cell culture from conjunctival biopsies   
Fresh conjunctival biopsies were placed into 1ml T cell medium with 1µg/ml PHA  
(phytohaemagglutinin;Sigma-Aldrich) and 20% human IL-2 (Lymphocult-T, Biotest 
Folex, Solihull, UK).  T cell medium was composed of RPMI 1640 (Dutch 
modification), 2mM L-glutamine, 2mM NEAAs non-essential amino acids, 2mM 
sodium pyruvate, 50µg/ml gentamicin, 2 x 10-
5M 2-Mercaptoethanol and 10% heat 
inactivated human AB+ serum (all from Gibco, Paisley, UK). 5% to 20% IL-2 was 
added every 3 days and the cells were restimulated with 1µg/ml PHA and 
mitomycin-C treated JY feeder cells weekly (2:1 ratio of feeders: T cells). 
Mitomycin-C treated JY feeder cells were prepared by incubating 50µg/ml 
mitomycin-C in RPMI to the required number of JY cells for 90 minutes at 37
oC 
then washing the cells 3 times in RPMI by centrifuging at 1200 rpm for 10 minutes. 
The aim was to maintain cells at approximately 2 x 10
5 cells/ml, in a 2ml T cell 
medium volume per well, of a 24 well plate. At least 4 rounds of feeder cell/PHA 
stimulation were performed before carrying out experiments to characterise the T   159
cells phenotypically, measure cytokine production or intracellular cytokine 
production. 
Peripheral blood mononuclear cell (PBMC) culture 
6-12ml heparinised peripheral blood was diluted 1:1 with RPMI 1640, then layered 
over Histopaque 1077 (Sigma-Aldrich) and centrifuged at 2400rpm for 20 minutes. 
Following centrifugation, the mononuclear cell layer was extracted from between 
the yellow plasma and clear Histopaque layers with a sterile pipette. PBMCs were 
washed twice with RPMI by centrifuging at 1200rpm for 10 minutes. The cells were 
either used immediately for culture or cryopreserved.  
 
If used immediately for culture, the number of cells was counted and then plated at 
approximately 2 x 10
5 cells/ml into wells of a 24-well plate containing 2ml T cell 
medium in each well, and 1µg/ml PHA was added. 5% to 20% IL-2 was added 
every 3 days and the cells were restimulated with 1µg/ml PHA and mitomycin-C 
treated JY feeder cells weekly (2:1 ratio of feeders: T cells).   
 
Cells were cryopreserved at a concentration of approximately 2 x 10
6/ml in 1ml T 
cell medium or RPMI containing 10% foetal calf serum, placed on ice and  
dimethylsulfoxide (DMSO) was added dropwise to a final concentration of 10%. 
The cryovials were immediately stored in an insulated box at -70
oC then 3-4 days 
later transferred into liquid nitrogen.   
5.3.11     Statistical Analysis 
Differences between 2 groups were examined for statistical significance using the 
Mann-Whitney U test and one-way analysis of variance (ANOVA) was used to 
compare the means of 3 or more unmatched groups. P < 0.05 was considered to 
be statistically significant.   160
5.4   Results 
5.4.1     IL-13 is expressed in mucous membrane pemphigoid conjunctiva, in both 
active disease and clinically uninflamed treated disease 
There was minimal expression of IL-13 in the substantia propria of normal 
conjunctiva (Figure 5.1 B). In contrast, in active conjunctivitis due to mucous 
membrane pemphigoid there was a significant increase in the number of stromal 
cells expressing IL-13 (39 ± 1 cells/mm
2) (Figure 5.1 D), 80% (31/39) of which 
were also positive for the T cell marker CD3 (Figure 5.2). Following 
immunosuppressive therapy, in clinically uninflamed treated mucous membrane 
pemphigoid patients, the number of stromal IL-13-expressing cells was significantly 
reduced to 44% (17/39) of the number of cells present in active disease (17 ± 0.5  
cells/mm
2, P < 0.001), but this was still 4-fold greater than the number of stromal 
IL-13-expressing cells present in normal conjunctiva (4 ± 0.3 cells/mm
2, P < 0.001). 
The proportion of CD3-positive cells was similar across the 3 groups (80% (31/39), 
76% (13/17), 75% (3/4) (Figure 5.2). Stromal cell IL-13 staining was present in 
11/11 patients with active ocular MMP and 10/10 patients with treated ocular MMP 
(Table 5.2). Occasional stromal cells stained positive in 5/9 normal controls. 
Epithelial IL-13 staining was present in 7/11 patients with active mucous 
membrane pemphigoid, 9/10 patients with treated mucous membrane pemphigoid, 
and 5/9 normal controls.   
.   161
 
Figure 5.1 Human conjunctiva of ocular MMP patients shows IL-13 
expression.   
Immunohistochemistry of bulbar conjunctival sections showing A. a negative 
isotype mAb control of a normal subject, B. very little IL-13 or CD3 staining in a 
normal subject, C. a negative isotype mAb control of a patient with actively 
inflamed mucous membrane pemphigoid, D. positive IL-13 (red, AEC) and CD3 
(brown, DAB) double staining in a patient with actively inflamed ocular MMP. Thick 
arrows indicate double-stained IL-13+CD3+ cells, thin arrow indicates single-
stained IL13-CD3+ cell. Bar = 100µm. AEC amino-ethyl carbazole, DAB 
3,3’diaminobenzidine. 
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Figure 5.2 Cell counts of positive stromal IL-13/ CD3 staining in MMP 
conjunctiva and normal controls. Many stromal IL-13-expressing cells are 
present in patients with active ocular MMP (39 ± 1 cells/mm
2), 80% (31/39) of 
which also express the T cell marker CD3. Following immunosuppressive therapy, 
in clinically uninflamed treated ocular MMP, the number of stromal IL-13-
expressing cells is significantly reduced to 44% (17/39) of the number of cells 
present in active disease (17 ± 0.5 cells/mm
2), but this is still 4-fold greater than the 
number of stromal IL-13-expressing cells present in normal controls (4 ± 0.3 
cells/mm
2). *P < 0.001. Results are the mean and SE from at least 9 individuals per 
group, counting at least 9 fields per individual. 
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Table 5.2 Stromal and epithelial IL-13 staining results for each patient 
Diagnosis Case  Stromal IL-13 Epithelial IL-13
number staining staining
(grade N to ++++) (grade N to ++++)
1 +++ ++++
2 ++++ ++
3+ + + /  N
4 ++++ ++
Active MMP 5 +++ +
6 +++ N
7+ N
8+ + N
9 +++ N
10 ++++ +++
11 ++ +/ N
1 ++ +++
2+ +
3+ N
4+ +
Treated uninflamed MMP 5 + +++
6 + +++
7+ + +
8+ + +
9 ++ +++
10 ++ +++
1+ + + +
2N +
3N + +
4+ /  N N
Normal control 5 +/ N N
6+ /  N N
7N +
8N N
9+ /  N +
MMP= mucous membrane pemphigoid, N = nil staining  
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5.4.2  IL-13 stimulates collagen contraction by normal human conjunctival 
fibroblasts, which is associated with decreased mmp-3 and mmp-10 
secretion 
IL-13 was found to stimulate collagen contraction by normal human conjunctival 
fibroblasts (Figure 5.3). Attempts to inhibit this collagen contraction using soluble 
IL-13Rα2 showed promising results on the preliminary dose-titration results 
(Figure 5.4 A), but when the experiments were repeated at the selected 
concentration of 1µg/ml, there was no significant difference between the results 
with or without the inhibitor, either following pre-treatment with IL-13 for 24 hours 
(Figure 5.4 B), or with simultaneous addition of IL-13Rα2 at the commencement of 
the assay (data not shown). Using an increased IL-13Rα2 concentration of 10µg/ml 
also did not show any significant difference (Figure 5.4 C).  
 
 
Figure 5.3 Contraction of fibroblast-populated collagen lattice gels by normal 
human conjunctival fibroblasts in response to the addition of IL-13 under 
serum-free conditions. The untreated negative control was 0.1% bovine serum 
albumin (BSA) serum-free medium (SFM). Fibroblast culture medium (FCM) 
containing 10% foetal calf serum (FCS) was used as a positive control.   Results 
are the mean and SE from 6 or more individual donors. IL-13 stimulates collagen 
contraction by normal human conjunctival fibroblasts.   165
 
 
 
Figure 5.4 Attempted neutralization of IL-13 by soluble IL-13Rα2. A. 
Preliminary dose-response curve showing inhibition of IL-13-mediated collagen 
contraction when IL-13Rα2 was added 24hours after commencement of the assay. 
The IL-13Rα2 concentration of 1µg/ml was selected for further experiments based 
on these results. B. Further experiments showed no difference in gel contraction 
with or without 1µg/ml of the soluble inhibitor. Results are the mean and SE of 4 
individual donors. C. Addition of IL-13Rα2 at the commencement of the assay 
(rather than 24hours later) also showed no difference, either at a concentration of 
1µg/ml (data not shown) or 10µg/ml (data shown). Results are the mean and SE of 
5 individual donors.    166
  
Secretion of mmp-3 and mmp-10 during collagen contraction was decreased in the 
presence of IL-13 (Figure 5.5). 
 
 
Figure 5.5 Matrix metalloproteinase (mmp) and tissue inhibitor of matrix 
metalloproteinase (timp) levels in conditioned medium of conjunctival 
fibroblast-populated collagen gels incubated over 7 days in the presence of 
IL-13, as detected by antibody-coated membrane array. Data are relative 
values compared with the membrane array negative control. There was a 
significant decrease in mmp-3 (P =0.04) and mmp-10 (P = 0.01) levels in the 
conditioned medium from IL-13-treated collagen gels, in comparison with the 
untreated control of 0.1% bovine serum albumin (BSA) serum-free medium (SFM). 
Results are the mean and SE from 6 individual donors. * P < 0.05     
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5.4.3  IL-13 stimulates chemotaxis of normal conjunctival fibroblasts. No detected 
change in collagen secretion or proliferation 
IL-13 was also found to stimulate chemotaxis of normal human conjunctival 
fibroblasts (Figure 5.6). 
 
No significant change in type I collagen production was detected in response to the 
addition of 10ng/ml IL-13 in both serum-free and serum-containing collagen lattice 
experiments (data not shown). No significant differences in fibroblast proliferation 
were observed in the presence of 10ng/ml IL-13 compared with the FCM negative 
control (data not shown).   
 
 
 
 
Figure 5.6 Effect of IL-13 on normal human conjunctival fibroblast migration. 
Conjunctival fibroblasts were seeded in the upper chambers of porous membranes 
and allowed to migrate overnight towards the lower chamber containing the test 
substance. The negative control used was 0.1% bovine serum albumin (BSA) 
serum-free medium (SFM), the positive control used was 10% foetal calf serum- 
containing fibroblast culture medium (FCM). IL-13 stimulated fibroblast migration 
under serum-free conditions. Results are the mean and SE of 5 individual 
experiments. * P  = 0.01. 
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5.4.4  IL-13 augments the stimulatory effect of T cell culture supernatant on 
fibroblast chemotaxis 
To evaluate whether IL-13 had synergistic effects, in combination with T cell- 
derived mediators, on normal human conjunctival fibroblasts, the effect of addition 
of T cell culture supernatant to the chemotaxis assay was investigated. The 
combination of IL-13 and T cell culture supernatant significantly augmented the 
effect of either treatments alone (Figure 5.7). 
 
 
 
 
 
Figure 5.7 Effect of IL-13 combined with T cell supernatant on normal human 
conjunctival fibroblast migration. The negative control used was 0.1% bovine 
serum albumin (BSA) serum-free medium (SFM). T cell supernatant (SN) was 
used at 1:10 concentration, and IL-13 at 10ng/ml. The combination of IL-13 and T 
cell supernatant acted synergistically to significantly enhance fibroblast migration. 
Results are the mean and SE of 3 individual experiments. * P = 0.03, one way 
ANOVA.    169
 
5.4.5  IL-13 upregulates surface expression of HLA-DR, CD80, CD40 and CD154 
on normal human conjunctival fibroblasts  
ICAM-1 was constitutively expressed by a high percentage of fibroblasts (84.3% ± 
13.5%), and there was no significant change in the percentage of cells expressing 
ICAM in the presence of IL-13 (Figure 5.8).  In contrast, HLA-DR, CD80, CD40 
and CD154 were minimally expressed under basal serum-free conditions (HLA-DR 
0.7% ± 0.4%, CD80 7.2% ±  2.5%, CD40 0.3% ± 1.8%, CD154 1.28% ± 2.0%), and 
all were significantly upregulated in response to stimulation by IL-13, but only at the 
maximum concentration of 100ng/ml (HLA-DR 7.5% ± 3.9% P = 0.01, CD80 12.7% 
± 9.4% P = 0.04, CD40 52.8% ± 9.9% P = 0.03, CD154 22.4% ± 5.6% P = 0.03, 
Figure 5.8 and Figure 5.9).  No significant change in either the percentage 
expression of CD86 was detected, nor in the intensity of expression of ICAM-1 
(data not shown). As a comparison, interferon-gamma (IFNγ) 1ng/ml was found to 
significantly upregulate HLA-DR, CD40 and CD154 expression, but not CD80 
(Figure 5.8).   170
 
 
 
 
 
Figure 5.8 Fibroblast expression of surface markers of activation and 
costimulatory molecules in response to IL-13.  Normal human conjunctival 
fibroblasts were treated with various concentrations of IL-13 [1, 10, 100 ng/ml] or 
IFNγ [1ng/ml] for 72 hours under serum-free conditions, and the percentage of 
conjunctival fibroblasts expressing on their cell surface HLA-DR, ICAM, CD80, 
CD86, CD40, and CD154 was determined by flow cytometry. Serum-free medium 
(SFM) containing 0.1% bovine serum albumin (BSA) was the negative control. 
100ng/ml IL-13 significantly upregulated the surface expression of HLA-DR, CD80, 
CD40 and CD154. As a comparison, 1ng/ml IFNγ upregulated HLA-DR, CD40 and 
CD154 expression. Results are the mean ± SE from 6 individual donors. *P < 0.05. 
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Figure 5.9 Representative density plots of surface marker expression flow 
cytometry. Upregulated surface expression of CD40, CD154, CD80 and HLA-DR 
was observed in the presence of 100ng/ml IL-13, compared with the untreated 
control 0.1% bovine serum albumin (BSA) serum-free medium (SFM), by a normal 
human conjunctival fibroblast primary cell line.  
 
5.4.6  T cell studies 
Attempts to culture T cells from the conjunctival biopsies were unsuccessful, in part 
due to fungal contamination and in part due to inability to maintain cell survival. 
Attempts to grow peripheral blood mononuclear cells, for the purpose of T cell-
fibroblast co-culture experiments, were similarly unsuccessful.  
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5.5 Discussion 
The results in this chapter show that IL-13 is expressed in the conjunctiva in the 
scarring condition mucous membrane pemphigoid, and that it has direct effects in 
stimulating normal human conjunctival fibroblast collagen contraction and 
migration, and modifying matrix metalloproteinase secretion in vitro, which could 
lead to connective tissue remodelling.  IL-13 may also promote the active 
involvement of these cells in pro-inflammatory activities via upregulating HLA-DR, 
CD80, CD40, and CD154 expression, thus enabling the fibroblasts to cross-talk 
with lymphocytes and other inflammatory cells. IL-13 appears to act synergistically 
with lymphocyte-secreted products to augment chemotaxis of conjunctival 
fibroblasts.  
 
The findings in this chapter of increased collagen contraction and migration in 
response to IL-13 are similar to reports from other studies where human lung 
fibroblasts were investigated (Kohyama et al., 2004; Liu et al., 2002).  Reduced 
matrix metalloproteinase- 3 secretion by normal human conjunctival fibroblasts in 
response to IL-13 has similarly been described by Fukuda et al (Fukuda et al., 
2006), but they did not investigate matrix metalloproteinase-10 secretion, which we 
also found was reduced by IL-13.  Moreover, they also found increased release of 
timp-2, which was not detected by our assay method.  These differences are 
probably due to different culture conditions. Matrix metalloproteinase-3 (mmp-3) is 
a stromelysin which cleaves pro-mmps 1,7,8,9,and 13, laminin and fibronectin 
(Wong et al., 2002). It is thus a key regulator of mmp activity, and reduced 
secretion of mmp-3 is consistent with reduced degradation of extracellular matrix 
and a net increase in collagen.  Matrix metalloproteinase-10 is also a stromelysin, 
and has similar activities to mmp-3. 
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The unsuccessful inhibition of IL-13 induced collagen contraction by soluble IL-
13Rα2 may have been because of several reasons: (1) the soluble IL-13Rα2 
needed to be pre-incubated with IL-13 alone, prior to adding it to the fibroblasts, in 
order for the soluble inhibitor to achieve a sufficient reduction of IL-13. Andrews et 
al carried out this preincubation for 6 hours. This was not done for the experiments 
in this study because it had been felt that, in the event of the soluble IL-13Rα2 
being utilized as therapy, the preincubation was unlikely to be representative of a 
physiological interaction in the tissues; (2) the concentration of soluble IL-13Rα2 
was not high enough to bind and prevent IL-13 from attaching to its active receptor 
on the fibroblasts; (3) the 24 hour pre-incubation with IL-13 was not successful in 
attenuating the response to IL-13 because the cells had not been washed after the 
24hour incubation and then re-stimulated with IL-13. Finding suitable IL-13 
inhibitors that work both in vitro and in vivo requires further investigation. 
 
An exciting preliminary observation from this study is that IL-13 upregulates 
expression of the T cell costimulatory molecules CD80, CD40 as well as CD154 
(CD40 ligand) on human conjunctival fibroblasts, and also upregulates HLA-DR 
expression. In comparison, IFNγ upregulated HLA-DR, CD40 and CD154 
expression. This upregulated surface molecule expression in response to IL-13 
and IFNγ could have been confirmedby using additional methods such as Western 
blotting, immunocytochemistry and/ or laser confocal microscopy of fibroblasts 
seeded in glass chamber slides, real time PCR for mRNA expression, and 
immunohistochemistry of pemphigoid conjunctival tissues investigating the 
expression of these molecules.  
 
Whilst the CD40/ CD154 pathway has been implicated in the development of 
fibrosis in the lung, it has not previously been investigated with respect to 
conjunctival fibroblasts. The CD40/ CD154 interaction is a potent activator of 
fibroblasts, and we hypothesise that the promotion of autocrine and paracrine 
activation of conjunctival fibroblasts via this pathway by IL-13, which upregulates   174
both expression of the ligand (CD40) and the receptor (CD154) on these cells, 
plays a role in the perpetuation of inflammation and wound healing responses in 
mucous membrane pemphigoid. Upregulated expression of CD154 in human lung 
fibroblasts by IL-13 has previously been reported by Kaufman et al (Kaufman et al., 
2004), who detected CD154 more readily intracellularly than on the surface of lung 
fibroblasts. It is possible that they were less able to detect surface CD154 because 
they used trypsin to detach fibroblasts for flow cytometry rather than collagenase. 
Trypsin cleaves surface molecules more readily than collagenase (Bluml, 2007). In 
contrast to Kaufman’s findings however, the results presented here showed that 
IFNγ also upregulated CD154 expression by fibroblasts. The findings in this 
chapter regarding persistently elevated expression of IL-13 in conjunctiva that 
appeared ‘white’ and clinically uninflamed following systemic immunosuppressive 
treatment but that still showed progressive fibrosis, are consistent with fibroblasts 
playing an active role in perpetuating this chronic inflammation.  
   
Upregulated expression of CD80 (B7-1) on conjunctival fibroblasts was also found 
in the results presented here. Whilst binding of CD80 to its receptor CD28 on T 
cells is an essential costimulatory step in T cell activation, there is an inhibitory 
receptor on T cells for the B7 ligands, CTLA-4 (cytotoxic T lymphocyte- associated 
antigen 4 / CD152) (Bhatia et al., 2006), which is upregulated after T cell activation 
has peaked, and limits the degree of activation.  It is possible that engagement of 
the inhibitory receptor CTLA-4 on T cells, by conjunctival fibroblasts expressing 
CD80, regulates the activation process.  Tesavibul et al have previously reported 
significantly high CD86 (B7-2) expression in the conjunctival substantia propria of 
mucous membrane pemphigoid compared with normal conjunctiva, and minimal 
detection of CD80 (Tesavibul et al., 1998). The CD86 positive cells were thought to 
be mostly tissue macrophages and Langerhans’ cells, and the differences in CD80/ 
CD86 expression may also reflect differences in regulation of expression, given 
that B7-1 (CD80) is expressed in a tightly regulated manner but B7-2 (CD86) is 
constitutively expressed on the cell surface of antigen presenting cells.    175
 
The principal mediators responsible for the observed synergistic enhancement of 
the chemotactic effect of IL-13 with T cell supernatant are most likely IL-2, IL-4, IL-
5 and/ or IFNγ (Crowston et al., 1997).  Antibody neutralization experiments would 
aid in identifying the responsible mediators. It is possible that other actions of IL-13 
on fibroblasts also require synergism with other growth factors. The unsuccessful T 
cell culture experiments meant that unfortunately further understanding of the 
relative importance of IL-13 and T cells in conjunctival fibrosis was limited.  
 
In contrast with a previous study (Fujitsu et al., 2005), an increase in proliferation of 
normal conjunctival fibroblasts in response to IL-13 was not able to be detected in 
the experiments presented here. This may have been due to differences in the 
method used. In addition, use of different IL-13 concentrations may have 
stimulated proliferation in our assay.  Leonardi et al have detected proliferation of 
conjunctival fibroblasts derived from vernal keratoconjunctivitis (VKC) patients in 
response to IL-13 using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay (Leonardi et al., 2003), but difficulty in getting the 
MTT assay to work led to the use of CFSE flow cytometry in our experiments. 
Leonardi also showed increased procollagen I production in response to IL-13 by 
VKC fibroblasts grown on culture plates in fresh ascorbic acid with 0.4% serum.  
Unlike the findings of Leonardi et al, no change in collagen secretion in the 
conditioned medium from contracting collagen lattices was detected in the results 
presented here, either under serum-free conditions or in the presence of 10% heat 
inactivated serum.  There could be several reasons for the difference in findings: in 
our experiments the fibroblasts were actively contracting the collagen lattices and 
thus unlikely to divert their metabolic activities to synthesizing collagen at the same 
time, or alternatively the medium conditions were not optimal for collagen 
synthesis, or because of phenotypic differences between VKC and normal 
conjunctival fibroblasts, or because IL-13 alone has only a modest effect on   176
collagen synthesis, and synergism with another factor such as TGF-β is necessary 
(Zhou et al., 2005).        
 
Developing effective therapies to inhibit the profibrotic effects of IL-13 on 
fibroblasts and other inflammatory cells will involve understanding the relative roles 
and actions of the IL-13 receptors and their signalling pathways.  There are 2 
different IL-13 receptor chains to which IL-13 binds (Hershey, 2003). First, the 
IL13Rα1 chain, which combines with the IL-4 receptor α-chain, to form a dimeric 
transmembrane IL-13 receptor which is expressed on IL-13-responsive cells, and 
is activated not only by IL-13, but also by IL-4. Secondly, the IL-13Rα2 chain, 
which binds IL-13 with high affinity, but was formerly considered to only function as 
a decoy receptor. Recently it has been shown in macrophages that IL-13 signaling 
via induction of cell-surface expression of IL-13Rα2, activates the TGF-β1 
promoter to synthesise TGF-β and cause fibrosis (Fichtner-Feigl et al., 2006).  
Induction of IL-13Rα2 requires the presence of both IL-13 (or IL-4) and TNFα.  The 
results in chapter 4 showed that TNFα is expressed in ocular mucous membrane 
pemphigoid, and it is possible that the presence of both cytokines (TNFα and IL-
13) activates TGF-β production and conjunctival fibrosis via this mechanism. A 
synergistic effect of TNFα and IL-13 on expression of VCAM-1 (vascular cell 
adhesion molecule-1) by corneal fibroblasts has also been reported (Kumagai et 
al., 2003).  
5.6   Conclusion 
IL-13 is expressed in actively inflamed and uninflamed conjunctiva in ocular MMP. 
It is likely to contribute to conjunctival fibrosis in mucous membrane pemphigoid via 
both indirect mechanisms involving TGFβ and other cytokines, and via direct 
effects on conjunctival fibroblast contractility, migration and mmp secretion. By 
upregulating the ability for cross-talk between conjunctival fibroblasts and other 
inflammatory cells, IL-13 may facilitate fibroblast-generated chronic inflammation 
and continued fibrosis.    177
 
Chapter 6 
 
Conjunctival fibroblasts from patients with 
mucous membrane pemphigoid appear to 
have a profibrotic phenotype 
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6.1 Introduction 
Chapters 4 and 5 highlighted the roles of the inflammatory cytokines TNFα and IL-
13 in acute and chronic inflammation in ocular MMP. Whilst inflammation typically 
precedes the development of fibrosis in most fibrotic disorders, some experimental 
models suggest that fibrosis is not always characterized by persistent 
inflammation, and that to a degree, the mechanisms regulating fibrosis are distinct 
from those controlling inflammation (Stramer et al., 2007).  In line with this 
viewpoint, an alternative theory for the observed progression of fibrosis in ocular 
MMP is that the fibroblasts have been transformed into an abnormally activated 
phenotype, or this abnormal phenotype has been preferentially selected and 
expanded, in a similar fashion to the profibrotic phenotype observed and 
maintained in vitro in fibroblasts from patients with systemic sclerosis, pulmonary, 
renal and colonic fibrosis (Ramos et al., 2001; Schuttert et al., 2003; Trojanowska, 
2004).   
 
There is some evidence of phenotypic changes in fibroblasts isolated from mucous 
membrane pemphigoid patients (Razzaque et al., 2003b; Razzaque et al., 2004; 
Roat et al., 1989), but whether there are pathological alterations in key aspects of 
fibroblast behaviour such as motility, contractile function, matrix synthesis, and 
development of myofibroblast characteristics, has not been investigated. Moreover, 
whether there are differences in fibroblasts isolated from actively inflamed tissue 
compared with fibroblasts isolated from clinically uninflamed tissue, is unknown.   
6.2 Aim 
The study in this chapter sought to establish whether there are phenotypic 
differences in fibroblast functional activity between mucous membrane pemphigoid 
conjunctival fibroblasts and normal conjunctival fibroblasts, and whether fibroblasts 
isolated from actively inflamed tissue differ from those isolated from clinically 
uninflamed tissue.    179
6.3 Research Design and Methods 
6.3.1 Conjunctival biopsies 
Bulbar conjunctival biopsies were obtained from 11 active ocular MMP patients, 8 
uninflamed ocular MMP patients, and from 11 patients with normal conjunctiva as 
described in Chapter 4, section 4.3.1. Details of the patients and controls from 
whom biopsies were used for the experiments in this chapter are shown in Table 
6.1.  
6.3.2  Isolation of Normal Conjunctival Fibroblasts 
Normal conjunctival fibroblasts, actively inflamed pemphigoid conjunctival 
fibroblasts and uninflamed pemphigoid conjunctival fibroblasts were grown from  
the conjunctival biopsies and passaged as described in Chapter 4, section 4.3.3. 
6.3.3 Proliferation 
Fibroblast cell division was analysed by flow cytometry using the fluorescent probe 
CFSE (carboxyfluorescein diacetate, succinimidyl ester) as described in Chapter 
4, section 4.3.7. The CFSE-containing cells were seeded into 6-well tissue culture 
plates at a density of 4 x 10
5 cells per well in 10% serum-containing FCM and 
cultured for 96 hours.     
6.3.4 Migration 
Fibroblast migration experiments were conducted as described in Chapter 4, 
section 4.3.4, in either (1) SFM, or (2) 10% serum-containing FCM.  
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Table 6.1 Details of patients and normal controls whose conjunctival biopsies were used in pemphigoid 
fibroblast studies 
Disease Bulbar
Diagnosis Age Gender duration inflammation Tauber stage Topical therapy Systemic therapy Other eye pathology
(yrs)  grade (0 to 4) (Upper stage/ Lower stage)
Active MMP 54 F 0.5 3 IIcIIId/ IIcIIId hypromellose, acetylcysteine, yellow soft paraffin nil
80 M 10 3 IIbIIIc(2)/ IIdIIId(2) carmellose mycophenolate + dapsone
55 M 13 3 IIcIIIc(2)/ IIdIIId(1) dexamethasone, carmellose mycophenolate + dapsone + deflazocort
74 M 2 2.5  IIa/ IIcIIIc(2) dorzolamide, bimatoprost nil glaucoma
76 F 2 2.5 IIc/ IIbIIIa(2) prednisolone, hypromellose, carmellose mycophenolate + dapsone sicca, blepharitis
81 M 2 2.5 IIaIIIa(1)/ IIbIIIb(2) carmellose mycophenolate + dapsone
83 M 1 3 IIbIIIa(1)/ IIcIIIc(2) ofloxacin, chloramphenicol nil
62 F 18 2  IIcIIIc(2)/IIdIIId(2) timolol, carbomer 980 mycophenolate glaucoma
64 F 1 2 IIa/ IIbIIIc(2) prednisolone nil
83 F 7 3 IIa/ IIbIIIb(2) brimonidine, latanoprost, timolol, dorzolamide, carmellose mycophenolate + doxycycline glaucoma
51 F 0.1 3 I/ IIIa(1) nil nil
Treated uninflamed MMP 59 F 10 1 IIbIIIb(2)/ IIdIIId(2) carbomer 980 dapsone
86 F 15 1 IIb/ IIcIIIb(2) nil nil
78 F 10 1 IIbIIIb(2)/ IIdIIId(2) nil nil
84 F 2 0 IIb/ IIcIIIc(2) nil mycophenolate
66 F 2 0 IIb/ IIcIIIb(2) nil dapsone
66 F 2 0 IIb/ IIcIIIb(2) nil dapsone
76 M 6 1.5 IIdIIId(2)/ IIbIIIb(2) chloramphenicol, hypromellose, retinoic acid, acetylcysteine cyclophosphamide
60 F 3 1 I/IIaIIIa(1) carmellose cyclophosphamide + dapsone
Normal control 50 F - 0 - nil nil cataract
76 M - 0 - nil nil cataract
65 M - 0 - nil nil cataract
70 F - 0 - nil nil cataract
65 M - 0 - nil nil cataract
75 F - 0 - nil nil cataract
73 F - 0 - nil nil cataract
57 M - 0 - nil nil cataract
65 M - 0 - nil nil cataract
79 F - 0 - nil nil cataract
62 M - 0 - nil nil cataract
MMP mucous membrane pemphigoid, F = female, M = male  181
6.3.5  Collagen contraction model 
Free-floating relaxed fibroblast-populated collagen gels were prepared as 
described in Chapter 4, section 4.3.5. The lattices were detached immediately 
after feeding with either (1) SFM, (2) 10ng/ml IL-13 in SFM (recombinant human IL-
13, R&D systems, Abingdon, UK), (3) 10ng/ml TNFα in SFM (recombinant human 
TNFα, R&D systems, Abingdon, UK), or (4) fibroblast culture medium (FCM) 
containing 10% gelatinase-free calf serum (Gibco). The gels were digitally 
photographed at days 1, 3 and 7, and gel areas were calculated using image 
analysis software (Image J).  
6.3.6  Matrix metalloproteinase protein levels 
Conditioned medium collected from the collagen lattice experiments between days 
0-3 and 3-7, and days 0-7, was analysed for matrix metalloproteinase-1 (mmp-1), 
mmp-2, mmp-3, mmp-8, mmp-10, mmp-13, tissue inhibitor of matrix 
metalloproteinase-1 (timp-1), timp-2 and timp-4 protein levels as described in 
Chapter 4, section 4.3.6. 
6.3.7  Type I collagen secretion 
Conditioned medium collected from contracting lattices was analysed for secretion 
of the C-terminal propeptide of type I collagen (CICP) using an ELISA (Quidel 
Corp, San Diego CA) carried out according to the manufacturer’s instructions.    
6.3.8 Chemokine  secretion 
To investigate whether pemphigoid fibroblasts are more secretory than normal 
fibroblasts, and have the potential to draw in large numbers of inflammatory cells 
and thus cause a greater degree of conjunctival inflammation by secreting 
chemoattractant molecules called chemokines, we evaluated secretion of 
chemokines following 72 hours’ stimulation with key ocular MMP cytokines. 
Confluent fibroblasts in 6 well culture plates were cultured in SFM for 24h then   182
stimulated for 72 hours with a panel of cytokines in 10% heat-inactivated serum-
containing FCM.   
 
The cytokines selected were those reported to be present in mucous membrane 
pemphigoid, including transforming growth factor-β1 (TGFβ1; 50ng/ml), IL-4 
20ng/ml, interferon-γ (IFNγ; 200ng/ml), TNFα 10ng/ml, and IL-13 100ng/ml. The 
culture supernatants were analysed for secretion of the chemokines IL-6, CXCL-8 
(IL-8), CXCL10 (IP-10, interferon-inducible protein 10), CCL11 (eotaxin-1), and 
CXCL9 (MIG, monokine induced by IFNγ) using a cytometric bead array and FCAP 
Array Software (BD Biosciences) and flow cytometer (Facscalibur, BD Pharmigen).  
6.3.9 Immunohistochemistry  for alpha-smooth muscle actin (α-SMA) 
Immunohistochemistry was carried out on glycol methacrylate resin-embedded 
sections of active pemphigoid conjunctiva, uninflamed pemphigoid and normal 
conjunctiva, prepared as described in Chapter 4, section 4.3.2. The staining 
procedure was identical apart from the primary antibody being a monoclonal 
mouse antibody against human alpha-smooth muscle actin (M0851 Dako, 
Cambridgeshire UK), diluted 1:10, and the secondary antibody being biotinylated 
rabbit anti-mouse immunoglobulin (Dako) diluted 1:200. Vascular smooth muscle in 
the sections was used as a positive control, and the two negative controls used 
were absence of the primary antibody and an isotype-matched irrelevant 
monoclonal antibody (mouse IgG2a, Dako), diluted 1:10.  The number of stromal 
cells stained with alpha-smooth muscle actin, were counted in a masked fashion in 
5 representative high power fields per patient, using an Olympus BX51 microscope 
with image analysis software. 
6.3.10 Immunodetection of myofibroblast differentiation in mechanically stressed 
fibroblast-seeded collagen lattices 
Mechanically stressed fibroblast-seeded collagen lattices were prepared to assess 
for myofibroblast differentiation (Garrett et al., 2004). To generate mechanical   183
stress in the collagen matrix, after polymerization of the lattice mixture, the lattices 
remained attached to the culture well and were cultured in FCM for 24hours. At 
24hours, the lattice was fixed with 4% paraformaldehyde, then gently detached 
completely with a pipette tip. Triplicate samples per donor were tested, and at least 
6 donors were tested in each of the groups: active pemphigoid fibroblasts, 
uninflamed pemphigoid fibroblasts, normal conjunctival fibroblasts. The fixed 
collagen lattices were permeabilised for 15 minutes with 1% Triton X-100 (Sigma-
Aldrich) at room temperature (RT). For immunostaining of α-SMA, monoclonal anti- 
α-SMA antibody conjugated with Cy3 (Clone 1A4; Sigma-Aldrich) was added to the 
lattices (1:200 in blocking buffer) for 3 hours at RT. After the lattices were rinsed 
with PBS and exposed for 1 minute to 4’,6-diaminidino-2-phenylindole (DAPI) dye 
(1:5000 in PBS; Sigma-Aldrich), they were rinsed and mounted on a 35mm MatTek 
glass-bottomed dish (MatTek Corporation, Ashland, MA) with a fluorescent  
mountant and covered with a coverslip. Cells were viewed with a laser scanning 
confocal microscope (Leica TCS_SP2, Milton Keynes UK). The proportion of 
myofibroblasts and fibroblasts was determined by counting the number of cells 
containing assembled α-SMA stress fibres as a proportion of the total number of 
cells visualized by DAPI-stained nuclei. Five random fields of view at x40 final 
magnification were analysed with Leica image analysis software. 
6.3.11 Surface expression of activation markers and costimulatory molecules by 
early passage pemphigoid fibroblasts and normal conjunctival fibroblasts.  
Preliminary experiments to characterize the surface expression of activation 
markers and costimulatory molecules by early passage pemphigoid versus normal 
fibroblasts were attempted. Passage 0 fibroblasts were obtained directly from the 
primary biopsies using trypsin/EDTA, in a similar manner to that described in 
chapter 4, section 4.3.3. As there was no reliable fibroblast marker, passage 0 
fibroblasts for these experiments were not obtained until at least 6 weeks in 
culture, to allow a sufficient time for any potential contaminating epithelial cells to 
die. Passage 1 fibroblasts were obtained from the 6 well-plate cultures which were   184
necessary to grow sufficient numbers of passage 1 cells for further passaging into 
flasks (as described in chapter 4, section 4.3.3). Three-colour 
immunofluorescence staining with either anti-ICAM-1
PE, anti-CD80
FITCand anti-
HLA-DR
PerCP, or anti-CD154
FITC, anti-CD86
PE, and anti-CD40
PECy5 was conducted 
as described in chapter 4, section 4.3.8.  
6.3.12 Statistical Analysis 
Differences between 2 groups were examined for statistical significance using the 
Mann-Whitney U test and one-way analysis of variance (ANOVA) was used to 
compare the means of 3 or more unmatched groups. P < 0.05 was considered 
significant.   185
6.4 Results  
6.4.1    Pemphigoid and normal conjunctival fibroblasts appear to have similar 
morphology 
No clear differences in the morphology of pemphigoid fibroblasts compared with 
normal conjunctival fibroblasts were detected (Figure 6.1), nor between 
pemphigoid fibroblasts obtained from acutely inflamed tissue compared with 
chronic uninflamed tissue. 
 
 
 
 
 
Figure 6.1 Morphology of normal and pemphigoid fibroblasts in vitro. Inverted 
phase contrast microscopy of A. normal conjunctival fibroblasts 6 days after the 4
th 
subpassage and B. pemphigoid conjunctival fibroblasts from acutely inflamed 
tissue 5 days after the 4
th subpassage. Pemphigoid fibroblasts were similar in 
appearance to normal conjunctival fibroblasts. Magnification x100, bar= 1mm.    186
 
6.4.2  Comparison of early versus late passage pemphigoid fibroblasts, and 
actively inflamed versus uninflamed pemphigoid fibroblasts 
Comparison of early versus late passage normal control conjunctival fibroblasts 
and pemphigoid conjunctival fibroblasts showed no significant differences in all 
assays including collagen contraction (Figure 6.2), proliferation and migration.  
Comparison of actively inflamed versus uninflamed pemphigoid conjunctival 
fibroblasts in all assays did not show any clinically or statistically significant 
differences (Figure 6.3).  
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Figure 6.2 Comparison of collagen contraction by early versus late passage 
fibroblasts. A. No difference in collagen contraction over 7 days in FCM between 
passage 3 versus passage 5 normal conjunctival fibroblasts. B. No difference in 
collagen contraction over 7 days in FCM between passage 3 and passage 6 
actively inflamed pemphigoid conjunctival fibroblasts. n= number of individual 
experiments. 
 
 
 
Figure 6.3 Comparison of actively inflamed versus uninflamed pemphigoid 
conjunctival fibroblasts. A. No difference in number of divided cells between 
actively inflamed versus uninflamed pemphigoid fibroblasts after 96 hours culture 
in FCM. n= number of individual donors. B. No clinically significant difference in 
collagen contraction over 7 days in FCM, between actively inflamed versus 
uninflamed pemphigoid fibroblasts. Although there appears to be a difference in 
the gel areas at day 3, the magnitude of this difference is small (34% - 23% = 11%) 
and not considered clinically significant. P = pemphigoid, n= number of individual 
experiments    188
 
6.4.3   Pemphigoid fibroblasts have a greater number of cell divisions than normal 
conjunctival fibroblasts 
Pemphigoid conjunctival fibroblasts showed significantly increased numbers of 
divided cells compared with normal conjunctival fibroblasts after 96 hours in culture 
(average 7026 ± 2020 vs 1216 ± 558 divided cells per 5000 events, P =0.01, 
Figure 6.4.)  
 
Interestingly, despite the increased number of cell divisions detected by flow 
cytometry, in practical terms when passaging and growing pemphigoid fibroblasts, 
a confluent flask of pemphigoid fibroblasts more often than not would yield fewer 
viable cells on a cell count compared with a same-size same-confluence flask of 
normal control fibroblasts. This could have been due to more rapid cell death of 
pemphigoid fibroblasts in response to trypsinisation, or due to a larger pemphigoid 
cell size (although the latter appeared to be less likely, based on subjective (non-
quantitative) morphology comparisons).   
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Figure 6.4 Fibroblast cell division assessed by flow cytometric measurement 
of dilution of the fluorescent label CFSE (carboxyfluorescein diacetate, 
succinimidyl ester). CFSE is bound to proteins in the cell. For each division, the 
amount of CFSE in each daughter cell is half that of the parent. A. After a 96-h 
culture period in 10% serum-containing medium, pemphigoid fibroblasts had 
significantly increased numbers of divided cells compared with normal control 
conjunctival fibroblasts (P = 0.01). The ratio of divided cells was calculated by 
measuring the number of cells with a diluted CFSE concentration per 5000 
undivided cells. Results are the mean and SE from 5 or more individuals in each 
group. B. Representative histogram of number of events (y axis) versus CFSE 
fluorescence (x axis) in a normal fibroblast line. Cell division is indicated by 
decreased fluorescence to the left of the time 0 peak.  Grey filled-in peak is the 
fluorescence of CFSE in the cells at time 0. Black line is the fluorescence at 96-h. 
C. Histogram of number of events versus CFSE fluorescence in a pemphigoid 
fibroblast line. Orange filled-in peak is the fluorescence of CFSE in the cells at time 
0. Red line is the fluorescence at 96-h.  There are more divided cells in the 
pemphigoid fibroblasts compared with the normal fibroblasts. There is only one 
peak of divided cells, suggesting that the size of the well limited further cell 
division.     190
 
 
6.4.4  Increased migration by pemphigoid conjunctival fibroblasts under serum-
free conditions 
The number of pemphigoid fibroblasts that migrated through the porous 
membranes towards the 0.1% bovine serum albumin serum-free medium (SFM) 
was significantly higher than the number of normal control fibroblasts that migrated 
towards SFM (72 ± 18 versus 33 ± 11, P = 0.04) (Figure 4). No significant 
difference between pemphigoid and normal fibroblasts in the number of cells 
migrating towards 10% serum-containing FCM was detected (data not shown).  
 
 
 
Figure 6.5 Comparison of pemphigoid versus normal conjunctival fibroblast 
migration towards 0.1% bovine serum albumin (BSA) serum-free medium 
(SFM). Conjunctival fibroblasts were seeded in the upper chambers of porous 
membranes and allowed to migrate overnight towards the lower chamber 
containing the test substance, in this case 0.1% bovine serum albumin (BSA) 
serum-free medium (SFM). Pemphigoid fibroblasts migrated more than normal 
control fibroblasts under serum-free conditions. Results are the mean and SE of 8 
individual experiments. *P  = 0.04.   191
6.4.5   Pemphigoid fibroblasts show increased collagen contraction in response to 
tumour necrosis factor-α, and reduced contraction in response to interleukin-
13, compared with normal conjunctival fibroblasts 
Collagen contractility of the fibroblasts was next assessed. Although there was no 
detectable difference in the contraction of relaxed collagen gel lattices by 
pemphigoid and normal conjunctival fibroblasts in either serum-free medium (SFM) 
(Figure 6.6 A)  or 10% serum-containing fibroblast culture medium (FCM) (Figure 
6.6 B), the pemphigoid fibroblasts did contract collagen in response to tumour 
necrosis factor-α (TNFα) (Figure 6.6 C). In comparison, the findings in chapter 4 
showed that normal conjunctival fibroblasts do not contract collagen in response to 
TNFα (see Chapter 4, section 4.4.2). In contrast, the addition of interleukin-13 (IL-
13) to the collagen lattice conditioned medium resulted in less contraction by 
pemphigoid fibroblasts compared with normal fibroblasts, relative to the amount of 
contraction in the SFM negative control (Figure 6.6 D).   192
 
 
Figure 6.6 Fibroblast-populated collagen gel lattice contraction over 7 days 
by pemphigoid versus normal conjunctival fibroblasts showing A. no 
difference in contraction in 0.1% bovine serum albumin (BSA) serum-free medium 
and B. no difference in contraction in 10% foetal calf serum (FCS)-containing 
medium. C. In the presence of 10ng/ml tumour necrosis factor-α (TNFα),   193
pemphigoid fibroblasts contract collagen more than normal fibroblasts by day 7 (P 
= 0.02). Differences in cell morphology in the TNFα gel observable at day 7 are 
shown below in E and F. D. In the other hand, in the presence of interleukin-13 (IL-
13), at day 3 pemphigoid fibroblasts contract collagen less vigorously than normal 
fibroblasts do at day 3 (P = 0.02), but by day 7 there is no significant difference. 
The reduction in gel area in response to IL-13 at day 3 is less in pemphigoid 
fibroblasts than normal fibroblasts (relative to the serum-free medium negative 
control). Results of all graphs are the mean and SE from 6 or more donors per 
group. E. Morphology of normal fibroblasts at day 7 in a collagen lattice treated 
with TNFα. The cells suspended in the collagen matrix have elegantly curved cell 
processes and there is no evidence of contractile bands of collagen. F. Morphology 
of pemphigoid fibroblasts at day 7 in a collagen lattice treated with TNFα. 
Fibroblast cell processes are straighter, shorter and thicker, and there are 
contractile bands of collagen radiating from the cell processes (arrowheads). 
Magnification x 200. Bar = 100nm.    194
 
6.4.6   Pemphigoid fibroblasts secrete more matrix metalloproteinase-3 (mmp-3) 
and less mmp-13 in the presence of serum 
During day 0-3 of collagen lattice contraction in 10% serum-containing medium, 
pemphigoid fibroblasts secrete more matrix metalloproteinase-3 (mmp-3) (P =0.04) 
and less mmp-13 (P =0.02) compared with normal conjunctival fibroblasts (Figure 
6.7 A). During day 3-7 of collagen lattice contraction in 10% serum-containing 
medium, there was no difference in mmp and tissue inhibitor of matrix 
metalloproteinase (timp) secretion between pemphigoid and normal fibroblasts 
(data not shown). In the presence of IL-13, both normal and pemphigoid fibroblasts 
secrete less mmp-3 (Figure 6.7 B,C), and when pemphigoid fibroblasts and 
normal fibroblasts are compared directly, pemphigoid fibroblasts secrete less mmp-
8 than normal fibroblasts in the presence of IL-13 (Figure 6.7 D). An increase in 
mmp-3 secretion by pemphigoid fibroblasts was also observed during collagen 
contraction in serum-free medium from day 0-7(data not shown).   195
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Figure 6.7. Matrix metalloproteinase (mmp) and tissue inhibitor of matrix 
metalloproteinase (timp) levels in conditioned medium of conjunctival 
fibroblast-populated collagen gels, detected by antibody-coated membrane 
array. Data are relative values compared with the membrane array negative 
control. A. During day 0-3 of collagen lattice contraction in 10% foetal calf serum 
(FCS)-containing medium, pemphigoid fibroblasts secreted higher levels of mmp-3 
(P =0.04) and lower levels of mmp-13 (P = 0.02) compared with normal fibroblasts. 
B. During day 0-7 of collagen lattice contraction in the presence of IL-13 10ng/ml in 
SFM, normal conjunctival fibroblasts secrete lower levels of mmp-3 (P =0.04) and 
mmp-10 (P =0.01), and C. pemphigoid fibroblasts similarly secrete lower levels of 
mmp-3 (P =0.004). D. When compared directly in the presence of IL-13, 
pemphigoid fibroblasts secrete less mmp-8 (P =0.02) compared with normal 
fibroblasts. Results are the mean and SE from 6 individual donors per graph. *P < 
0.05    **P < 0.01    197
 
6.4.7     Pemphigoid fibroblasts secrete more type I collagen. 
During day 3-7 of collagen lattice contraction in 10% serum-containing medium, 
pemphigoid fibroblasts secrete more C-terminal propeptide of type I collagen 
(CICP) compared with normal conjunctival fibroblasts (median 62.2 versus 31.4 
ng/ml, P = 0.03) (Figure 6.8). 
 
 
 
Figure 6.8 Comparison of C-terminal propeptide of type I collagen (CICP) 
secretion by pemphigoid fibroblasts versus normal conjunctival fibroblasts 
during day 3-7 of collagen lattice contraction in 10% serum-containing medium.  
Pemphigoid fibroblasts secrete more type I collagen than normal fibroblasts (P 
=0.03). Results are from 4 individual donors in box-whisker plots showing median, 
upper and lower quartiles, maximum and minimum.   198
 
6.4.8   Pemphigoid fibroblasts secrete more CCL11 (eotaxin-1) in response to IL-
13. 
Pemphigoid fibroblasts secreted more CCL11 (eotaxin-1) in response to IL-13 
(Figure 6.9).  No significant differences between pemphigoid and normal 
fibroblasts with respect to secretion of IL-6, CXCL8 (IL-8), CXCL10 (IP-10) or 
CXCL9 (MIG) were detected, either in the absence of cytokines or in response to 
stimulation by IL-4, IFNγ or TGF-β.  
 
 
 
Figure 6.9 Comparison of CCL11 (eotaxin-1) secretion by pemphigoid 
fibroblasts versus normal fibroblasts in response to IL-4 and IL-13.  
Pemphigoid fibroblasts secrete more CCL11 in response to IL-13 than normal 
fibroblasts (P =0.04). Results are the mean and SE from at least 6 individual 
donors.   199
 
6.4.9 Myofibroblast  differentiation 
There was very little stromal α-SMA staining in both pemphigoid and normal bulbar 
conjunctiva, and no differences were detected between pemphigoid and normal 
conjunctiva. No significant differences were detected between pemphigoid 
fibroblasts and normal fibroblasts, regarding the expression of assembled α-SMA 
filaments in collagen lattices after 24 hours of mechanical stress (data not shown). 
6.4.10 Surface expression of activation markers by early passage pemphigoid 
fibroblasts  versus normal conjunctival fibroblasts 
It was not possible to obtain sufficient numbers of passage 0 cells for flow 
cytometry. Results of preliminary experiments using passage 1 cells from two 
normal control fibroblast cell lines, one active pemphigoid cell line and one 
uninflamed pemphigoid cell line, are shown in Figure 6.10. These experiments 
need to be repeated before any conclusions can be made, but the findings suggest 
that there does not appear to be any difference in HLA-DR or costimulatory 
molecule expression, between early passage pemphigoid versus normal 
conjunctival fibroblasts. The active pemphigoid fibroblast cell line tested appeared 
to have reduced ICAM expression compared to the other cell lines.  
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Figure 6.10 Expression of surface markers of activation and costimulatory 
molecules by passage 1 pemphigoid and normal conjunctival fibroblasts. 
Passage 1 cells from two normal, one active pemphigoid and uninflamed 
pemphigoid conjunctival fibroblast cell lines were tested. A. The percentage of 
conjunctival fibroblasts expressing on their cell surface HLA-DR, ICAM, CD80, 
CD86, CD40, and CD154 was determined by flow cytometry. High ICAM 
expression was detected in all cell lines except the active pemphigoid cells. B. 
shows a magnified view of surface expression of the other molecules apart from 
ICAM. There was negligible expression of HLA-DR and costimulatory molecules 
apart from 5.5% CD40 expression by the control 2 cell line. C. shows 
representative density plots of the control 2 and active pemphigoid cell line.     201
6.5   Discussion 
The results in this chapter show that conjunctival fibroblasts from ocular mucous 
membrane pemphigoid (ocular MMP) patients display a distinct fibrotic phenotype 
characterized by increased cell division, chemotaxis, collagen and matrix 
metalloproteinase synthesis, that is maintained over multiple passages in vitro.  In 
the presence of the pro-fibrotic type 2 helper T cell mediator interleukin-13 (IL-13) 
which was shown to be expressed in ocular MMP in chapter 5, pemphigoid 
fibroblasts appear to respond with less contraction and reduced matrix 
metalloproteinase production, but with increased secretion of the chemokine 
CCL11 (eotaxin-1). We did not detect any differences between pemphigoid 
fibroblasts isolated from acutely inflamed versus uninflamed tissue.  
 
Increased proliferation of ocular MMP conjunctival fibroblasts has previously been 
observed (Roat et al., 1989), as has increased expression of macrophage 
migration inhibitory factor, macrophage-colony stimulating factor, connective tissue 
growth factor and heat shock protein 47 by ocular MMP fibroblasts (Razzaque et 
al., 2003b; Razzaque et al., 2004). Preliminary studies have also suggested that 
ocular MMP fibroblasts express the proto-oncogene c-myc (Hunt LE, et al. IOVS 
1991;32:ARVO Abstract 938) and show ultrastructural changes indicating 
increased protein synthesis which persist in culture (Biesman BS et al. IOVS 
1994;Suppl 35(4):ARVO Abstract 170). The findings in this chapter of increased 
proliferative, secretory and matrix synthetic activity by pemphigoid fibroblasts are in 
agreement with these previous reports.   
 
Unlike the findings in scleroderma however, no difference in myofibroblast 
differentiation by pemphigoid fibroblasts and tissues compared to normal cells and 
tissues was able to be detected.  Simple cytoplasmic expression of unassembled 
actin alone is not an indicator of myofibroblast differentiation; morphologic 
detection of α-smooth muscle actin (α-SMA) filaments assembled as stress fibres   202
by confocal microscopy is necessary (Tomasek et al., 2002).  It is possible that 
24hrs duration of mechanical stress was too short to enable differences between 
pemphigoid and normal fibroblasts to emerge, and perhaps 48 hours might have 
allowed differences to have been observed.  The immunohistochemical staining of 
normal versus pemphigoid conjunctival tissue needs to be repeated using an 
alternative α-SMA antibody, and the mechanically stressed gel experiments also 
need to be repeated using different durations of mechanical stress and/ or in the 
presence of TGFβ, which promotes myofibroblast differentiation particularly in the 
presence of mechanical tension (Vaughan et al., 2000). It is also possible that cell 
types other than the resident tissue fibroblasts are the source of myofibroblasts in 
ocular MMP.  There is emerging evidence from studies of pulmonary fibrosis and 
other disorders that epithelial cells could be an important source of myofibroblasts, 
via the process of epithelial-mesenchymal transdifferentiation (EMT) (Radisky & 
LaBarge, 2008).  
 
Increased matrix metalloproteinase-3 (mmp-3) and decreased mmp-13 secretion 
by pemphigoid conjunctival fibroblasts during collagen lattice contraction was 
observed in this study. Mmp-3, also known as stromelysin-1, degrades pro-mmps-
1,-7,-8,-9,-13, proteoglycans, laminin and fibronectin. It has been found to play a 
role in skin and corneal wound healing and pterygia (Daniels et al., 2003b; Li et al., 
2001; Wong et al., 2002), and is produced during collagen lattice contraction by 
human Tenon’s capsule fibroblasts (Daniels et al., 2003a).  Broad spectrum 
inhibition of mmp activity has reduced matrix contraction and collagen production in 
vitro (Daniels et al., 2003a) and in an animal model of glaucoma surgery . On the 
other hand, the profibrotic mediator IL-13, which was found to be present in the 
stromal tissues of ocular MMP in chapter 5, causes a reduction in mmp-3 synthesis 
by both normal and pemphigoid conjunctival fibroblasts, so whether the effect of IL-
13 overrides the inherent behaviour of pemphigoid fibroblasts with regard to mmp-
3 synthesis in vivo is yet to be determined. Mmp-13 (collagenase-3) digests 
collagens I,II, II,IV, gelatin, fibronectin, and proteoglycans. Reduced mmp-13 could   203
either result in a net increase in matrix due to reduced matrix degradation, or could 
be associated with reduced mmp-dependent fibroblast locomotion through the 
extracellular matrix and subsequent matrix contraction (Daniels et al., 2003a). 
Which of these two alternatives is the dominant process in vivo is currently 
uncertain.   
   
Characteristics of fibrotic fibroblasts are probably unique to each disease, given 
that, for example, migration can be increased or decreased, depending on the 
disease from which the fibroblasts have been isolated (Rieder et al., 2007). There 
is also evidence that the phenotype of fibrotic fibroblasts varies according to 
disease duration and severity (Corriveau et al., 2008).   
 
Developing effective antifibrotic therapies will require understanding of both the 
cellular sources of the profibrotic fibroblasts, and the mechanisms that activate and 
recruit these cells to sites of scarring. In order to elucidate what happens in ocular 
MMP, knowledge of what happens in a disease such as scleroderma provides 
framework from which to work, with the understanding that although the processes 
occurring in the two diseases are clearly not identical, there are some definite 
similarities. In scleroderma, there appears to be a process of selection leading to 
the propagation of certain apoptosis-resistant profibrotic subpopulations of 
fibroblasts, which are preferentially expanded or selectively activated within 
lesional tissue (Abraham et al., 2007). Moreover, it appears that both resident and 
circulating cell types can contribute to fibroblast differentiation, thus in part 
accounting for the observed heterogeneity of fibroblasts both derived from within 
and between tissues. Potential sources of profibrotic fibroblasts include resident 
mesenchymal cells, bone-marrow-derived mesenchymal precursors (Hashimoto et 
al., 2004), circulating fibroblast progenitors including peripheral blood mononuclear 
cells (Abraham et al., 2007), epithelial-mesenchymal transition (EMT), and 
pericytes. Apart from selective amplification of subpopulations of activated 
phenotype fibroblasts derived from various sources, induction of the profibrotic   204
fibroblast phenotype is also thought to be influenced by profibrotic mediators in the 
inflammatory milieu (Abraham et al., 2007; Karlson et al., 2006), and sometimes 
cell-cell contact between immune cells and fibroblasts (Trojanowska, 2004). The 
phenotypic changes have been shown, in pulmonary fibrosis fibroblasts, to reflect 
genome-wide derangements of the gene expression pathway (Larsson et al., 
2008).  
  
In ocular MMP, there is significant inflammation induced by the autoimmune 
process which could selectively amplify resident, bone-marrow derived or 
circulating mesenchymal cells influenced by the inflammatory milieu (Bernauer et 
al., 1993b).  Furthermore, TGFβ-driven epithelial-mesenchymal transition (EMT) 
could also play a role, given that when conjunctival epithelial injury is incurred in 
the absence of treatment with systemic immunosuppression, rapid worsening of 
ocular MMP is observed (Mondino et al., 1979).  
6.6 Conclusion 
Conjunctival fibroblasts from ocular MMP patients appear to have a profibrotic 
phenotype, which is maintained in vitro. This indicates that the mechanisms 
regulating fibrosis in ocular MMP are distinct from those controlling inflammation. It 
is likely that immunosuppressive therapy targeting inflammation is ineffective at 
completely arresting fibrosis in ocular MMP because of this dissociation of 
inflammation from fibrogenesis. Fibroblasts from actively inflamed ocular MMP 
tissue do not appear to differ significantly from fibroblasts derived from uninflamed 
tissue. This suggests that the altered phenotype may be induced at the initiation of  
the conjunctival scarring pathway, and does not vary according to the current 
inflammatory milieu. The altered phenotype may be dependent on the severity of 
scarring and disease duration rather than on the current inflammatory milieu.   
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Chapter 7 
 
Conclusions   206
7.1 Significance 
There are a number of key findings from this work. Although there is clear evidence 
that acute inflammation following conjunctival injury in ocular MMP, either 
iatrogenic due to surgery or due to the autoimmune process, triggers rapid and 
progressive fibrosis, conjunctival fibrosis in ocular MMP can still progress despite 
apparent clinical control of inflammation by treatment with immunosuppressive 
therapy. This echoes the situation in many fibrotic disorders where 
immunosuppressive therapy affords limited benefit in attenuating fibrosis.  
 
Administering higher doses of systemic immunosuppression in the form of pulse 
intravenous methylprednisolone as adjunctive therapy to patients receiving high 
dose oral cyclophosphamide and corticosteroids cannot be recommended on the 
basis of the findings in this study. Although relatively well tolerated, it does not 
induce more rapid control of inflammation, and can lead to bone loss.   
 
Discovering the lack of effect of pulse intravenous methylprednisolone provides a 
stimulus to assessing alternative therapies for treating recalcitrant inflammation in 
ocular MMP, such as TNFα antagonists. Such therapy might be expected to have 
an effect in up to 90% of patients with active ocular MMP, given the observed 
frequency of tissue expression of TNFα in these patients. The findings of modest 
pro-fibrotic effects of TNFα on conjunctival fibroblasts in vitro are reassuring in 
regard to the possible anti-fibrotic, rather than profibrotic, effects of TNFα 
antagonists. The persistently elevated expression of TNFα in clinically uninflamed 
conjunctiva is in keeping with previous descriptions of ‘white inflammation’, which 
may be driving progressive fibrosis. Administering higher doses of systemic 
immunosuppression might possibly control this underlying residual inflammation, 
however the majority of mucous membrane pemphigoid patients are elderly and 
susceptible to toxicity resulting from high dose immunosuppression; furthermore, 
some of the patients in whom underlying residual inflammation was detected were   207
already on maximal tolerated immunosuppression (including cyclophosphamide) 
when the clinically uninflamed biopsy was taken. Finding a suitable local anti-
inflammatory, anti-fibrotic therapy as an adjunct to maximal dose- minimal adverse 
effect-systemic immunosuppression would be ideal. 
 
The modest profibrotic effects of TNFα and prominence of T cells in the ocular 
MMP substantia propria led to work investigating the key pro-fibrotic T cell-derived 
cytokine IL13. The expression of IL-13 in ocular MMP indicates a role for Th 2 cells 
in fibrosis in ocular MMP. The persistent elevated expression of IL-13 in clinically 
uninflamed conjunctiva suggests that IL-13 has direct profibrotic effects on 
conjunctival fibroblasts, and that these effects may be enhanced by synergism with 
other T cell-secreted products.  
 
Finally, although inflammation due to TNFα and IL-13 is likely to play a important 
role in fibrogenesis in ocular MMP, the question of whether ocular MMP fibroblasts 
behave autonomously, independent of cytokine influences has been answered. 
Ocular MMP fibroblasts show a profibrotic phenotype in vitro which is clearly 
different from that of normal conjunctival fibroblasts. Further work investigating the 
cellular sources of the profibrotic fibroblasts, and the mechanisms that activate and 
recruit these cells to sites of scarring, is necessary. Figure 7.1 shows the proposed 
immunopathogenesis of fibrosis in ocular MMP including the findings from this 
thesis.   208
 
Figure 7.1 Proposed immunopathogenesis of fibrosis in ocular MMP, including findings from this thesis. See 
next page for detailed legend.TNFα (tumour necrosis factor-alpha), IL-13 (interleukin-13) and conjunctival fibroblasts 
with a profibrotic phenotype have been shown to be involved. 
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Legend to Figure 7.1 Proposed immunopathogenesis of fibrosis in ocular MMP. 
 
INJURY PHASE: Autoreactive T cells recognise BMZ (basement membrane zone) antigens (BP180 bullous 
pemphigoid180kDa antigen, laminin 5, collagen VII, α6β4 integrin) causing B cells in germinal centres to produce 
autoantibodies IgG (immunoglobulin G) and IgA. These bind to the BMZ and initiate a type II cytotoxic 
hypersensitivity reaction, activating the complement cascade to cause subepithelial bulla formation.  
 
INFLAMMATION AND PROLIFERATION PHASE: Complement-mediated BMZ, epithelial and connective tissue 
damage cause vasodilation, release of blood cells and plasma proteins into the damaged site and attracts an 
acute inflammatory cell infiltrate consisting of neutrophils, activated macrophages, mast cells, platelets, 
Langerhans cells, and lymphocytes, as well as acute inflammatory cytokine IL-1 (interleukin-1) and TNFα (tumour 
necrosis factor-alpha) production. TNFα has profibrotic and proinflammatory effects on conjunctival fibroblasts. T 
cell activation and proliferation characteristic of a Th1 (type 1 helper T cell) response occurs, with IFNγ 
(interferon-gamma) and IL-2 (interleukin-2) production. Th2 (type 2 helper T cell) cytokines IL-4, IL-5 and IL-13 
are also synthesised. IL-13 has a strong profibrotic and proinflammatory effect on conjunctival fibroblasts. 
Macrophages proliferate and play an important role in scar tissue formation, and also contribute to production of 
the fibrogenic cytokines TGFβ (transforming growth factor-beta) and PDGF (platelet-derived growth factor).  
 
FIBROSIS PHASE: Fibroblasts become activated, proliferate and synthesise increased extracellular matrix, 
CTGF (connective tissue growth factor), TGFβ and other cytokines. Endothelial cells may proliferate, forming 
fibrovascular granulation tissue. The scar tissue is then remodelled, becoming less cellular, and the final result is 
subconjunctival scarring.      
 
Other abbreviations in Figure 1.4: APC antigen presenting cell, m-CSF macrophage-colony stimulating factor, 
MIF macrophage migration inhibitory factor, NFkB nuclear factor-kappa B, HSP47 heat shock protein 47, ECM 
extracellular matrix, mmps matrix metalloproteinases, timps tissue inhibitors of matrix metalloproteinases.  
 
Adapted from Elder (Elder, 1997c) and Razzaque (Razzaque et al., 2003a)   210
7.2 Strengths and limitations of this study 
A major strength of this work was the large patient population from which both the 
clinical studies and the conjunctival biopsies were able to be obtained, and the 
novel idea of evaluating in vitro the consequences of successful systemic 
immunosuppressive treatment. This provides an indication of the molecular and 
cellular alterations following treatment, and could potentially indicate protein 
expression which is unaffected by immunosuppressive treatment. 
 
The main limitation of this work was its broad scope, which did not allow time for 
more in depth experiments exploring questions raised by the initial findings. 
Furthermore, the work is limited in terms of the mechanistic insights it can provide, 
in part because inability to culture T cells hampered investigation of the 
consequences of T cell-fibroblast co-culture, and also because of my inability to 
block IL-13 activity, which meant that experiments isolating the effect of IL-13 could 
not be carried out. Also, inhibiting fibroblast functional activity in vitro may not 
necessarily translate into a clinically significant reduction in scarring, hence the use 
of an animal model will be necessary in order to elucidate potentially therapeutic 
avenues.      
7.3 Future work 
On the clinical front, for treatment of recalcitrantly inflamed ocular MMP, 
investigating biological agents such as TNFα antagonists and the anti-B cell agent 
rituximab in initial pilot studies, followed by appropriately powered controlled 
studies if these are shown to be feasible, are needed. Such studies may be 
feasible in MMP because the biological agents probably have a more favourable 
side effect profile than cyclophosphamide, and could be extended to the larger 
group of patients with less severe disease; currently only 10% of new referrals to 
our centres have severe enough disease to meet our criteria for the use of 
cyclophosphamide, whereas about 80% of all referrals will start systemic   211
immunosuppressive therapy. Our criteria for the use of cyclophosphamide could 
also be revised, given that more effective control of inflammation and also fibrosis 
were observed with the use of this agent in the retrospective review (Chapter 2), 
although it is more toxic. The results of the IVMP trial (Chapter 3) will be of 
substantial value in the design and planning of studies using biological therapies. 
These agents may reduce the time to control and prevent fibrosis more effectively 
than therapy currently on the “top level” of the immunosuppressive stepladder, 
cyclophosphamide and steroids.  
 
Given that there is not much difference in terms of cost or side effect profile 
between TNFα antagonists and rituximab, and rituximab will target the 
immunopathology upstream of TNFα expression in ocular MMP, rituximab is 
currently the preferred biological treatment for severely inflamed recalcitrant ocular 
MMP in our centre. A potential next step for us is to collate the data on patients 
that we know have been treated with rituximab, both within the IVMP trial and 
those treated by us and others outside a trial setting, and to use this to plan a pilot 
study of rituximab, providing the data from the case series is promising. 
 
With regard to in vitro work, investigating the effect of TNFα antagonists on normal 
and pemphigoid conjunctival fibroblasts would be of key interest. If TNFα 
antagonists are anti-fibrotic, as well as being anti-inflammatory, they would be of 
clear interest for use in preliminary clinical studies of either frequent 
subconjunctival or topical therapy, used in conjunction with systemic 
immunosuppression. Topical TNFα antagonists may also be anti-angiogenic, given 
that they may increase timp-2 and timp-4 levels.   
 
Successful culture of T cells from ocular MMP biopsies would permit experiments 
further exploring T cell-fibroblast interactions leading to conjunctival scarring. If 
increased fibroblast activity was discovered upon co-culture with T cells, 
investigating whether blockade of IL-13 inhibits this effect would affirm a central   212
role of IL-13 in T cell-prominent conjunctival fibrosis. These experiments would 
need to be carried out on both normal and pemphigoid fibroblasts. Effective 
blockade of IL-13 will require investigation and understanding of the IL-13 
receptors present on fibroblasts, and this could be established by immunostaining, 
flow cytometry, and immunohistochemical staining of the tissues. After confirmation 
of upregulated protein (and mRNA) expression by fibroblasts of the costimulatory 
molecules CD154, CD40 and CD80 in response to IL-13, investigating whether 
blockade of these costimulatory molecules inhibits the effect of T cell co-culture on 
fibroblasts would also be of interest. The selective costimulation inhibitor abatacept 
(cytotoxic T lymphocyte-associated antigen 4-Ig) binds to CD80 and CD86 on 
antigen-presenting cells and is approved for the treatment of rheumatoid arthritis.   
 
Investigating the effects of IL-13, TNFα and also TGFβ on pemphigoid fibroblasts 
(rather than normal fibroblasts) with respect to other fibroblast functions not 
explored in this study, such as surface expression of HLA-DR, CD80, CD40, 
CD154 would be of key interest, given the altered phenotype of pemphigoid 
conjunctival fibroblasts. Repeating the investigations regarding myofibroblast 
differentiation in ocular MMP would also be important, to confirm whether or not 
myofibroblasts are involved in MMP conjunctival scarring.   
 
Establishing the existence of profibrotic subpopulations of fibroblasts in ocular 
MMP is necessary to support the theory of selective amplification of profibrotic 
subpopulations. Following this, identifying the cellular sources of the profibrotic 
fibroblasts, by defining the contribution of circulating and resident mesenchymal 
progenitor populations in the development of disease, and also identifying the 
factors that activate and recruit these cells to lesions would be relevant.  
 
Developing a suitable animal model of conjunctival fibrosis will enable testing of 
some of the hypotheses raised by these findings, and guide development of 
effective antifibrotic therapies. Possible animal models which could be used   213
include: (1) the neonatal rabbit model described by Roat et al using a monoclonal 
mouse anti-rabbit BMZ antibody injected either subconjunctivally or 
intraperitoneally into neonatal rabbits (Roat et al., 1990). A single injection, given 
either subconjunctivally or intraperitoneally, evaluated to day 9, resulted in acute 
conjunctival inflammation and conjunctival basement membrane-bound murine 
antibody. Modifying this model into a chronic inflammatory model using weekly 
injections for at least 5 weeks could provide a model of chronic anti BMZ-antibody 
mediated conjunctivitis which would probably exhibit conjunctival fibrosis; (2) 
modifying a previously described model of conjunctival scarring in the mouse 
(Reichel et al., 1998). In this model, a single 25µl subconjunctival injection resulted 
in scar tissue formation by day 14 in BALB/c mice. Modifying this model into a 
chronic inflammatory model using weekly injections for at least 5 weeks could 
provide a suitable model to investigate the immunopathogenesis of inflammation-
associated fibrosis in the conjunctiva. Other investigators have used similar 
models, for example weekly intrarectal injection of the irritant TNBS (2,4,6-
trinitrobenzene sulfonic acid) in BALB/c mice to investigate inflammation-
associated fibrosis in chronic colitis which mimics human inflammatory bowel 
disease (Fichtner-Feigl et al., 2007). In the latter model, Th1 cytokines were 
produced in the first 2 weeks, followed by IL-13 at about week 5, which was 
followed soon thereafter by TGFβ secretion and the occurrence of fibrosis. As the 
unscarred mouse eye is very small, using a larger animal such as the rabbit might 
be preferable.    
 
Reaching the endpoint of studies investigating scar tissue formation and its 
inhibition by a selected therapy can take prolonged periods of time waiting for scar 
tissue to form, such that these studies may need to be conducted over several 
years. A disadvantage of this is that during this prolonged period, alternative new 
molecules and inhibitory therapies may be discovered, which one might then want 
to similarly investigate, and moreover, understanding of the effect of the therapy 
under investigation may also change. Establishing sensitive and specific markers   214
of pro-scarring activity that can be processed relatively rapidly, such as 
measurement of upregulated mRNA synthesis of pro-scarring molecules by PCR 
from a conjunctival swab, could aid in more rapid evaluation of outcomes of anti-
scarring therapy in animal models and also in patients, and could obviate the need 
for such trials to be conducted over prolonged durations of time.  
 
In summary, this work has shown that conventional immunosuppressive therapy 
does not control conjunctival fibrosis in ocular MMP, that adjunctive pulse IVMP in 
combination with high dose oral corticosteroids and cyclophosphamide probably 
has no place in clinical therapy, and that both TNFα and IL-13 are involved in the 
pathogenesis of ocular MMP. This work has also shown that the mechanisms 
governing fibrosis are, to a degree, independent of inflammation, due to the 
findings of an altered profibrotic pemphigoid fibroblast phenotype. Together, these 
findings show benefit future research investigating conjunctival scarring and the 
search for new therapeutic options to improve the outcomes in ocular MMP.   215
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A. Study Protocol 
Upper and Lower Conjunctival Fornix Depth- A method of objective assessment: 
Protocol v2, 16.1.2007 
Claire Daniel, Valerie Saw, Scott Hau, David Carpenter, Catey Bunce, Wen Xing, John 
Dart 
 
Introduction 
Measurement of conjunctival cicatrisation in ocular mucous membrane pemphigoid, 
according to Mondino, Tauber and Rowsey, focuses only on in inferior fornix depth.
1-3  
Progression of cicatrisation by a reduction in superior fornix depth is often overlooked.  
Schwab and coauthors designed a custom-made inferior fornix measurement instrument, 
which was shown to produce reliable, reproducible results.  Normal inferior fornix depth 
has been shown to be 10mm in those aged over 80, and 11mm in those aged 60 or less.
4 
However little attention has been given to the normal upper fornix depth.   
 
Aim 
This study will be undertaken to develop, as an extension of the work of Schwab and 
colleagues, an objective technique for measuring upper fornix depth.  The purpose of this 
is to aid detection of and measure progression in cases of suspected cicatrising 
conjunctivitis, and enable measurement of progression of upper fornix cicatrisation in 
ocular mucous membrane pemphigoid.   
 
Materials & Methods 
Instrument 
We have designed an adaptation of the Schwab instrument to measure the upper 
conjunctival fornix.  The same instrument can be used to measure the inferior conjunctival 
fornix.  Whilst the Schwab instrument is made of aluminium, our instrument is made of 
plastic, and similarly biconcave and designed to fit between the globe and the upper lid.  A   286
standardized scale is inscribed on the outer surface with 2mm black line gradations, and 
red lines at 10 and 20mm.  The maximum number of gradations on the instrument is 22 to 
24.  A longer instrument, with more gradations, could be made where necessary, for 
measurement of deeper fornices such as in patients with giant fornix syndrome.  The 
measurements are performed without the use of a slit lamp.  
 
After administration of topical anaesthetic, the patient is asked to look down and the fornix 
measure is gently inserted upwards vertically in the upper cul-de-sac, until resistance is 
felt, taking care to avoid stretching the cul-de-sac.  In the same manner as with the 
Schwab instrument, where the upper eyelid margin rests on the scale inscribed on the 
fornix measure is taken as the measurement of the upper fornix.  If the lid margin falls 
between two marks, an additional 0.5mm is added to the total.  The measurement of the 
upper fornix is taken in downgaze as it uncomfortable for the patient to attempt primary 
gaze with the instrument in place.  The measurement of the lower fornix is taken in upgaze 
for similar reasons.   
 
The instrument is disinfected between subjects  by soaking in hypochlorite for 5 minutes 
then washing off the hypochlorite with sterile saline (see sterilization protocol).  The 
instrument does not come in contact with the cornea. 
 
Subjects 
Both eyes of 120 patients in each age group (50-59, 60-69, 70-79, 80+) will be collected 
for the study. “Normal” subjects will be selected from the outpatient clinics and emergency 
department of Moorfields Eye Hospital.   
 
A separate subset of 25 normal subjects will be measured by 2 separate observers to 
calculate interobserver error.  These subjects will be measured again at a later time by one 
of the observers in a masked fashion to calculate intraobserver error.   
 
Inclusion criteria for “normal” subjects; 
Not using any topical medication apart from lubricants. 
No history of ocular surface disease or ophthalmic surgery other than small incision phaco-
emulsification.     287
 
Exclusion criteria; 
Patients with ptosis, ptosis surgery or giant fornix syndrome 
Patients with a history of ocular allergy, rosacea.. 
Patients with conjunctival scarring (post adenoviral conjunctivitis or membranous bacterial 
conjunctivitis, chemical or thermal burns, Stevens Johnson syndrome, mucous membrane 
pemphigoid, atopic keratoconjunctivitis, trachoma, radiotherapy). 
 
Results/ Statistical analysis 
Age stratified measurements of normal subjects will be compared. A Bland and Altman 
plot will be used to compare the variance of the study population within the age ranges 
and between the chosen age groups. Analysis of inter and intraobserver error will be 
performed. 
 
Value of this study:  We have designed a modified fornix measure which enables 
objective measurement of both upper and lower conjunctival fornix depth.  Establishing 
what the normal upper fornix depth will assist in evaluating cases of suspected cicatrising 
conjunctivitis and will aid monitoring progression in these cases and in other conditions 
with conjunctival scarring.  
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E. Preliminary Results 
50-59 60-69 70-79 80+ All
n = 28 n = 36 n = 41 n = 23 n=127
Mean upper conjunctival fornix depth (mm) 15.5 15.2 15.4 14.6 15.2
Standard deviation 1.9 1.3 1.7 1.6 1.6
Range 12 to 20 12 to 18 12 to 20 12 to 18 12 to 20 
Age (years)
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Appendix 6: Investigating Fibroblast and Epithelial cell markers 
A. Cytokeratin as an epithelial cell marker 
Anti-pan-cytokeratin (Sigma) was initially evaluated as an epithelial cell marker, 
and CD44, a transmembrane protein present on the surface of most vertebrate 
cells which binds to the extracellular matrix protein hyaluronan, was used as a 
label for both the epithelial cells and fibroblasts.  However, cultured human 
fibroblasts can express cytokeratins 5, 8, 14, 16 and 17 (Katagata et al., 2002), 
and it was found that over 90% of cultured conjunctival fibroblasts stained 
positively with the cytokeratin marker (see Figure 1).  An additional disadvantage 
to using cytokeratin to exclude epithelial cells was that it is an intracellular protein 
and the cells had to be fixed and permeabilised for cytokeratin staining; the cells 
could not be sorted on a cell sorter and then used for further experiments as the 
fixation process would render the cells non-viable. 
 
Some groups have judged the purity of conjunctival fibroblast cultures based on 
both cell morphology and positive staining with vimentin and negative staining with 
cytokeratins (Fujitsu et al., 2003; Leonardi et al., 2002). However vimentin, an 
intracellular filament protein, can also be expressed in epithelial cells.   
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Figure 1. CD44 and cytokeratin expression in normal passage 7 (p7) 
conjunctival fibroblasts, in response to 16 hours of cytokine stimulation   306
B. Thy-1 and FSP1 as fibroblast markers, and CD326 as an epithelial cell marker 
Thy-1 (CD90) and fibroblast surface protein-1 [1B10] as fibroblast markers were 
investigated on 2 fibroblast cell lines, human corneal fibroblasts and human 
embryonic lung fibroblasts. Thy-1 (also known as CD90 or AS02) has been 
frequently used as a fibroblast surface marker (Puxeddu et al., 2006), as its 
expression is restricted to fibroblasts, neurons and some CD34+ blood stem cells.  
However, it has been reported that loss of fibroblast Thy-1 expression correlates 
with increased fibrogenesis in the lung (Hagood et al., 2005), so its value as a 
fibroblast marker in fibrogenic diseases is questionable.  Fibroblast surface protein 
[1B10] is present on fibroblasts, smooth muscle differentiated fibroblasts, tissue 
macrophages and 95% of peripheral blood monocytes, but is absent on human 
epithelial cells, lymphocytes and vascular smooth muscle cells (Ronnov-Jessen et 
al., 1992; SundarRaj et al., 1984).   
 
CD326 (also known as EpCAM, epithelial cell adhesion molecule) is a 
transmembrane glycoprotein involved in cell adhesion, which is expressed on most 
epithelial cells and carcinomas, but is not found on normal fibroblasts.  
  
C. Flow cytometry of human corneal fibroblasts and human embryonic lung 
fibroblasts 
Almost all (97%) the passage 6 human corneal fibroblasts tested showed both Thy-
1 and FSP staining, and were CD326 negative (Figure 2).  However only 77% 
were CD44 positive.   These experiments need to be repeated to confirm the 
results.  
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Figure 2. Thy-1, FSP, CD326 and CD44 expression by passage 6 human 
corneal fibroblasts 
 
a. Forward scatter versus side scatter showing 2 populations of cells, gated as 
Region 13 (red) and Region 14 (blue).  
 
b. Thy-1 expression versus FSP expression.  
The majority of cells in both Region 13 and Region 14 cells are both FSP positive 
and Thy-1 positive. R13 cells show greater intensity FSP staining.  Within both R13 
and R14 there are 2 populations of cells with differing intensities of Thy-1 staining.  
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c. CD326 expression versus CD44 expression.  
Almost all cells are CD326 negative (97%).  77.33% of all cells are CD44 positive; 
almost all Region 14 cells are CD44 positive, but a proportion of Region 13 cells 
are CD44 negative.  
 
 
Human embryonic lung fibroblasts did not express FSP and only 26% expressed 
Thy-1 (Figure 3).  CD326 did not appear to be expressed by these fibroblasts, and 
CD44 expression was only 12%.  It may be that these embryonic cells are not 
differentiated enough to express these fibroblast markers. These preliminary 
findings need to be repeated to confirm the results. 
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Figure 3. Thy-1, FSP, CD326 and CD44 expression by human embryonic lung 
fibroblasts 
 
a. Forward scatter versus side scatter 
 
 
 
b. Thy-1 expression versus FSP expression: Thy-1 expression 26% and FSP 
expression 2% 
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c. CD326 expression versus CD44 expression: CD326 expression 1% and 
CD44 expression 12% 
 
In summary, FSP may be a suitable fibroblast surface marker, and an alternative to 
Thy-1.  CD326 does not appear to be expressed on the two types of fibroblasts 
tested.  Along with confirmation of the results by repeating the above experiments, 
the next step would be to evaluate CD326 expression in an epithelial cell line, and 
to show that by mixing both a fibroblast cell population and an epithelial cell 
population, that there is specific staining for each cell type, which can identify the 
two populations.  These markers could then be tested on the explant-derived 
human conjunctival fibroblasts to show reduction in the proportion of epithelial cells 
with increasing passage number.   
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